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ABSTRACT 
 
The genus Streptomyces is the source of approximately two thirds of all clinically 
used antibiotics.  Despite being the source of so many specialised metabolites, 
genomic analysis indicates that most Streptomyces strains have the potential to 
produce around 25 bioactive metabolites, some of which may be the basis of 
novel therapies.  This makes culture collections of Streptomyces spp. an easily 
accessible but underused resource to mine for genomic and metabolomic variety.  
Therefore, the main aim of this project was to initiate exploitation of the culture 
collection at NCIMB Ltd. by expanding the available chemical space from 
underutilised Streptomyces for the production of novel antibiotics.  This primarily 
used a mixture of metabolomic and genomic methods.  
A high-throughput culture parameter screen was designed around multiple 
carbon sources, nitrogen sources, and extraction sample times.  This was tested 
on the model species S. coelicolor A3(2) to compare differences in the production 
of known specialised metabolites, using UPLC-MS to analyse crude extracts from 
growth on agar.  Data was analysed using MZmine and putative metabolites 
identified using freely available MS/MS databases, primarily GNPS.  This showed 
clear variation in production of 9 identified metabolites including deferoxamines, 
germicidins, undecylprodigiosin and coelichelin as a result of different culture 
parameters.  Therefore, the screen successfully expanded the available chemical 
space, so was applied to non-model Streptomyces strains. 
The screen was used to compare the total metabolomic variety produced by 3 
Streptomyces isolated from different environments in order to select a strain for 
further investigation.  Comparing metabolomic features using principal 
component analysis showed the Costa Rican soil isolate S. costaricanus to 
produce the most variety versus the other 2 Streptomyces strains.  The 
metabolite family most responsible for principal component separation was 
identified as the actinomycins.  Scale-up of both agar and broth culture was used 
for metabolite dereplication and bioassays against multidrug resistant 
Acinetobacter baumannii, one of the bacteria on the World Health Organisation’s 
list of pathogens most urgently requiring new therapies.  Fractions were derived 
from broth culture supernatant and agar crude extract by flash chromatography, 
resulting in semi-purified fractions.  The predominant metabolite families in 
  
xii 
 
fractions were actinomycins and deferoxamines, which were further split by 
polarity into separate fractions.  This resulted in rapid purification of metabolites, 
with 1 fraction comprising 80% deferoxamine B by weight.  Fractions were tested 
against A. baumannii using the 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5-
[(phenylamino) carbonyl]-2H-tetrazolium hydroxide (XTT) assay, which showed 
partial inhibition of growth at 50 µg/ml.  Examining the bioactive fractions 
showed potentially novel minor peaks which could be responsible for bioactivity.   
A high-quality full genome of S. costaricanus was obtained using a combination 
of MiSeq and MinION sequences.  This was analysed with RAST and antiSMASH 
to determine the specialised metabolite potential of S. costaricanus.  AntiSMASH 
detected 33 biosynthetic gene clusters (BGCs), above the mean for 
Streptomyces.  Thus, the confirmed genomic potential also suggested a wider 
metabolite variety, as indicated by the metabolomic screen.  Some of the 33 BGC 
products had been previously detected by UPLC-MS, like actinomycin D and 
deferoxamine B.  Other BGCs had 0% homology to known BGCs, including a 
terpene BGC which only showed core gene homology to 2 other Streptomyces.  
One of these strains shared all of the BGCs with S. costaricanus, including their 
sequential order and closely approximated genomic locations.  Comparison of 
marker genes with autoMLST gave preliminary evidence for the taxonomic 
reclassification of S. costaricanus as a strain of S. griseofuscus.   
Starting from a large collection of unexploited Streptomyces, this project 
catalogued the metabolomic and genomic diversity of a single strain and its 
bioactive potential. Together, the project stages formed a workflow for further 
exploitation of NCIMB Streptomyces and other microbes. 
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1 Introduction 
 
1.1 An overview of modern microbial antibiotic discovery 
 
Modern microbial derived antibiotic discovery can be traced back to 2 main 
events.  The first of these was the accidental, but hugely significant, discovery of 
penicillin by Alexander Fleming in 1928 (Fleming, 1929). While penicillin is 
sometimes referred to as the first microbially-derived antibiotic (Gaynes, 2017), 
this is not strictly correct.  Pyocyanin (Figure 1.1), produced by Pseudomonas 
aeruginosa, was shown to inhibit microbial growth including that of Bacillus 
anthracis in infected rabbits (Woodhead & Wood, 1890; Gould, 2016).  Pyocyanin 
has likely been overlooked as it had limited applicability compared to penicillin, 
along with the fact that most of the original publications were not in English. 
 
 
 
 
 
 
 
The second event was the development of a systematic antibiotic discovery 
platform by Selman Waksman, beginning what was later termed the “golden 
age” of antibiotic discovery running for approximately 20 years from 1940 – 
1960 (Katz & Baltz, 2016).  This platform led to the discovery of many of the 
antibiotics currently used in the clinic (Brown & Wright, 2016).  The origins, 
microbes, and derived antibiotics are outlined in the following sections, 
demonstrating the early successes of microbial specialised metabolites (SMets) 
as medical therapies. 
 
Figure 1.1 Structure of pyocyanin. 
C13H10N2O 
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1.1.1 Origins of antibiotic discovery: penicillin 
 
Fleming’s original research that gave rise to the discovery of penicillin was on 
colony variation in “pyogenic Staphylococcus”, or Staphylococcus aureus 
(Fleming, 1944).  This involved routine microscopy, which required removing the 
lid from a culture plate.  Following the exposure of one plate to the air, and after 
several days of incubation at room temperature, a mould contaminant – 
described by Fleming as a “felted mass”, indicating a filamentous species of fungi 
– was seen on the plate, along with the inhibition and lysis of S. aureus colonies.     
After isolation and nutrient broth culture of the contaminant, the culture 
supernatant was found to inhibit multiple pathogenic microbes including 
Streptococcus pyogenes, Streptococcus pneumoniae, Neisseria gonorrhoeae, and 
diptheroid Corynebacterium spp.  No toxic effects were seen when intravenously 
injected into rabbits or mice, after hourly application to human conjunctiva, and 
human leukocyte function was not impaired (Fleming, 1929).  Antimicrobial 
bioactivity remained even when diluted up to 800-fold, which was greater than 
the maximum useful dilution factor for the commonly used antiseptic phenol.  
This indicated production of a potent antibacterial compound with clear 
therapeutic applications.   
The mould itself was originally identified as a Penicillium species, hence the name 
penicillin for the newly discovered antibiotic.  Multiple natural, or non-synthetic, 
penicillins are now known; penicillin G, shown in Figure 1.2 is the major product 
and the one referred to in this section, with other minor metabolites like 
penicillins V, F, and K also present (Torres et al., 1999). 
 
 
 
 
 
 
 
Figure 1.2 Structure of penicillin G. 
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Taxonomic characterisation of the organism producing penicillin has undergone 
multiple revisions.  It was putatively classified as being closest to P. rubrum 
(Fleming, 1929), but later reidentified by Thom (1945) as a strain of P. notatum, 
which itself was then merged into the species P. chrysogeneum (Samson et al., 
1977).  Though still commonly referred to as P. chrysogenum, Houbraken et al. 
(2011) used more recent metabolic and molecular methods to further separate P. 
chrysogeneum and what they propose as Fleming’s original strain, P. rubens. 
Despite this, P. chrysogenum is still sometimes used in the literature as the first 
discovered producer of penicillin (Ziemons et al., 2017). 
Production of penicillin by strains of P. rubens was demonstrated to vary across a 
wide range of concentrations, from 0 to 129 µg/ml (Raper et al., 1944).  P. 
rubens is known to undergo high levels of mutation, which led Thom (1945) to 
hypothesise that this was to support SMet variety.  Thom (1945) therefore 
suggested that the strain was present at low levels within Fleming’s lab until it 
mutated to produce enough penicillin to outcompete other microbiota.  Thom 
(1945) also reported that his collection continued to receive requests for P. 
rubrum for several years after its renaming to P. notatum, which were replied to 
by sending P. notatum with an explanation of the then current taxonomy.  This 
emphasises that, while taxonomic processes may lead to re-classification of 
industrially and medically relevant strains, culture collections are important for 
both maintaining the original strain and ensuring that requests for a SMet 
producer are correctly documented.   
Penicillin was introduced to the clinic in the early 1940s with good results, 
though not all patients survived as problems with scale-up and isolation led to a 
limited supply of pure drug (Abraham et al., 1941); treatment was also 
hampered by penicillin’s low stability, which continues to be a problem (Miller, 
2002).  Following successful production trials in Oxford (Chain et al., 1940), 
production was extended across the United States in 1941, eventually providing 
enough to treat allied forces in World War II (Gaynes, 2017).  While Fleming’s 
discovery of penicillin was not intentional, its importance was realised and 
successfully transformed into a successful medical product.  It also hinted at 
other similar microbial SMet with similar activities, ready to be discovered and 
exploited through a systematic antibiotic discovery programme.  This would be 
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confirmed through the research of Selman Waksman, investigating soil microbes 
and their specialised metabolites, predominantly from the genus Streptomyces.  
1.1.2 Origins of antibiotic discovery: The Waksman platform 
 
1.1.2.1 Pre-antibiotic era research 
 
The Waksman platform was an antibiotic discovery system focused on using soil 
bacteria to produce bacteriostatic or bactericidal compounds active against a 
range of pathogenic microbes.  Waksman’s research originally concentrated on 
the interactions of different soil microbes with the environment and aspects of 
primary metabolism.  As examples, Waksman (1918) focused on proteolytic 
enzymes of soil fungi and “actinomycetes”, which refers to the now famous 
natural product producing order Actinomycetales and particularly the genus 
Streptomyces (Hua Zhu et al., 2014). Waksman & Joffe (1922) concentrated on 
soil sulphur oxidation, and Waksman & Skinner (1926) on cellulose 
decomposition.  In reference to Streptomyces, many of the strains were 
originally assigned to the Actinomyces genus when their antibiotics were 
discovered; one example is Actinomyces griseus, the producer of streptomycin 
(Schatz et al., 1944).  These were later reclassified into Streptomyces, which is 
how they are referred to here unless in a direct quote from an article. 
There was a brief mention of the Actinomycetales as producers of “substances 
toxic to bacteria” resulting in a zone of inhibition “free from fungus and bacteria” 
on agar plate culture in Waksman & Starkey (1923), though the main focus of 
the paper was on soil sterilisation.  However, a link was not made between these 
toxic substances and their potential effects on other microbes including human 
pathogens (Woodruff, 2014).  So, while Waksman was familiar with 
Actinomycetales that had the ability to inhibit the growth of other microbes, this 
was more in an ecological context rather than as sources of medicines.  The first 
article specifically on soil microbes and their potential for medicinal use was 
published in 1940 (Waksman & Woodruff, 1940), in which 4 microbial groups of 
special interest were identified.   
The first, Pseudomonas spp. has already been mentioned in section 1.1 as the 
source of pyocyanin, the first antibiotic derived from a microbe.  The second 
group was Bacillus spp., including Bacillus brevis which had recently been found 
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by a past student of Waksman to produce a substance active against Gram-
positive bacteria (Dubos, 1939).  This substance, named tyrothricin, was actually 
a mixture of the antibiotics gramicidin and tyrocidine (Dubos & Hotchkiss, 1941).  
The mixture and the overall components, especially tyrocidine, are unsuitable for 
clinical use as they induced haemolysis (Rammelkamp & Weinstein, 1942).  The 
remaining 2 groups are Actinomycetales and then fungi, with Penicillium and 
Trichoderma noted as 2 genera of interest.  Actinomycetales, especially 
Streptomyces spp., were the main workhorse of the platform and so will be 
explored in more detail.   
1.1.2.2 Discovery of actinomycin 
 
Dubos’ identification of a new use for B. brevis was responsible for Waksman’s 
refocusing on antibiotic discovery, especially those active against Gram-
negatives as penicillin, gramicidin, and tyrocidine are mostly limited to Gram-
positive bacteria (Woodruff, 2014).  Initial tests used the same method as Dubos 
(1939): supplementing soils with a target pathogen over multiple months, 
selecting for any microbes able to destroy the pathogens and use their nutrients 
for metabolism.  The major difference was the use of Gram-negatives to 
supplement the soil pre-plating, with the logic that any enriched soil microbes 
should be able to kill Gram-negatives.  Whether this actually affected results is 
unknown since no negative control was done. 
By enriching with Escherichia coli and Klebsiella aerogenes then plating out serial 
dilutions of the soil, one Actinomycetales species (Waksman & Woodruff, 1941) 
was found to consistently inhibit the target pathogens.  K. aerogenes is referred 
to as Aerobacter aerogenes in Waksman & Woodruff (1941); its reclassification 
to Entereobacter aerogenes and then K. aerogenes is described in Tindall et al. 
(2017).  Similar to the above confusion over Penicillium names for culture 
collection requests, this highlights the importance of maintaining a collection 
aware of these differences to drug discovery projects, as an inconsistent target 
test pathogen would prevent reproducible experiments.  
The antagonist microbe was determined to be a new species now known as S. 
antibioticus (Katz et al., 1956), and the antibiotic named actinomycin.  An early 
version of the One Strain Many Compounds, or OSMAC, (Bode et al., 2002) 
method was applied to culture S. antibioticus and assay bioactivity, varying 
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nitrogen sources with starch as the carbon source.  This showed it to be primarily 
active against Gram-positives: K. aerogenes was not inhibited at all by 200 
μg/ml crude extract, though E. coli was inhibited at the same concentration from 
multiple media extracts.  In comparison, B. subtilis was totally inhibited at 1 
μg/ml. 
It should be noted that as this experiment took place before the current 
antibiotic crisis, these are unlikely to be multi-drug resistant strains so 
actinomycin is now even less effective than in Waksman & Woodruff (1941).  
Alongside this, actinomycin was also found to be toxic to animals.  Mice were 
killed by a dosage of 10 μg per 20 g body weight, and was lethal whether 
injected into the body, subcutaneously, or taken orally (Waksman & Tishler, 
1941).  The bioactivity of actinomycin against both prokaryotes and eukaryotes 
is due to its mechanism of action, as it forms a complex with DNA by inserting 
itself at CpG sites, prevent RNA Polymerase accessing the DNA and so stopping 
transcription.  While it is not used as an antibiotic, the cytotoxic effects of 
actinomycin do make it suitable for anticancer chemotherapy (Lo et al., 2013).  
Actinomycin has historically been used to treat Wilms tumour, a renal cancer 
(Fernbach & Martyn, 1966), but more recently as an enhancer of immunotoxins 
which target cancerous cells (Liu et al., 2016) 
Actinomycin was the first antibiotic to be discovered by the Waksman platform, 
and while it was not the ideal Gram-negative antibiotic with no toxic side effects, 
it was proof of the concept that a targeted screen of Actinomycetales would 
produce novel bioactive metabolites.   
1.1.2.3 Platform expansion and discovery of streptomycin 
 
The screening platform was modified to directly plate soil suspensions onto agar 
plates and test the colonies for bioactivity; the two methods are summarised in 
Figure 1.3.  This led to the discovery of antibiotics from fungi: fumigatin and 
fumigacin from Aspergillus fumigatus, and clavacin from Aspergillus clavatus 
(Waksman et al., 1943).  Continuing with the trend of Gram-negatives being 
more difficult to target, fumigatin and fumigacin showed antibiotic activity 
against Gram-positives but not Gram-negatives with the exception of some 
against E. coli.  Clavacin showed strong activity against both types at similar 
levels, but all 3 of these antibiotics were toxic to eukaryotic cells and therefore 
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not suitable for widescale usage.  The first platform antibiotic to show potent 
activity towards Gram-negative and Gram-positive bacteria with apparently 
minimal toxicity was streptothricin from S. lavendulae (Waksman & Woodruff, 
1942).  Unfortunately streptothricin was later found to have delayed kidney 
toxicity, halting clinical trials (Inamori et al., 1979).   
 10 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
   
Figure 1.3 Waksman Platform antibiotic discovery methods (a) initial method based on soil supplementation with target 
pathogen, and (b) revised method using isolation then bioactivity screening.   
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Screening soil isolates for bioactive SMet producers had led to the discovery of 
novel compounds, but none of them exhibited inhibition of Gram-negative strains 
while causing minimal toxic side effects to animal models.  The first metabolite 
discovered by the platform to fulfil this was streptomycin, produced by S. griseus 
(Schatz et al., 1944).  Streptomycin is effective against both Gram-positive and 
Gram-negative bacteria with no lethally toxic effects to eukaryotes since, unlike 
actinomycin, it acts on a prokaryote-specific target.  Streptomycin disrupts protein 
synthesis by binding to the 30S ribosomal subunit (Luzzatto et al., 1968), warping 
the structure at the 16S codon recognition site (Demirci et al., 2013) resulting in 
an incorrect translational complex which misreads codons and produces random 
sequence proteins.  Some neurotoxic effects were seen, but the reduced derivative 
dihydrostreptomycin was found to alleviate these (Waksman & Lechevalier, 1949); 
later experiments did find a nephrotoxic effect to the broader class of antibiotics, 
but these are avoided through correct body mass to dosage level calculations 
(Pedersen et al., 1987). 
Initially streptomycin was used to treat tuberculosis, caused by another 
actinobacterium Mycobacterium tuberculosis.  Streptomycin was the first drug to 
inhibit tuberculosis progression in the commonly used animal model, guinea pigs 
(Hinshaw et al., 1946).  It was also the first of the aminoglycoside antibiotic group 
to be discovered, which are characterised by an inositol derivative – streptamine 
for streptomycin – bonded to an aminosugar group, with 2 or more further amino 
groups and free hydroxyls (Becker & Cooper, 2013) shown in Figure 1.4.   
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Another aminoglycoside, neomycin, would later be discovered in Waksman’s lab 
(Waksman & Lechevalier, 1949).  Produced by S. fradiae, it was – like 
streptomycin – active against M. tuberculosis, but crucially against strains which 
were already displaying resistance to streptomycin.  It also displayed similar if 
not better levels of Gram-negative antibiotic activity, with 5 μg/ml being enough 
to totally prevent growth of streptomycin resistant E. coli. 
1.1.2.4 Common classes of bioactive specialised metabolites 
 
Streptomycin belongs to the polyketide metabolite class, which are produced by 
polyketide synthases (PKS) (Gomes et al., 2013).  Biosynthetic gene clusters 
(BGCs) for PKS are common throughout Streptomyces spp. and other 
Actinomycetales genera (Risdian et al., 2019), and synthesise a wide range of 
metabolites with a variety of structures and bioactivities.  These include 
antibacterials like josamycin from S. narbonensis, the antifungal amphotericin B 
from S. nodosus, antihelminith avermectin from S. avermitilis, or the antitumour 
tetracenomycin produced by S. glaucescens (Caffrey et al., 2001; Thompson et 
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Figure 1.4 Structure of streptomycin with inositol derivative segment 
noted. 
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al., 2004; Petkovic et al., 2006; Katz & Baltz, 2016).  Structures are shown in 
Figure 1.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
PKS operate as an assembly line, with each segment performing a different 
enzymatic function to construct the metabolite.  There are 3 types of PKS in 
Streptomyces, types I, II, and III, which differ in their mechanisms and product 
classes, and may also be combined to build hybrid metabolites.  The two most 
common types in Streptomyces, types I and II, are briefly outlined below.  An 
acyl-CoA unit is generally used as the starting building block for both types.  
In type I PKS, the acyl-CoA is processed by multiple modules, with each module 
containing a set of functional domains.  A module must include a ketosynthase 
(KS), an acyltransferase (AT), and end on an acyl carrier protein domain (ACP) 
as a minimum. The starter unit is built into a metabolite through addition of 
extender units like methylmalonyl-CoA, which are joined through the KS 
catalysing C-C bond formation.  The extender unit is selected by the AT domain, 
and the product transferred to the next module by the ACP.  Further 
modifications are done by other domains, like keto reductases or dehydrateases 
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Figure 1.5 Structures of (a) josamycin, (b) amphotericin B, (c) avermectin, 
and (d) tetracenomycin C 
C42H69NO15 
C47H73NO17 
C48H72O14 C23H20O11 
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(Risdian et al., 2019).  This results in PKS megastructures which must be 
associated to synthesise the product, which unidirectionally passes through each 
module, until release from the C terminus of the PKS is catalysed by a 
thioesterase (Musiol-Kroll & Wohlleben, 2018)  
In comparison, type II PKS are discrete, iterative enzymes, which include a KS, 
chain-length factor, and ACP.  Additional downstream tailoring enzymes like 
ketoreductases, aromatses, or cyclases can be included to enhance the minimal 
PKS, followed by further tailoring to the scaffold from methyltransferases, 
oxygenases, and glycosyltransferases.  Type II PKS produce polycyclic aromatic 
compounds, with most of the structural variety and bioactivity coming from the 
downstream tailoring (Zhang & Tang, 2009). 
A 2nd common class of biosynthetic enzymes are the non-ribosomal peptide 
synthases (NRPS).  Similar to PKS, Streptomyces NRPS construct a variety of 
metabolites with multiple bioactivites, but unlike PKS, directly incorporates amino 
acids into the structure without using ribosomal products.  These include the 
antitumour antibiotic actinomycin from S. antibioticus, antibacterial daptomycin 
from S. roseosporus, and antiviral feglymycin produced by S. sp. DSM 11171 
(Férir et al., 2012; Katz & Baltz, 2016); structures are shown in Figure 1.6.  
Similar to type I PKS, most NRPS operate as sequence of modular multifunctional 
enzymes, specifically condensation (C), adenylation (A), and peptidyl carrier 
protein (PCP) domains.  The C domain forms C-N bonds between amino acids, 
which are recruited by the A domain, and transferred to the PCP domain to be 
recognised by the C domain on the next module, or released from the NRPS by 
the hydrolysing or cyclysing effects of a thioesterase (Nikolouli & Mossialos, 
2012).  NRPS and PKS clusters can form combined hybrid products for even 
more structural diversity, and correspondingly varied bioactivity, such as 
oxazolomycin from S. albus JA3453 (Zhao et al., 2010). 
 
 
 15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O
H
N
H
N
O
NH
O
H
2
N
O
H
N
O
HO
O
HN
O
O
N
H
O
N
H
O
NH
O
NH
O
NH
O
NH
O
H
N
O
HN
O
HN
O
NH
2
O
HO
O
HO
OH
O
HO
O
H
2
N
O
HN
O
N
O
N
ON
O
O
HN
O
O
O
N
O
HN
O
O
N
O
N
O
N
O
NH
O
H2N
O
HN
HO OH
O
HN
OH
O
H
N
OHHO
O
N
H
OH
O
H
N
OHHO
O
N
H
O
H
N
O
H
HO
O
HN
OH
OHN
O
HN
O
OH
O OH
N
H
O
OHHO
H
N
O
OH
H2N
Figure 1.6 Examples of non-ribosomal peptides produced by Streptomyces spp. (a) actinomycin D, (b) daptomycin, 
(c) feglymycin. 
(a) (b) 
(c) 
C62H86N12O16 C72H101N17O26 
C95H97N13O30 
 16 
 
A final class of metabolites are the ribosomally synthesised and post-
translationally modified peptides, or RiPPs.  RiPPs undergo multiple rounds of 
post-translational processing from the precursor peptide to form the mature 
product.  In Streptomyces, starting at the N terminus, the precursor product is 
generally made of a leader peptide, followed by the core peptide, then a 
recognition sequence.  The leader peptide is involved in assigning post-
translational tailoring to the core peptide and export, while the recognition 
sequence can cyclise or enable proteolytic cleavage and produce the mature RiPP 
(Arnison et al., 2013).   
As with polyketides and non-ribosomal peptides, RiPPs are present in 
Streptomyces in numerous sub-types, including lassopeptides, thiopeptides, and 
bottromycins.  As RiPPs are less well studied than polyketide and non-ribosomal 
peptides, there are few current  commercial or medical applications for them, 
with the food additive nisin from Lactotoccus lactis as an exception (Tan et al., 
2019).  Despite this, multiple bioactivites are still exhibited by RiPPs.  S. sp. 
AA6537 produces the lasso peptide siamycin I, which inhibits human 
immunodeficiency virus envelope fusion (Lin et al., 1996). S. azureus, S. 
laurentii and other species synthesise the antibacterial thiostrepton (Mocek et al., 
1993), and the MRSA-inhibiting bottromycins (Hou et al., 2012; Arnison et al., 
2013).  Structures for these metabolites are shown in Figure 1.7. 
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1.1.2.5 Adoption by other researchers 
 
As a result of the success of Waksman’s research into Actinomycetales, 
particularly Streptomyces there was widespread stimulation of similar research in 
both academia and industry (Woodruff, 2014).  These resulted in the rapid 
discovery of other new antibiotics through to the 1960s.  Some of these are 
shown in Table 1.1, which has been limited to just antibacterial metabolites 
produced by Streptomyces, and corresponding structures in Figure 1.8.  All of 
the listed metabolites attack the ribosome through various different mechanisms 
of action.  This was not an intentional selection but does reflect the importance 
of having a prokaryote-specific target in chemotherapy which is more likely to 
lead to a successful drug with minimal side effects in eukaryotes. 
As a result of this drive towards Streptomyces based antibiotic discovery, over 
half of known antibiotics are produced by Streptomyces (D’Costa et al., 2006) as 
well as approximately two thirds of commonly used clinical and veterinary drugs 
(Hopwood, 2013).   
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Table 1.1 Streptomyces derived antibiotics from the golden age of discovery. 
Metabolite Species Mechanism Activity Reference 
Chloramphenicol Streptomyces 
venezualae 
Binds to 50S 
ribosomal subunit, 
halting peptide 
chain elongation 
Gram + 
Gram - 
Ehrlich et 
al. (1947) 
Oxytetracycline Streptomyces 
rimosus 
Binds to 30S 
subunit, preventing 
tRNA binding 
Gram + 
Gram - 
(Duggar, 
1948) 
Oleandomycin Streptomyces 
antibioticus 
Binds to 50S 
subunit, preventing 
complex formation 
Gram + 
Gram -
(weak) 
Garrod 
(1957) 
Lincomycin Streptomyces 
lincolnensis 
Binds to 23S RNA, 
stopping peptide 
bonding 
Gram + 
Gram – 
(weak) 
Macleod et 
al. (1964) 
Kanamycin Streptomyces 
kanamyceticus 
Binds to 30S 
subunit, causing 
mRNA misreads 
and incorrect 
amino acid 
recruitment 
Gram + 
Gram - 
Maeda et 
al. (1957) 
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Figure 1.8 Structures of (a) chloramphenicol, (b) oxytetracycline, (c) lincomycin, (d) oleandomycin, and (e) 
kanamycin. 
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Some of the novel metabolites like neomycin were explicitly noted to be of use 
as resistance was increasing to a previously effective drug.  Unfortunately, the 
rate of SMet discovery was declining: approximately 12000 SMet discovered up 
to the 1960s – of which 160 were used as drugs or as the chemical scaffold for 
development – but only a further 10000 SMet were found by 2002 (Marinelli, 
2009).   
Since the end of the Golden Age in the 1960s, only 2 new classes of antibiotics 
have been discovered, both of which are only active against Gram-positive 
species: daptomycin, a lipopeptide produced by S. roseosporus (Debono et al., 
1987), and teixobactin from Eleftheria terrae (Ling et al., 2015), for which no 
mechanisms of resistance have yet been found.  The likelihood of discovering a 
new class is estimated to be low: based on the frequency of commonly found 
BGCs, 10% of species produce streptothricin, 1% streptomycin, and 0.1% 
tetracycline; daptomycin has a discovery probability of 2 × 10-7 (Lewis, 2013). 
Shortly after the widespread production of penicillin, Fleming predicted in 1945 
that the increased prescription of penicillin would lead to selection of resistant 
strains (Rosenblatt-Farrell, 2009).  This had already been confirmed 5 years 
earlier (Abraham & Chain, 1940) with the discovery of a β-lactamase from E. 
coli.  Antibiotic usage has increased along with population and intensive 
agriculture or farming.  The majority of antibiotic usage in the US has been on 
livestock, with over 13,000,000 kg – about 80% of total US consumption – being 
used to prevent disease (Chang et al., 2015).   
The selective pressure is further increased by routine administration, increasing 
the chance of antimicrobial resistance (AMR) becoming a stable trait, leading to 
AMR related diseases and further transfer of AMR genes to different 
environments.  Along with an increase in global travel, AMR has become not only 
more difficult to treat but also to contain.  This is expanded in the next section, 
which briefly describes the progression of AMR.  It also emphasises why novel 
antimicrobials are desperately needed, especially for nosocomial infections in 
immunocompromised patients (Terra et al., 2018). 
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1.2  Rise of antimicrobial resistance 
 
1.2.1 Origins of AMR genes 
 
AMR is not a new phenomenon.  Some form of resistance must have existed as 
long as antibiotics themselves have been produced, since microbes producing 
bioactive SMet must have been able to prevent any damage being done to their 
own cells.  Genes for streptomycin resistance have been found in Siberian 
permafrost approximately 3,000,000 years old (Mindlin et al., 2008).  These 
genes (strA, strB, and aadA) were not found in permafrost-preserved S. griseus 
or any other Streptomyces, but in a mixed population of different genera; the 
Gram-negative species included Pseudomonas sp. and Acinetobacter sp., both of 
which are on the World Health Organisation’s (WHO) list of pathogens most 
needing new treatments (Tacconelli et al., 2018).  In S. griseus strA and strB 
produce self-resistance by inactivating intracellular streptomycin through the 
enzyme streptomycin 6-phosphotransferase. This accounts for 1 of 4 main 
mechanisms for AMR: drug inactivation, altering the target structure, blocking 
drug uptake, and efflux pumps.  
β-lactams, such as penicillin, are inactivated by the β-lactamases. β-lactams are 
generally associated with fungi, and were originally thought to not require any 
self-resistance mechanisms since they are not active against fungi (Ogawara, 
1981).  However, Streptomyces produces β-lactam antibiotics such as the 
carbapenem thienamycin, isolated from S. cattyleya (Ogawara, 2016), or the 
cephamycin family (Stapley et al., 1972).  Carbapenems differ from the subclass 
penicillins belong to (penams) through the substitution of a sulphur to carbon, 
and an unsaturated 5-carbon ring, hence “carbapenems” (Figure 1.9).  
Though β-lactams are primarily active against Gram-positive bacteria, 
Streptomyces spp. are highly resistant to β-lactams due to penicillin-binding 
proteins which facilitate β-lactam capture inside the cell for release outside it 
(Ogawara, 2016).  In comparison, Gram-negative pathogens use β-lactamases to 
destroy the lactam ring and bioactivity, which would seem to be totally separate 
mechanisms of action.  However, β-lactamases are thought to have evolved from 
penicillin-binding proteins (PBP) and have some sequence homology (Meroueh et 
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al., 2003), presenting a 2nd class of AMR which may have its origins in 
Streptomyces. 
 
 
 
 
 
 
 
 
 
Streptomyces species are generally not pathogenic to humans, though the genus 
does include notable plant pathogens such as the cause of potato scab, S. 
scabies (Seipke & Loria, 2009).  S. somaliensis and S. sudanensis (Seipke et al., 
2012) are the main exceptions in humans, with recent unprecedented instances 
of S. griseus mycetoma (Chander et al., 2015) and S. atratus pneumonia (Ariza-
Prota et al., 2015).  Therefore, the problem is not so much the AMR-gene 
reservoir with Streptomyces but the mishandling of antibiotics leading to the 
selection of cassettes for multidrug resistance, and their inevitable spread. 
1.2.2 Global Spread of AMR 
 
1.2.2.1 ESKAPE pathogens 
 
The most dangerous group of MDR-microbes are termed the “ESKAPE” 
pathogens: Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and 
Enterobacter spp. (H. Zhu et al., 2014), especially dangerous when acquired as 
nosocomial infections.  The ESKAPE list correlates with the WHO designations of 
 β-lactam ring 
Figure 1.9 Structure of (a) thienamycin with (b) core penam structure of 
penicillin for comparison. 
(a) (b) 
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pathogens most urgently requiring new medicines, which includes all of the 
ESKAPE Gram-negative strains (Tacconelli et al., 2018). From the 2 Gram-
positive members, methicillin-resistant Staphylococcus aureus (MRSA) became 
an important nosocomial and eventually community-associated pathogen 
(Mediavilla et al., 2012).  Resistance in MRSA is due to the expression of another 
PBP, PBP 2a, derived from the mecA gene carried within the staphylococcal 
cassette chromosome mec (SCCmec) (Kwon et al., 2005).  SCCmec confers 
resistance to methicillin, a 2nd generation β-lactam, giving MRSA its name, along 
with resistance to all other β-lactams (Ender et al., 2004).  Resistance to other 
antibiotics can be acquired through the incorporation of different genes into 
SCCmec such as Tn554 (Wielders et al., 2002) which confers resistance to 
erythromycin and spectinomycin (Murphy et al., 1985). 
Resistance can also occur through a non-specific efflux pump or preventing 
diffusion through a porin.  However, much of resistance is due to the inactivation 
of the frontline drug class, the carbapenems, by β-lactamases.  Biofilms are also 
a major contributor to AMR for the ESKAPE pathogens, but this section will be 
restricted to the genetic basis of it (Eze et al., 2018) 
The major set of recent resistance enzyme genes in K. pneumoniae, and the 
Enterobacteriacae as a whole, confer resistance to carbapenems along with other 
drugs.  MDR-Carbapenem resistance in K. pneumoniae can be acquired through a 
variety of genes, recently including the blaNDM-1 gene, standing for New Delhi 
metallo-β-lactamase after its discovery location (Kumarasamy et al., 2010).  Its 
product, NDM-1, hydrolyses all β-lactams apart from aztreonam.  blaNDM-1 is 
horizontally transferred with 2 other genomic regions on the plasmid in 
conjugation, which together provide resistance against all antibiotics aside from 
fluoroquinolones and colistin (Yong et al., 2009).   
Since its discovery, NDM-1 producing strains have been detected across the 
world, including the UK.  This strain was only treatable using colistin and 
tigecycline, a tetracycline derivative (Kumarasamy et al., 2010).  Colistin 
resistance, acquired through a mutated mgrB gene which modifies the 
lipopolysaccharides in the outer membrane, were recently reported in India 
(Pragasam et al., 2016), indicating that a microbe resistant to all the antibiotics 
of last resort is a definite possibility.   
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A. baumanii infections are typically associated with already highly 
immunocompromised hospitalised patients in intensive care, surgical patients, or 
those exposed to contaminated medical devices (Kumburu et al., 2019).  As a 
predominantly nosocomial infection, MDR strains are even more deadly to these 
groups, especially if general hygiene procedures are not followed.  It is also 
naturally competent, readily taking up exogenous DNA, increasing the likelihood 
of novel virulence or resistance mechanisms, of which β-lactamases are the most 
common mechanism to date (Lee et al., 2017)   
A. baumannii resists carbapenems through a class of enzymes termed oxacillin-
hydrolysing, or “OXA”, primarily through OXA-23, OXA-40, and OXA-58  though 
many other OXA-variants exist; the number refers to the order in which they 
were discovered and not any specific similarity (Evans & Amyes, 2014).  
Carbapenemases have significant structural homology with oxacillinases, so are 
classed as a subset of oxacillinase.  Despite this, A. baumannii carbapenemases 
are technically inefficient at hydrolysing oxacillins (Santillana et al., 2007). 
MDR genes and cassettes are known to spread throughout the ESKAPE 
pathogens – for example, between Pseudomonas aeruginosa and A. baumanii 
(DaSilva & Domingues, 2016) – increasing the dangers of widespread AMR. 
1.2.2.2 Factors Contributing to Widespread AMR 
 
The rise of AMR is intrinsically linked to the misuse of antibiotics over a range of 
issues, with each country having its own set of issues that ultimately make AMR 
a global problem.  These can be a complex mixture of unnecessary prescriptions 
or over the counter antibiotic purchases, large volume usage in agriculture, 
failure to complete a course of medication, and waste drugs leaching into the 
environment.  Examples of some of these are given below, but not all the 
literature is necessarily negative: Finland lowered the incidence of erythromycin 
resistant Streptococcus pyogenes infections from 9.2% to 7.5% over 1997 to 
2000 with a decrease in overall macrolide consumption (Bergman et al., 2004), 
so positive change is realistic.  
 Adopting a One Health approach using combined policy across multiple areas is 
an essential strategy (Zinsstag et al., 2011), of which new antibiotics are a vital 
part.  Antimicrobial stewardship in medicine is often the focus of public 
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engagement or prescription regulation efforts, but medical uses are not the main 
usage of antibiotics in the US.  An estimated 70% of antibiotics are bought by 
the agricultural sector as preventatives to promote growth (O’Neill, 2016).  In 
1996, with just streptomycin and oxytetracycline, this amounted to 136,000 kg 
of antibiotic (Fair & Tor, 2014).  This further leaches into the soil, expanding the 
microbial resistome beyond the already present AMR-genes.   
The implications of unnecessary prescriptions and over the counter purchases 
can be illustrated by examples from the United States and South Asia.  Each year 
in the US, 40 million people are diagnosed with respiratory diseases.  Of those, 
27 million are given antibiotics unnecessarily (O’Neill, 2016), either selecting for 
multidrug resistant (MDR) strains within the patient’s microbiome or in nearby 
waterways as they are discarded; this is at least a decrease from 34 million 
inappropriate antibiotic prescriptions in 2010-11 (Fleming-Dutra et al., 2016).  
More broadly, across all emergency care visits, Fleming-Dutra et al. (2016) 
estimate that up to 30% of oral antibiotics were incorrectly prescribed, totalling 
46 million cases, likely contributing to the 23,000 deaths a year in the US due to 
MDR pathogens. 
Many countries in South Asia have minimal regulation on access to antibiotics, 
leading to it becoming a reservoir for MDR strains.  Chung The et al. (2016) 
studied the prevalence of resistance to ciprofloxacin in treatment of infections by 
Shigella sonnei, which causes diarrhoea through damaging the gastrointestinal 
mucosa.  They found an MDR strain of S. sonnei distinct from other resistant 
strains which had achieved global dominance over other strains.  This was clearly 
linked to rates of over the counter purchasing of antibiotics from pharmacies in 
south Asia: Nepal & Bhatta (2018) show that ciprofloxacin was the most 
frequently purchased fluoroquinolone in South East Asian pharmacies, and is 
used by over 40% of the self-medicating population.  
In contrast, rates in Europe range from 1% to 4%, partially due to stricter 
restrictions on what pharmacies can sell. While rates may vary between 
countries, the global nature of travel means that AMR genes can easily be spread 
across the world.  ESBL-containing Enterobacteriaceae are often found in popular 
tourist areas, with up to 67% of visitors to Southeast Asia and 88% to India 
becoming colonised (if not infected) by these strains (Frost et al., 2019).  
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Fortunately colonisation is not permanent and will often disappear after 3 months 
(Arcilla et al., 2017), but this may be long enough for a hospital or other 
vulnerable community outbreak or to transfer new resistance genes to the 
established microbiota. 
The prevalence of resistance genes in the environment has been illustrated by 
multiple studies.  An examination of 480 soil strains by D’Costa et al. (2006) 
found widespread resistance genes for a set of 11 clinically important natural and 
synthetic antibiotics.  Daptomycin resistance was the most common, with 100% 
of the strains being resistant and 80% of a further screen of 80 strains able to 
inactivate daptomycin on top of their resistance to it.  Resistance was not only 
found to natural antibiotics, as 294 of the 480 were resistant to synercid, a 
semisynthetic combination of two Streptomyces metabolites which target 
different sections of the 50S ribosomal subunit.   
Wastewater treatment plants are common reservoirs for AMR as they provide a 
link between human antibiotic waste in the influent and the wider environment in 
the effluent, facilitating the dispersal of resistant strains (Marti et al., 2013).  
Marti et al. (2013) studied one plant on the Ter river in Spain, recording 
antibiotic concentrations and AMR gene prevalence upstream and downstream of 
the plant.  Their results showed 0.91 µg/ml of ciprofloxacin and 0.18 µg/ml 
clarithromycin in the influent, down to 0.23 µg/ml ciprofloxacin and 0.16 µg/ml 
clarithromycin in the effluent.  Comparing AMR gene levels in biofilms upstream 
and downstream of the plant showed lower levels of the β-lactamase genes 
blaTEM and blaSHV downstream of the plant, with minimal effect on AMR gene 
prevalence in sediment.    
Chen et al. (2018) studied the prevalence of AMR genes in response to β-lactam 
and aminoglycoside overusage in Chinese aquaculture.  The majority of 
resistance genes – 77% – were for resistance against a single class of antibiotics, 
but approximately 85% of resistance plasmids included at least 3 types of AMR 
genes, resulting in strains resistant to multiple antibiotic classes.  Since 
aquaculture farm dosages can use multiple classes of antibiotics at a time, this 
likely contributes to the formation of multidrug resistance cassettes on single 
plasmids. 
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A solution to AMR will have to involve both the healthcare and industrial sectors.  
Initiatives to increase good antimicrobial stewardship across hospitals, nursing 
homes (Barlam et al., 2016) and pharmacies (Wickens et al., 2013) are of 
undeniable importance, but do not help develop new therapies. Although there 
was initial substantial financial investment into antimicrobial SMet discovery, 
much of this lessened following the decrease in discovery rates (Woodruff, 
2014).  Though the global market for antibiotic sales is $40 billion/year, $35.3 
billion is from unpatented antibiotics (O’Neill, 2016), removing much incentive 
for investing in early stage discovery of novel unique metabolites.   
New antibiotics are clearly needed to help combat AMR.  Streptomyces, and 
other Actinomycetales genera, are the most prolific producers of antimicrobial 
SMet, with a wide variety of biosynthetic mechanisms.  Understanding which 
Streptomyces characteristics contribute to its SMet-producing capabilities is 
essential for the discovery of novel SMet and the development of new therapies.  
1.3 Streptomyces and specialised metabolism 
 
1.3.1 Characteristic Streptomyces biology 
 
The family Streptomycetaceae was proposed by Waksman & Henrici (1943) 
originally containing two genera, Streptomyces and Micromonospora.  
Streptomyces are Gram-positive filamentous microbes, typically with a mycelia 
diameter of 0.7 µm (Manteca, Fernandez, et al., 2005).  Streptomyces spp. are 
primarily known for their SMet production and chemotherapeutic potential, but 
this is underpinned by a variety of biological traits rarely found in other bacteria, 
such as multicellularity, morphological differentiation, and even cannibalism 
through programmed cell death (PCD) (González-Pastor et al., 2003; Manteca, 
Fernandez, et al., 2005; van Dissel et al., 2014).  These characteristics, and 
some of their relevance to SMet, are summarised in Table 1.2.  
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Table 1.2 Streptomyces characteristics and their contribution to SMet. 
Streptomyces 
characteristic 
Contribution to SMet Reference 
Large genome size 
 
Genome usually 8 to 12 MB, 
provides raw material for SMet 
evolution 
 
Harrison & 
Studholme 
(2014) 
Linear genome Core stable region flanked by 
genetically diverse arms which 
contain most SMet genes 
 
van Keulen 
(2014) 
Multicellular  Different cells produce different 
compounds within one colony 
 
Yagüe et al. 
(2012) 
 
Multistage differentiation SM production varies through 
stages, so culture metabolome 
varies over time 
Yagüe et al. 
(2012) 
Niche diversity Different niches select for 
production of different metabolites 
Rateb et al. 
(2011); Niu 
et al. 
(2016) 
 
Some of these characteristics are shared with other Actinomycetales genera such 
as Nocardia, Micromonospora or Amycolatopsis, which are also known for their 
SMet (Tanaka et al., 2013; Barka et al., 2016; Holmes et al., 2016).  However, 
as stated, historically Streptomyces have been identified as the most prolific 
producers of SMet.  While this may be due to their relative overabundance from 
environmental isolates (Tiwari & Gupta, 2013), screening over 700 
Actinomycetales genomes for their BGC content showed Streptomyces to have 
the largest amount of BGCs/genome at a mean of 21.6 BGCs (Doroghazi et al., 
2014).  Therefore, within Actinomycetales, Streptomyces retains the most 
potential for antibiotic discovery projects. 
While characteristic of Streptomyces, the individual traits are not necessarily 
relevant for SMet.  A linear genome is not a predictor of bioactive metabolite 
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production, as the Gram-negative order Myxococcales contains multiple SMet 
producers – notably Sorangium cellulosum and Myxococcus spp. (Gerth et al., 
2003) – which have a conventional circular genome (Garcia et al., 2009).  The 
shared traits between the two orders (multicellular, predominantly soil dwelling, 
multistage differentiation, large GC rich genome) do reinforce that the other 
characteristics are important for SMet producers (Zaburannyi et al., 2016).  The 
linear architecture may be important within the phylum Actinobacteria: essential 
primary metabolism gene synteny exists across both SMet producers and non-
producers, such as the pathogen M. tuberculosis, and so the genomic 
architecture could potentially lead to more rapid BGC evolution on the genome 
terminal regions (Hopwood, 2006).  
The list of characteristics most relevant to SMet production are multicellularity, 
multistage differentiation, and niche variety, since all of those will require 
different compounds by necessity to cope with extreme growth conditions.  Niche 
variety is not an essential part of the Streptomyces lifecycle.  The ability to 
quickly mutate and evolve novel chemistry aids Streptomyces survival in a range 
of standard soil to extreme environments (Pathom-aree et al., 2006; Rateb et 
al., 2011; Terra et al., 2018), but is more a consequence of its characteristics 
not a reason for its SMet variety.  In contrast, differentiation expands SMet 
production by requiring a different set of SMet at each lifecycle stage, and 
multicellularity enables differential expression of SMet over different cells.  As 
these characteristics are more closely linked to SMet production, they will be 
focused on in the next section. 
1.3.2 Streptomyces lifecycle 
 
1.3.2.1 Lifecycle on solid media  
 
The majority of work on Streptomyces lifecycle and differentiation has been 
achieved on solid agar media.  This is outlined in Figure 1.10, and is broadly 
defined by 4 main stages: spore gemination, growth of primary 
compartmentalised mycelium (“MI”) through the substrate, multinucleate 
secondary compartmentalised mycelium (“MII”) which are the main SMet 
producers, and spore formation (Yagüe et al., 2012).   
 31 
 
After contact with a suitable location with enough resources to fuel germination, 
a spore sends out a germ tube, potentially 1 from each tip of the spore (Čihák et 
al., 2017).  The tube grows by tip extension, incorporating peptidoglycan into the 
apex (Sigle et al., 2016), eventually forming branches and becoming the 
substrate MI hyphae (Bush et al., 2015).  
The MI hyphae forms cross-membranes producing compartments approximately 
1 µm wide, giving an early uninucleate MI hyphae which is more frequently 
protoplasmic than later stages (Yagüe et al., 2016).  A round of PCD then occurs, 
producing a variegated dead/alive sequence of cells along the hyphae with the 
dead cells acting as fuel for the remaining viable segments to transition to 
multinucleate MII hyphae (Manteca, Fernandez, et al., 2005).   
The MII hyphae are the main producer of SMet.  Transcriptomic analysis of S. 
coelicolor A3(2) MI and MII phases showed a distinct correlation of SMet 
transcripts to MII.  Transcripts for the blue pigment actinorhodin (ACT), 
undecylprodigiosin (RED), calcium dependent antibiotic, geosmin, and the cryptic 
polyketide cpk were all associated with the MII hyphae (Yagüe et al., 2013).  
This stage can be further separated into two sub-categories: the early substrate 
MII, which lacks a hydrophobic layer, and the late aerial hyphae, which 
expresses the hydrophobic rodlins and chaplins (Manteca et al., 2007).  The 8 
chaplins (ChpA – H) form amyloid-like fibrils woven into the cell walls, which are 
sorted into the mature rodlet layer by rodlins RdlA and B, both of which are 
necessary to fully complete the lifecycle (Claessen et al., 2004).  Production of 
these, and the aerial hyphae, is fuelled by a 2nd round of PCD, after which the 
multigenomic aerial hyphae is compartmentalised into unigenomic pre-spores 
(Yagüe et al., 2013).   
After maturation, the spores are spread by an external force to other suitable 
media, where the cycle restarts.  In case an appropriate location is not 
immediately available, the spores are able to go into a dormant state with low to 
no levels of metabolic activity (Bobek et al., 2017) until conditions are more 
favourable for successful germination.  Spore germination may not totally 
depend on external forces like nutrition levels as levels of the cell wall protein 
NepA can also affect germination levels.  De Jong et al. (2009) knocked out the 
gene for this putative dormancy regulator increasing germination from 6% to 
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19% of total spores after 3 h, reaching 100% germination 4 h before the wild 
type (10 h against 14 h).  Spores also contain elevated levels of the sugar 
trehalose, which makes up to 25% of the dry weight of S. griseus spores 
(McBride & Ensign, 1987) and is potentially used as an initial energy source in 
suboptimal conditions.   
In total, Streptomyces undergo a hugely complex set of multicellular 
differentiation and programmed cell death processes, though it is unclear if these 
are actually necessary for its SMet productivity.  One potential solution is the 
tradeoff in resources required between maintaining biomass and SMet 
production.  If sporulation occurs too early in a strategy to escape adverse 
conditions, less total biomass may be produced resulting in the strain being 
outcompeted anyway; on the other hand, overproducing SMet to defend its 
resources may not leave enough for sporulation.   
PCD could allow relative overproduction and defence, followed by PCD to free up 
more resources for sporulation.  This is reinforced by Streptomyces moving 
relatively slowly compared to other species, except in rare cases (Jones et al., 
2017), which limits its access to nutrients.  Preventing other organisms from 
using the available resources is therefore more important, hence why 
overproduction of antimicrobials is desirable.  While uncommon across known 
prokaryotes, PCD has been recorded in other soil species.  Once stressful 
conditions trigger sporulation, a Bacillus subtilis cell will secrete sporulation-
blocking metabolites to block development of other B. subtilis cells around it, 
eventually lysing them to use the additional nutrients to fuel sporulation 
(González-Pastor et al., 2003).   
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Figure 1.10 Streptomyces lifecyle showing main stages of differentiation on agar: germination, MI and MII PCD, aerial 
hyphae and sporulation.   
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1.3.2.2 Genetic regulation of morphology and metabolism 
 
Expression of SMet by Streptomyces is tightly regulated and can correlate with 
morphological development.  Most of the research into Streptomyces lifecycle 
and genetics has been done using the model species S. coelicolor A3(2), from 
which 2 main mutant phenotypes have been generated: bald mutants, which lack 
aerial hyphae and affect the bld genes, and white mutants, which affect the whi 
gene family and cannot produce mature spores (Yagüe et al., 2012; Hackl & 
Bechthold, 2015).  Each of these S. coelicolor A3(2) mutant types has different 
specialised metabolomes, reflecting different stages of morphological 
development.  Both gene families are also known to code for sigma factors which 
redirect RNA polymerase to specific genes, or act as pleiotropic and specific 
regulators of SMet (Manteca et al., 2010; Bush et al., 2015). 
Both whi and bld genes are conserved in all known Streptomyces as of 2015 
(Kim et al., 2015). Therefore, results obtained with S. coelicolor A3(2) are 
unlikely to be limited to just S. coelicolor A3(2), so examples of mutants will be 
given for both genes.  
 
1.3.2.3 Effect of whi mutants on specialised metabolism 
 
Mutagenesis of whiA forces hyphae to take a tightly coiled spring-like form 
lacking the characteristic grey polyketide SMet associated with S. coelicolor 
A3(2) mature spores.  Normally, wild-type spores are compartmentalised into 1 
μm segments by septa which split the multigenomic aerial hyphae into 
unigenomic spores (Sigle et al., 2016).  These septa are not seen in whiA 
mutants, producing hyphae longer than in the wild-type at 100 μm long (Findlay 
et al., 1999).  Similar phenotypes are seen from other whi mutants (whiG, whiB, 
whiH), all unpigmented, and varying in the intensity of hyphal coiling and septa 
loss. 
Production of the grey pigment in S. coelicolor A3(2) is controlled by whiE 
(Kelemen et al., 1998).  This gene is conserved in other Streptomyces, though 
the pigment colour can vary – S. halstedii mature spores are green, not grey.  
whiE is under the regulation of multiple other genes and their products.  One of 
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these is sigF, which codes for the sigma factor σF (Kelemen et al., 1998).  
Negative sigF mutants are not totally devoid of pigment, as some parts of the 
whi cluster remain active, specifically the whiEP1 promoter.  whiEP2 is made 
inactive, preventing expression of whiE-ORFVII which results in a brown spore 
pigment.  σF therefore likely regulates part of modification of the pigment’s 
chemical structure instead of its production.  Which genes are ultimately 
responsible for the full regulation of whiE is unknown, as well as the ecological 
function of the pigment (Salerno et al., 2013).  One suggestion by Chater et al. 
(2010) is that it provides protection against a range of stresses, whether abiotic 
like heat and radiation, or biological ones like digestive enzymes from predatory 
microbes. 
 
1.3.2.4 Effect of bld mutants on specialised metabolism  
 
bld mutants are affected earlier in the morphological cycle than whi, so it could 
be assumed that the effect on SMet would be more inhibitory.  This is the case 
for the bldD global regulator, which if mutagenised, pleiotropically affects SMet 
such that none of the characteristic antibiotics expected to be produced by S. 
coliecolor A3(2) are detected (Elliot et al., 2003).  As a global regulator, bldD 
affects the expression of many genes: its product, the 18 kDa DNA binding 
protein BldD, was found to control around 170 transcriptional genes (den Hengst 
et al., 2010).   
Within those, 42 genes coded for DNA-binding regulators, with known targets 
including genes for morphological differentiation and antibiotic production.  These 
included cvn9 – ACT regulation - and nsdA.  In the wild type, BldD binds 
upstream of nsdA, preventing it from being transcribed.  If nsdA is knocked out 
then S. coelicolor displays increased sporulation and overproduction of ACT and 2 
other antibiotics, methylenomycin and the Calcium Dependent Antibiotic (Li et 
al., 2006).  One other gene found to be controlled by BldD was bldC, which codes 
for a DNA binding protein which also controls morphology and production of ACT 
(Hunt et al., 2005). 
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1.3.2.5 Differentiation in liquid media and soils 
 
A broth lifecycle is not discussed in detail as, unlike on agar, most species do not 
undergo full multicellular differentiation in broth culture (Yagüe et al., 2013; 
Manteca & Yagüe, 2018).  The MI hyphae do differentiate to MII as evidenced by 
PCD and SMet production at the centre of bacterial pellets.  Examples of these 
dense pellets with central SMet production after 72 h in S. costaricanus (pellet 
diameter approximately 0.1 mm) are shown in Figure 1.11.  There are 
exceptions, notably S. venezuelae which does fully sporulate in liquid media, but 
the majority of species do not display the full lifecycle occurring on agar 
(Glazebrook et al., 1990). 
 
 
 
 
 
 
 
 
 
 
Less work has also been done on Streptomyces development in more soil-like, or 
natural, conditions.  The literature indicates that the MI hyphae are the dominant 
hyphal type, unlike in the lab where MII hyphae lasts the longest, and no 
sporulation was seen after 30 days (Manteca & Sanchez, 2009).  As no PCD nor 
sporulation was observed, it is possible that other nutritional or biological stimuli 
are needed to induce these in the wild.   
(a) 
Figure 1.11 (a) S. costaricanus 1 L culture at 72 h displaying pellet formation 
and (b, c, d) pigment production within pellets at 40x magnification. 
(b) (c) (d) 
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The slow growth would also make this unsuitable for a generalised SMet 
discovery project unless genetic modification of natural condition-specific SMet 
genes was incorporated.  Many methods exist for SMet discovery and choosing 
the correct one for a project is essential to its success. 
1.4 Antimicrobial discovery using Streptomyces 
 
1.4.1 Production potential of unexploited Streptomyces 
 
As the golden age of antibiotic discovery ended and synthetic drug libraries 
began to receive more attention, it was assumed that most Streptomyces 
metabolites had already been discovered.  It had been known for many decades 
that culture parameters affect SMet production (Waksman & Tishler, 1941; 
Schatz et al., 1944), but there was no evidence to suggest that Streptomyces 
was definitively able to produce other undiscovered antibiotics.  This changed 
with the full genome sequence of S. coelicolor A3(2), which showed many more 
potential antibiotic BGCs within the genome than had been seen in the lab 
(Bentley et al., 2002); the same proved to be true for other Streptomyces, with 
typically about 30 BGCs in total (Baltz, 2016).  The vast majority of these BGCs 
are either unexpressed or weakly expressed in the lab, and so termed “cryptic” 
or “silent” BGCs (Moore et al., 2012).  Finding the right conditions to elicit 
expression of all of these BGCs is crucial for microbial drug discovery.  
This means that all the previously examined Streptomyces used in the initial 
surge of research, plus all those isolated since, have huge unexploited potential 
to contribute novel bioactive compounds and scaffolds in the fight against AMR.  
Following their initial analysis, these predominantly soil Streptomyces, 
Actinomycetales and other microbes have been deposited in culture collections.  
This corresponds to a huge amount of potential metabolomic diversity in a 
regulated and accessible collection.  Therefore, the simplest way to access a 
huge amount of niche diversity and the corresponding chemical space is to use 
the less researched strains in culture collections.  One collection is NCIMB Ltd., 
which contains approximately 500 strains of Streptomyces in its collection 
(NCIMB Ltd, 2017). 
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1.4.2 Strategies to discover new metabolites from Streptomyces 
 
There is a huge diversity of potential methods in SMet discovery from 
Streptomyces, each suited to specific projects.  The major ones are listed below 
in Table 1.3 (genetic methods) and Table 1.4 (culture dependent).  Other 
methods do exist, such as engineering the biosynthetic machinery by mutating 
the ribosome and RNA Polymerase (Ochi et al., 2004; Shentu et al., 2016), but 
this is arguably more suited to product optimisation (Kawai et al., 2007; Wang et 
al., 2008) than discovery so will not be discussed further.  Metagenomic methods 
are also not included although they are valuable for discovering novel BGCs 
without having to rely on culture (Reen et al., 2015) as this is unsuited to a 
culture collection based project. 
Table 1.3 Genetic manipulation strategies for metabolite discovery, primarily in 
Streptomyces. 
Method Advantages Disadvantages Source 
Alters a BGC’s 
regulatory 
elements to 
control expression 
 
Single product with 
known regulation 
Identification of 
regulatory elements 
needed, just one 
product 
Bunet et 
al. 
(2011); 
Luo et al. 
(2013) 
Modifies 
pleiotropic 
regulators to 
affect multiple 
BGCs 
Expression of 
multiple BGCs using 
genus-conserved 
regulators 
Relies on known 
regulators, little 
predictive ability 
McKenzie 
et al. 
(2010); 
Becerril et 
al. (2018) 
Links BGC to a 
reporter, 
indicating 
activation 
Simplifies 
detection, high-
throughput 
mutagenesis 
BGC/reporter may 
not combine properly 
Guo et al. 
(2015); 
Xiang et 
al. (2009)  
Cloning and 
heterologous 
expression of 
specific BGC 
Chosen production 
host, simplifies 
detection 
BGC may not clone 
and express, size 
limits 
Lin et al.  
(2006); 
Jiang et 
al. (2012) 
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Table 1.4 Culture dependent strategies for metabolite discovery, primarily in 
Streptomyces. 
Method Advantages Disadvantages Source 
Pleiotropic 
regulation via 
altering nutrition  
Applicable to all 
species, many 
growth conditions 
No predictive power, 
complex results 
Bode et al.  
(2002); Rateb 
et al. (2011) 
Trigger BGC 
production with 
stringent 
response 
Variety of 
stresses, 
applicable to all 
species 
May damage 
organism too much, 
little initial predictive 
power 
Sevcikova  et 
al.  (2004); 
Jakeman et al. 
(2006) 
Co-culture to elicit 
ecology-based 
reactions to 
invasion or 
mutualism  
Potentially specific 
activity against 
eliciting microbe, 
can use co-
isolated strains 
Other microbes may 
increase extract 
complexity or have 
no effect on SMet 
production  
Onaka  et al.  
(2011); Shin et 
al. (2018) 
 
As the Streptomyces strains used will be previously underexploited, they are 
unlikely to have any significant genetic manipulation tools developed nor a full 
genome sequence to identify BGCs. This makes the genetic tools initially 
unsuitable, though a full genome sequence is desirable to combine SMet 
genomics and metabolomics. This leaves the culture dependent methods, which 
are more applicable to a library of ecologically diverse strains, with the potential 
to elicit a different set of SMet with each culture condition.   
This set of methods is typified through the One Strain Many Compounds method 
or OSMAC, briefly mentioned in section 1.1.2.2.  Varying culture parameters has 
long been known to produce different levels of SMet as evidenced by its usage in 
early optimisation of actinomycin, and it was not fully codified as a method for 
cryptic BGC activation until Bode et al. (2002).  The authors identified 20 SMet 
from a single strain, covering many types of chemical scaffolds and natural 
product class. Different culture conditions included temperature, pH, type of 
vessel, oxygenation, pressure, and minerals; ideally, being able to mimic the 
ecological conditions a strain was isolated from would be a good application of 
OSMAC to identify any ecological cues that drive SMet production.  Of these 
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conditions, changing the nutrients in media is the easiest with potentially 
pleiotropic effects (Rateb et al., 2011), and avoids the complications of co-
culture. 
1.4.2.1 Carbon source regulation of specialised metabolism 
 
The simplest way to vary culture conditions is through the carbon and nitrogen 
sources.  Carbon catabolite repression (CCR) is a well-studied feature of SMet, 
where one carbon source can lead to repression of some BGCs and expression of 
others until that carbon source has been exhausted (Romero-Rodríguez et al., 
2016).  Glucose is normally repressive, since it is an excellent energy source 
which indicates that nutrient levels are high, making spending resources on SMet 
an uncompetitive strategy as any bioactive compounds may be unable to repress 
growth levels of other microbes while restricting growth of the producer (Ruiz et 
al., 2010).  Other less preferred carbon sources will, since they are not as 
immediately energetically rich, be either neutral or upregulate expression 
(Sánchez et al., 2010). 
As one example, wild-type S. lividans is known to contain the BGC for ACT but 
does not normally express it under standard lab conditions (Kim et al., 2001).  
Both rich and minimal glucose containing media do not allow production of ACT 
but using glycerol as a carbon source induced expression through upregulation of 
afsR2 mRNA.  Its product, AfsR2, is a pleiotropic regulator of specialised 
metabolism through its upregulation of the enzyme guanosine pentaphosphate 
synthetase/polyribonucleotide nucleotidyltransferase, which is involved in the 
synthesis of the alarmone (p)ppGpp (Kim et al., 2005).  (p)ppGpp is partially 
responsible for stress response in bacteria, and correlates with the induction of 
SMet and differentiation (Hesketh et al., 2007; Wang et al., 2008). 
SMet can also be upregulated through the addition of the carbon and nitrogen 
source N-acetyl glucosamine (GlcNAc), though this depends on whether it is 
added to rich or poor media (Rigali et al., 2008).  As a component of both 
bacterial and fungal cell walls (Konopka, 2012), its presence can indicate either 
breakdown of neighbouring hyphae and other microbes, or fungi invading the 
Streptomyces’ space.  Both of these are hostile conditions, but under rich media, 
GLcNAc represses SMet; under growth on poor media, SMet production is 
pleiotropically upregulated.   
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GlcNAc is transported into the cell via the sugar transferase system, which also 
phosphorylates it to GlcNAc-6-P.  This is then acetylated by NagA to 
glucosamine-6-P (Rigali et al., 2008), which is an allosteric effector of DasR, a 
global regulator.  The binding of glucosamine-6-P to DasR releases it from the 
DNA, where it is located upstream of multiple antibiotic-linked genes.  In S. 
coelicolor A3(2), expression of actII-ORF4 and redZ, which are involved in ACT 
and RED synthesis, are upregulated (Rigali et al., 2008).   The difference with 
rich media is thought to stem from the origin of GlcNAc, since it can be both from 
fungal (chitin degradation) or bacterial (peptidoglycan degradation) cells.  It is 
suggested by Rigali et al. (2008) that under “feast” conditions where external 
chitin is abundant and useful as a food source, this implies sufficient external 
nutrients to continue growth without needing to produce SMet.  Under “famine” 
conditions where cell wall hydrolysis is taking place, conditions are more 
stressful, so SMet production is upregulated.   
The full mechanism of CCR is not fully known (Romero-Rodríguez et al., 2016) 
across the genus, likely differing between species and carbon sources.  In S. 
coelicolor A3(2), high levels of glucose represses at transcription enzymes for the 
alternate carbon sources galactose, fructose, arabinose and glycerol (Hodgson, 
1982), potentially mediated through glucose kinase which converts glucose to 
glucose-6-phosphage.  Glucose kinase mutants do not show glucose catabolite 
repression (McCormick & Flärdh, 2012), indicating an essential part in CCR, but 
the mechanism is also unknown.  Glucose kinase does not contain a DNA binding 
region, so may interact with other regulators for its effects like AfsR2 (Liu et al., 
2013). 
1.4.2.2 Phosphate and nitrogen regulation of specialised 
metabolism 
 
Phosphate availability is monitored through the two-component system PhoR-
PhoP.  PhoR, a histidine kinase, is triggered by a lack of phosphate to 
phosphorylate PhoP (Santos-Beneit et al., 2009; van Wezel & McDowall, 2011).  
PhoR is normally prevented from phosophorylating PhoP by the Pst phosphate 
transport system, which under phosphate rich conditions is bound to PhoP (van 
Wezel & McDowall, 2011).  The phosphorylated PhoP then binds to areas of DNA 
known as PHO boxes, regulating transcription of those regions.  High phosphate 
 42 
 
is known to reduce production of many antibiotics, including jadomycin B in S. 
venezuelae, rapamycin in S. hygroscopicus, and nikkomycin in S. tendae (Hege-
Treskatis et al., 1992; Cheng et al., 1995; Jakeman et al., 2006).  Phosphate 
limitation is therefore an important part of regulating SMet across Streptomyces. 
Similar to carbon source regulation, any nitrogen source which is too effective at 
promoting growth is likely to repress SMet production since it will not promote a 
stress response.  A well characterised nitrogen-reliant regulatory mechanism is 
the AfsQ two-component system, which is comprised of AfsQ1 and AfsQ2 (R 
Wang et al., 2013).  Upon growth in glutamate-containing media, the membrane 
bound AfsQ2 phosphorylates AfsQ1 which is then able to perform a variety of 
functions, including upregulation of antibiotic genes when bound to a conserved 
pair of 5 base pair sequences separated by a 6 base pair interval.  The exact 
mechanism which triggers AsfQ2 to phosphorylate AsfQ1 in the presence of 
glucose is still unclear (Liu et al., 2013).Upregulated antibiotic genes include 
actII-ORF4, redZ and cdaR, the last of which is involved in calcium dependent 
antibiotic synthesis.   
AsfQ1 shares binding sites with the nitrogen regulator GlnR (R Wang et al., 
2013).  The GlnR regulon includes at least 15 genes, mostly for enzymes, which 
facilitate nitrogen uptake and alternative source usage.  Chromatin 
immunoprecipitation-microarray analysis (ChIP-chip) showed 36 GlnR binding 
sites, mostly upstream of other genes involved in nitrogen metabolism (He et al., 
2016).  GlnR not only affects SMet by regulating primary metabolic precursors, 
but in some cases regulates SMet directly though fewer examples are known.  
The gene jadR1, part of the jadomycin BGC in S. venezuelae, contains a GlnR 
binding site predicted to activate transcription of the gene; GlnR was also found 
to bind to the commonly assayed ACT and RED activator genes actII-ORF4 and 
redZ (He et al., 2016).   
1.4.2.3 Stressors and elicitors 
 
Nutrient variety is not the only abiotic factor Streptomyces must respond to, as 
all environments will present fluctuations in salinity, pH (Jiang et al., 2018), 
metals (Morgenstern et al., 2015), temperature, antibiotics from other microbes, 
and other challenges.  These, and the survival responses Streptomyces exhibit, 
can function as signals which lead to the expression of cryptic BGCs that require 
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specific ecological conditions.  This can lead to unexpected new functions for the 
signalling molecule, such as sub-inhibitory levels of antibiotics acting as 
transcriptional triggers of otherwise cryptic BGCs (Yim et al., 2006).   
This method has the advantage of being very easy to carry out: the addition of 
3% dimethyl sulfoxide to media increased production of chloramphenicol and 
tetracenomycin C in S. venezuelae, and thiostrepton from S. azureus (Chen et 
al., 2000).  As these are all different classes of metabolite, this implies a global 
method of action for solvent-based induction, likely as a result of triggering the 
stringent response and increasing chaperone activity to protect from the 
denaturing effects of DMSO (Yoon & Nodwell, 2014).  However, this approach is 
wholly reliant on luck so should not be the sole strategy.   
Jadomycin B is also upregulated by adding a solvent, in this case 6% ethanol, 
but also through heat shock.  Doull et al. (1993) found that raising the culture 
temperature from 27°C to 42°C increased jadomycin B from essentially 0 to 25 
μg/ml.  The jadomycin B BGC contains 2 well characterised pathway transcription 
factors, the activator jadR1 and repressor jadR2, which negatively regulates 
jadR1 through its product JadR2 (Yoon & Nodwell, 2014).  Exactly how heat 
shock upregulates SMet in Streptomyces in general is unclear.  It has been 
suggested that the chaperone DnaK, which would normally stabilise binding of 
the transcription factor HspR, would be removed by increased numbers of 
misfolded proteins after heat shock and allow HspR to initiate transcription of its 
target genes (Bucca et al., 1997; Yoon & Nodwell, 2014).  Unfortunately, there is 
no HspR recognition site in the jadomycin BGC, nor in another ethanol and heat 
shock activated BGC, validamycin A (Liao et al., 2009). 
Cryptic BGCs have also been elicited in response to the rare earth metal 
scandium, usually as scandium chloride.  After initial proof of concept 
demonstration by upregulating ACT in S. coelicolor A3(2), scandium was found to 
increase expression of otherwise cryptic or very low expression clusters by 2.5 to 
12 fold (Kawai et al., 2007; Tanaka et al., 2010).  Similar to solvents, this is a 
simple method which is applicable to most strains but will require optimisation to 
avoid over or under stressing the culture.  Unfortunately, the mechanism by 
which scandium activates Streptomyces is not known, and there are few other 
examples in the literature despite it being suggested as generally applicable. 
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Antibiotics, as microbial products, can also elicit a reaction without harmful 
inhibitory effects.  The addition of lincomycin, produced by S. lincolnensis, to S. 
lividans culture resulted in multiple novel SMet which were not seen without 
lincomycin (Imai et al., 2015).  Levels of ACT, though not a cryptic BGC, were 
also increased in S. coelicolor by adding erythromycin.  Whether antibiotics are 
actually produced in large enough concentrations to kill other microbes in the 
soil, and if they function both as messengers and antibiotics, is unfortunately 
outside the scope of this thesis.  Despite that, this is a novel way to trigger SMet 
using an aspect of microbial ecology which could potentially be very effective 
when co-culturing microbes found from the same niche.  
There are further methods, such as epigenetic modification (Kumar et al., 2016) 
to allow RNA Polymerase access to the genome, salt shock (Kol et al., 2010), pH 
shock (Kontro et al., 2005; Jiang et al., 2018) and messenger molecules like γ-
Butyrolactones which both stimulate and inhibit a wide range of SMet (Demain, 
1998; Liu et al., 2013).  While the large number of culture-dependent methods 
does give a huge amount of choice when working with an unexploited 
Streptomyces, they are much less useful if the metabolomic output cannot be 
precisely examined.  Analytical natural product chemistry is a vital part of the 
drug discovery process, especially as samples have become faster to analyse in 
greater detail. 
1.4.3 Analytical chemistry enhances specialised metabolite 
discovery  
 
An ideal untargeted natural product metabolomics experiment will be able to 
immediately identify the known metabolites within an extract, assign putative 
structural analysis to unknowns, link together families of metabolites, and 
discard any irrelevant media ingredients.  While not possible yet, this is 
becoming more likely through more advanced ultra-high pressure liquid 
chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance 
technologies, which are the primary tools in microbial SMet analysis (Rao et al., 
2013; Wu et al., 2015; Wu et al., 2016; Covington et al., 2017).   
LC-MS is a combined technique, using polarity-based column separation to 
untangle the mix of compounds within a sample.  These sequentially elute into 
the mass spectrometer, where due to the separation they are ideally analysed 
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one at a time, producing an LC-MS chromatogram of all the metabolites within 
an extract (that were able to ionise).  The whole process can be separated into 3 
main blocks: extract preparation, chromatographic separation, and MS detection 
(Walker, 2013).  These must remain consistent in order to compare any new 
results against previous ones, and so obtain a proper metabolite profile.  An 
element of bias will be introduced based on the extraction, chromatography, and 
MS methods chosen so an experiment will not be truly untargeted (Krug & 
Müller, 2014), but this can be said for most analytical techniques.  
Analytical chemistry is arguably the key difference in a modern untargeted 
metabolomics project to the older OSMAC efforts, since it facilitates the 
important task of preventing work on already known compounds, or dereplication 
(Zhang, 2005).  If the aim is novel metabolites and an extract contains mostly 
known compounds then it can easily be discarded, and focus shifted to another 
culture condition or microbe.  While this was also possible through large 
databases of natural products, these often require a subscription or lack mass 
spectral data.  Recent attention has been on freely available mass spectral 
databases, designed to facilitate the metabolite discovery process in light of AMR 
challenges, increased computational power, and LC-MS advances.   
The primary LC-MS/MS database, Global Natural Products Social molecular 
networking (GNPS) uses both donated user data and larger scale government 
spectral databases to dereplicate samples.  While a metabolite not appearing in 
the database does not mean that it is novel, it can be used in combination with 
other tools to focus prioritisation efforts on specific extracts or metabolomic 
features.  
1.5 Thesis aim 
 
1.5.1 Biosynthetic potential of unexploited Streptomyces 
 
Streptomyces has been the main workhorse for drug discovery projects.  
Continued improvements in genomic and metabolomic analysis have highlighted 
the SMet variety that many Streptomyces strains can potentially produce, so 
long as the correct culture parameters are used.  Therefore, there is still much 
unexploited potential for Streptomyces to produce novel bioactive SMet, 
especially when selecting from a geographically and ecologically diverse culture 
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collection.  Using an OSMAC screen is a rapid method to access this potential and 
is applicable to any of the strains in the collection.   
SM diversity can be robustly assessed using UPLC-MS based metabolomics, as 
there are various bioinformatics tools which allow comparison of large 
metabolomics data sets to explore the variety within them.  This can be used to 
choose scale-up conditions, link metabolites to specific elicitors, and calculate 
concentration of a metabolite.  The combination of OSMAC and UPLC-MS should 
therefore provide information on the pleiotropic regulation of SMet, single 
elicitor-SMet links, and initial structural determination through mass spectra.  
1.5.2 Selection of target for bioactivity assays 
 
Despite the surge in Gram-negative AMR, as of 2017 only 31% of drugs in 
development are active against the Gram-negative ESKAPE pathogens, and 
many of these will not necessarily be active against the most resistant strains 
identified by the WHO (Simpkin et al., 2017).   Resolving this will need urgent 
widespread action on fundamental research combating the critical priority 
pathogens through multiple strategies, one of which is novel antibiotics.   A 
recent assessment of the antibiotic pipeline found only 1 ongoing clinical trial 
against MDR A. baumannii (Hesterkamp, 2016).  Therefore, A. baumannii and 
potentially the other ESKAPE Gram-negatives are excellent initial targets.   
1.5.3 Primary aim 
 
The hypothesis of this thesis is that Streptomyces culture collections are an 
underexploited source of novel specialised metabolites.  The primary aim will 
therefore be to enhance specialised metabolite diversity by expanding the 
available chemical space from an underexploited Streptomyces strain, which can 
be used as a basis for bioactivity assays against A. baumannii.  This will be 
achieved through 4 main objectives.   
1) Development of a robust culture parameter-based screen to elicit 
production of multiple SMet, verified by testing on the model species S. 
coelicolor A3(2). 
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S. coelicolor A3(2) is the most widely researched Streptomyces strain for 
genomics and metabolomics studies (Bentley et al., 2002; Liu et al., 2013; 
Hoskisson & van Wezel, 2019).  Therefore, there is a correspondingly large 
amount of published literature on its SMet, aiding identification of any detected 
compounds and so validation of the screen for non-model strains. 
2) Application of the screen to underexploited Streptomyces strains to select 
a main strain and culture parameters. 
The majority within NCIMB are soil isolates, so these will be studied first and 
then compared with non-soil isolate strains to ensure rational selection of a final 
underexploited strain.  SMet identification will be more difficult than with S. 
coelicolor A3(2) due to the lack of published literature, but the usage of 
metabolomics software will aid separation of metabolites from media compounds. 
3) Full genome sequencing of the strain to determine its SMet biosynthetic 
potential. 
As an underexploited strain, there will likely not be a full genome sequence 
available at the start of the project.  Therefore, acquisition and analysis of a 
novel high-quality sequence will allow prediction of its BGCs and comparison to 
other Streptomyces strains. 
4) Culture scale-up, bioactivity assays and metabolite dereplication to inform 
isolation of bioactive SMet. 
The final objective will use the cumulative strain and media selection data to 
produce enough culture for fraction-based purification and bioactivity assays.  
This will enable focused analysis on specific fractions and ideally isolation of 
novel bioactive SMet. 
Together, these objectives link genomic and metabolomic data for a previously 
unexploited Streptomyces strain, developing a framework for the exploitation of 
further strains.   
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2 Metabolomic screening of S. coelicolor A3(2) 
 
2.1 Introduction 
 
2.1.1 Specialised metabolism of the model species S. coelicolor   
 
S. coelicolor A3(2) has been the most well studied species of Streptomyces, at 
least from a genetic perspective, for over 50 years (Kieser et al., 1992; Rutledge 
& Challis, 2015; Hoskisson & van Wezel, 2019).  This has contributed to its 
common use in the lab, eventually becoming the first Streptomyces to be fully 
sequenced (Bentley et al., 2002).  The specific strain sequenced was S. coelicolor 
A3(2) M145, which lacks the giant linear plasmid SCP1 and circular plasmid 
SCP2.   
S. coelicolor is taxonomically more closely related to S. violaceoruber ISP5049 
than the S. coelicolor Müller type strain.  The difference between the two S. 
coelicolor strains has been noted for over 50 years (Kutzner & Waksman, 1959), 
but the name S. coelicolor has been maintained due to its use as a model 
species.  Therefore, for this thesis, “S. coelicolor” refers to the model species S. 
coelicolor A3(2) and the type strain will be given as S. coelicolor Müller.   
Much of the research on S. coelicolor has focused on unravelling the genetics of 
differentiation, sporulation, and how these processes affect specialised 
metabolism (SMet).  Most Streptomyces will undergo the characteristic 
differentiation cycle of germination, vegetative growth, aerial hyphae production 
and ultimately sporulation in the lab.  These can be easily distinguished from 
each other and as such are used as markers to connect the effect of a gene to a 
developmental stage, which many Streptomyces species could be used for.  What 
has made S. coelicolor so widely used is its production of two main pigments: the 
blue actinorhodin (ACT) and red undecylprodigiosin (RED), which can be used as 
proxies for the effect a gene has on SMet. 
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2.1.1.1 Regulation of spore development and pigmentation by whi 
genes 
 
The whi genes, named for the deficient mutant’s white aerial hyphae colour, 
regulate both SMet and differentiation.  For example, if whiA is knocked out, S. 
coelicolor spores germinate, go through vegetative growth and produce aerial 
hyphae, indicating that standard cellular processes and programmed cell death 
are not affected (Findlay et al., 1999).  However, after developing aerial hyphae, 
whiA mutants do not further differentiate into spores at the hyphae tips.  
Instead, the hyphae take a tightly coiled spring-like form lacking the 
characteristic grey polyketide associated with S. coelicolor mature spores.  Wild-
type spores are separated by septa, splitting the unigenomic spores into 
approximately 1 μm segments (Sigle et al., 2016).  The whiA mutants generated 
by Findlay et al. (1999) lack septa, forming hyphae over 100 μm long if uncoiled.  
Other whi mutants (whiG, whiB, whiH) produced similarly white unpigmented 
phenotypes, varying in hyphal coiling intensity and septa numbers. 
The gene cluster directly responsible for “grey pigment” production in S. 
coelicolor is whiE (Kelemen et al., 1998), which is conserved in other 
Streptomyces even if the associated colour can change: S. halstedii produces a 
green spore pigment.  The genes are regulated by multiple other elements, with 
partial regulation by sigF and its sigma factor product σF (Kelemen et al., 1998).  
Knocking out sigF does not affect each gene within whiE, since the activity of the 
whiEP1 promoter is not altered, but whiEP2 is neutered.  This prevents 
expression of whiE-ORFVII, resulting in a brown spore pigment, indicating that 
σF regulates the pigment’s chemical structure rather than its whole production.  
The final structure of the pigment is not known, but the intermediate Tw95a has 
been characterised (van Keulen & Dyson, 2014) following heterologous 
expression of whiE and whiE-ORFIV to produce a functional PKS.  Its structure is 
shown in Figure 2.1. 
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The full regulation of whiE, and the actual function of the pigment, is unknown 
(Salerno et al., 2013).  Chater et al. (2010) speculate that the pigment is 
covalently linked to the cell wall to provide some level of stress protection, 
whether from abiotic factors like heat or radiation, or against predatory 
organisms and their digestive enzymes.  Similarly, decaying plant matter is a 
common food source for Streptomyces, but may end up consumed by animals 
like earthworms also eating the plants.  If the pigment provides some protection 
against digestion by one of the most numerous soil animals its genes will be 
heavily selected for (Chater & Chandra, 2006). 
2.1.1.2 Production of undecylprodigiosin is linked to increased 
cell death and sporulation in S. coelicolor 
 
The whi example shows how specialised metabolism and differentiation, in this 
case sporulation, are tightly linked in S. coelicolor.  Specialised metabolites and 
other stages of the lifecycle are similarly connected. One of the most well studied 
S. coelicolor compounds, RED, was found by Tenconi et al. (2018) to contribute 
to programmed cell death, a trait characteristic of complex multicellular species.  
Expression of redD, the corresponding BGC, was specifically found where cell 
lysis was occurring, potentially to prevent other microbes from taking advantage 
of free nutrients through cytotoxic activity of RED.  Removing redD reduces cell 
OH
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OH
OHOH
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O
O
HO
Figure 2.1 Structure of the grey spore pigment intermediate Tw95a. 
C24H18O9 
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death, and so lessens available fuel for sporulation.  Since not all Streptomyces 
contain redD it is unknown if there are other metabolites involved in cell death 
and if they are also intracellular instead of being secreted like many other 
antibiotics. 
2.1.2 Metabolites produced by S. coelicolor 
 
Prior to genome sequencing, S. coelicolor was known to produce five specialised 
metabolites with some antibiotic activity.  Most of these were easily identified 
due to being pigments : blue ACT, brown methylenomycin, whiE grey spore 
pigment, RED, and the non-pigmented calcium dependent antibiotic (CDA) (van 
Keulen & Dyson, 2014).  The impact of culture conditions on pigment production, 
primarily ACT and RED, had been observed since the isolation of S. coelicolor 
(Kutzner & Waksman, 1959) hence their use as general indicators of SMet. Since 
sequencing a further 16 biosynthetic gene clusters (BGCs) have been identified 
in S. coelicolor (Rutledge & Challis, 2015).  
Despite being the model Streptomyces, there are still clusters remaining which 
do not have an associated product.  A list of metabolites with known BGCs is 
given inTable 2.1, using van Keulen & Dyson (2014) and Challis (2014) as 
guides.  van Keulen & Dyson (2014) note 9 additional BGCs with unknown 
products: a type I PKS, type II fatty acid, an NRPS, 4 ribosomally synthesised 
polypeptide BGCs, and 2 unknown siderophores. 
The previously mentioned ACT and grey spore pigment are both polyketides, as 
is the yellow pigmented coelimycin P1 (cpk cluster).  Coelicmycin was originally 
discovered by removing the clusters for ACT, RED, and CDA, thereby increasing 
the metabolic flux to the otherwise silent cpk cluster (Gomez-Escribano et al., 
2012).  Therefore, it is unlikely to be detected in any metabolomics experiments 
which does not use genetic engineering given the common expression of those 3 
BGCs.  Structures of characteristic S. coelicolor metabolites are shown in Figure 
2.2. 
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Table 2.1 S. coelicolor BGCs with known products.  Some genes are labelled 
“SCO”, indicating S. coelicolor nomenclature. 
BGC class Product Gene or 
BGC 
Bioactivity Source 
PKS     
TI PKS Coelimycin cpk Antibiotic Gomez-
Escribano 
et al. 2012 
TII PKS Actinorhodin act Antibiotic Mak & 
Nodwell 
(2017) 
TII PKS Tw95a whiE - Lee et al., 
(2012) 
TIII PKS Flaviolin thns - Izumikawa 
et al., 
(2003) 
TIII PKS Germicidin A gcs Anti-spore 
germination 
Chemler et 
al., (2012) 
Peptide     
NRPS-
lipopeptide 
CDA cda Antibiotic Wang et 
al., (2013) 
NRPS Coelibactin SCO 7676–
7692 
Zincophore  
NRPS-
hydroxamate 
Coelichelin cch Siderophore Lautru et 
al., (2005) 
RiPP SapB ram Antibiotic Kodani et 
al., (2004) 
Terpene     
Tetraterpene Isorenieratene crtEIBV - Takano et 
al., (2005) 
Triterpene Hopene SCO 6759–
6771 
- Seipke & 
Loria, 
(2009) 
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Sesquiterpene Albaflavenone cyp170A1 Antibiotic Čihák et 
al., (2017) 
Sesquiterpene Geosmin cyc2 - Yagüe et 
al. (2013) 
Fatty acid     
PKS/TI fatty 
acid 
Eicosapentaenoic 
acid 
pufA - Shulse & 
Allen, 
(2011) 
Miscellaneous     
Oligopyrrole Undecylprodigiosin red Anticancer, 
antibiotic 
Hu et al., 
(2002) 
Siderophore Deferoxamine B des Siderophore Tunca et 
al., (2007) 
γ-
Butyrolactone 
SCB1 scbA Signalling Hsiao et 
al., (2007) 
Cyclopentanone Methylenomycin A mmy Antibiotic Hobbs et 
al., (1992) 
Butenolide Methylenomycin 
furans 
mmfRLHP Antibiotic Corre et 
al., (2010) 
 
Terpenes are common Streptomyces BGCs, though are found throughout 
microbial and plant life (Marinelli, 2009).  In S. coelicolor the most well-known is 
geosmin (Gust et al., 2003), which is so far universal to Streptomyces (Kim et 
al., 2015) and is responsible for the earthy smell of soil.  While the smell makes 
it easy to superficially detect, geosmin’s volatility makes it unsuitable for LC-MS 
analysis.  Though it is a common metabolite, like many other compounds its 
function remains unknown.   
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Figure 2.2 Structures and formulae of characteristic S. coelicolor metabolites (a) actinorhodin, (b) 
undecylprodigiosin, (c) calcium dependent antibiotic, (d) geosmin, (e) methylenomycin, and (f) albaflavenone. 
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However, Gust et al. (2003) do note that mutants in cyc2, one of the genes 
responsible for geosmin biosynthesis, show “reduced” sporulation.  As with RED 
and spore pigment, this again correlates a metabolite to a key part of the 
Streptomyces lifecycle.  Geosmin is also produced by a range of other microbes 
within Actinomycetales, Myxobacteria, Cyanobacteria, and within fungi 
Penicillium spp. (Mattheis & Roberts, 1992; Giglio et al., 2008).  While not all of 
these are spore formers, indicating potential functions other than sporulation, all 
of these clades include prolific natural product producers.  
Other metabolite classes include the oligopyrroles, like RED and streptorubin B, 
and the siderophore deferoxamines B, E, G, and D.  Like geosmin, deferoxamines 
are highly conserved in Streptomyces (Kim et al., 2015), but are not the only 
siderophores produced by S. coelicolor. The non-ribosomal polypeptide 
coelichelin is another siderophore, but it is not conserved to the same extent as 
deferoxamines.  Following its identification in the partial genome structure of S. 
coelicolor, Lautru et al. (2005) detected coelichelin by comparing culture 
supernatants of coelichelin cluster (ccH) mutants with the wild type after growth 
in iron deficient media.  Genome mining can lead to an overload of genomic 
information with little corresponding metabolomic data, so this is a good example 
of a targeted genomics/metabolomics strategy to isolate the product of a cluster 
of interest.   
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2.1.3 Chapter aim and objectives 
 
The project requires a robust untargeted metabolomics system to reliably 
identify known metabolites over a variety of culture time points, highlight 
productive growth conditions of both known and unknown metabolites, all 
following removal of media associated compounds.  S. coelicolor was the ideal 
choice to develop this method given the large amount of research on its 
metabolites, their regulation, and how this links to the phenotype.  Therefore, 
the aim was to establish an untargeted metabolomics method which can assess 
the change in metabolites over different growth conditions.  Within this, the 
objectives were to:  
 
1) Culture S. coelicolor in a range of conditions to observe pigmentation and 
morphological variety. 
2) Examine how sample time effects the chemotype within a growth 
condition. 
3) Develop a combined microbiology and analytical chemistry method which 
can be applied to NCIMB Streptomyces and other microbes. 
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2.2 Materials and Methods 
 
2.2.1 Chemicals 
 
2.2.1.1 UPLC-MS solvents 
 
Methanol, acetonitrile and formic acid (HPLC grade) were purchased from Fisher 
Scientific (Loughborough UK).  Water was purified using a Purelab Flex system 
(18.2 MΩ, ELGA LabWater, High Wycombe UK). 
Undecylprodigiosin (>93% purity) was purchased from Abcam (Cambridge UK). 
2.2.1.2 Growth media  
 
A full list of culture media and ingredients is given in Appendix table 1.   
Media were selected based on their use in the International Streptomyces Project 
(Shirling & Gottlieb, 1966), general specialised metabolite production 
enhancement (Goodfellow & Fiedler, 2010) maintenance and sporulation effects 
(Shepherd et al., 2010), minimal media (H. Zhu et al., 2014), or made based on 
components in other media.  The overall set included a mixture of rich and poor 
media (especially SEA and MMM) to compare metabolites upregulated by 
nutrient-deficient growth with ones potentially upregulated by large culture 
densities, and a mixture of carbon source alteration (maltose yeast-malt or MYM, 
proline yeast malt or ProYM) to potentially simplify the reason for any 
metabolomic or phenotypic differences. 
2.2.2 Streptomyces selection from NCIMB collection 
 
It was earlier stated that S. coelicolor A3(2) would always be referred to as S. 
coelicolor.  An exception is made here as the culture collection uses the correct 
taxonomic name.  S. violaceoruber (Waksman and Curtis) BAA-471 was 
purchased from the American Type Culture Collection (Manassas, US).   
The NCIMB collection was searched for Streptomyces strains with minimal recent 
specialised metabolite research, and ideally those with minimal bioactivity 
research overall.  More recent accessions with potentially ongoing research were 
also included based on the novelty of their native environment.  S. coelicolor 
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Müller was also included to demonstrate its difference to S. coelicolor.  The 
selected NCIMB strains are listed in Table 2.2. 
Table 2.2 Streptomyces species selected from the NCIMB collection 
Strain NCIMB 
Number 
Isolated from Year of 
accession 
S. coelicolor Müller 9798 - 1965 
S. halstedii 9839 “Deeper soil layers” 1966 
S. 
pseudoechinosporeus 
9918 Desert sand, 
Kazakhstan 
1966 
S. avellaneus 11000 Cave soil, Italy 1973 
S. flaviscleroticus 11008 Soil, India 1973 
S. purpureus 11313 Soil, Hawaii 1977 
S. sp 12947 Lavender field soil, 
Hungary 
1989 
S. costaricanus 13455 Soil, Costa Rica 1997 
S. rhizosphaericus 13674 Ectorhizosphere, 
Indonesia 
1997 
S. sanyensis 14820 Mangrove sediment, 
China 
2012 
S. aridus 14965 Atacama Desert, Chile 2014 
 
2.2.3 Lyophilised strain revival and maintenance 
 
2.2.3.1 Lyophilised strain resuscitation 
 
NCIMB strains are stored in glass ampoules (Figure 2.3) which require snapping 
to access the freeze-dried culture for resuscitation.  The ampoule was scored 
with a diamond tipped cutter and snapped inside a laminar flow hood to prevent 
contamination, and a sterile Pasteur pipette used to suspend the culture in 
approximately 1 ml glucose yeast-malt (GYM) broth.  The suspended culture was 
spotted onto a GYM plate and spread to isolate single colonies, and into a 20 ml 
GYM vial, both of which were incubated at 30°C.  This was repeated for all 
Strains in Table 2.2, and the American Type Culture Collection S. coelicolor 
ampoule. 
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2.2.3.2 Streptomyces strain maintenance 
 
2.2.3.3 Spore plate culture 
 
The GYM broth Streptomyces cultures (100 μl) were used to inoculate GYM and 
Soya Flour Mannitol plates, then spread for confluent growth.  The plates were 
incubated at 30°C until the culture had sporulated.    
2.2.3.4 Spore suspensions 
 
Spores were harvested to create spore suspensions for later inoculations, 
modifying the method described in Shepherd et al. (2010).   
All non-biological materials were sterilised either by autoclaving or by the 
manufacturer prior to use.  A spore filter was constructed by placing a 20 ml 
syringe barrel into a 50 ml centrifuge tube (Fisher Scientific) and filling the 
bottom of the barrel with sterile cotton wool.  The spores were harvested by 
pipetting 5 ml sterile reverse osmosis (RO) water onto the plate and gently 
rubbing the surface with a cotton bud to dislodge and suspend spores.  The 
suspension was then pipetted into the cotton wool and filtered by replacing the 
syringe plunger.  The syringe was discarded. 
The tube was then centrifuged at 5,000 x g for 5 min, after which the 
supernatant was removed with a pipette and discarded.  The spore pellet was 
resuspended in 1 ml 25% sterile aqueous glycerol, vortexed to mix, and stored 
at -80°C.  
NCIMB number 
Biomass 
Bung to prevent contamination if 
ampoule unexpectedly breaks 
Figure 2.3 NCIMB lyophilised culture ampoule. 
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A 10 μl aliquot was incubated on a fresh Soya Flour Mannitol plate to check for 
contamination; 50 μl was used for further extract cultures on 9 cm agar plates, 
and 20 μl into 24 and 25-well plates. 
2.2.4 S. coelicolor co-culture with NCIMB strains in 25-well 
plates 
 
S. coelicolor was cultured in Sterilin square 25-well plates (Fisher Scientific) with 
each well containing 2 ml M19 media.  M19 was selected as it induced relatively 
early and high production levels of the blue pigment ACT from S. coelicolor 
compared to the other media, which acted as a crude proxy for specialised 
metabolite production (Kim et al., 2007; Wang et al., 2008) 
Spore suspension (20 μl) of S. coelicolor were spotted into the wells along with 
20 μl suspension of each of the 11 soil NCIMB Streptomyces (Table 2.2).  Aside 
from S. coelicolor, each of the 11 strains was inoculated into 2 wells: one for 
axenic growth, and another for co-culture with S. coelicolor.  S. coelicolor had its 
own axenic well as a control. 
2.2.5 Evaluation of S. coelicolor lifecycle and metabolites 
 
2.2.5.1 Culture of S. coelicolor on agar for metabolite extraction 
 
S. coelicolor spore suspension (50 μl) was spread to give confluent growth across 
63 agar plates, which were incubated at 30°C.  At each sample point, triplicate 
plates were sampled by cutting each into approximately 2 cm3 pieces and 
crushing with a glass homogeniser (Fisher Scientific).   Samples were taken at 3, 
6, 9, 12, 24, 27, 30, 48, 54, 72, 96, 120, and 168 h then every following 24 h up 
to 15 d, requiring preparation of multiple spore suspensions. 
2.2.5.2 Extraction of S. coelicolor metabolites 
 
Samples were processed by transferring 3 x 1 g homogenised agar culture to 3 
separate 15 ml centrifuge tubes per plate, which were then stored at -20°C until 
all samples had been collected.  After defrosting, each tube was used for 
extraction with a different solvent: water, 50% aqueous methanol, and 
methanol, to cover a medium-high to high extract polarity range.  Common less 
 64 
 
polar solvents such as ethyl acetate or butanol were avoided to prevent 
extraction and rediscovery of known metabolites.  
Extraction solvent (4 ml) was added to the respective tubes and shaken at room 
temperature in a rotary incubator (220 rpm) for 1 h with vortexting every 15 
min.  An aliquot (800 μl) of crude extract was transferred to a 1.5 ml 
microcentrifuge tube and centrifuged at 5000 x g for 5 min, and the supernatant 
filtered through a Whatman 0.5 μm PTFE filter into LC-MS autosampler snap top 
vials (ThermoFisher Scientific). 
2.2.5.3 Metabolite analysis 
 
Two sets of LC-MS conditions were used for S. coelicolor metabolite analysis.  
The first, Method A, used lab standard microcystic-optimised settings, and were 
used in the Lifecycle extraction trial.   
Samples were analysed using a Waters Acquity UPLC coupled to a Waters Acquity 
PDA and Xevo G2 QToF (Manchester, UK) controlled by Masslynx v4.1. 
Separation was achieved using a BEH C18 column (2.1 x 50 mm, 1.7 μm particle 
size) with a target column temperature of 40°C.  The mobile phase was ultrapure 
18.2 MΩ water with 0.1% formic acid (solvent A) and acetonitrile with 0.1% 
formic acid (Solvent B) run on the gradient shown in Table 2.3.  The auto 
sampler was maintained at 5°C and took 5 μL sample for injection into the LC-
MS. 
 Table 2.3 LC settings for Method A. 
 
 
 
 
 
 
Centroid data was acquired using electrospray in positive ionisation mode with a 
mass scanning range of m/z 50 to 2000.  Scan duration was 0.25 s and inter-
scan delay 0.025 s.  The capillary, sampling and extraction cones were set to 3.3 
Time/min % A % B 
0 95 5 
10 30 70 
11 0 100 
12 0 100 
12.5 95 5 
15 95 5 
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kV, 25 V and 3 V respectively, with source and desolvation temperatures at 80°C 
and 350°C respectively.  Desolvation and cone gas flows were 500 l/h and 50 
l/h. with cone gas at 50 l/h.  Collision energy was 15 V. The reference calibration 
compound was Leu-enkephalin (Sztáray et al., 2011) with a reference scan 
frequency of 10 s and reference cone voltage of 25 V.   
 
Data was collected using MSE.  After an ion has been scanned it is subjected to a 
collision energy ramp to generate a second data set which approximates MS/MS 
fragmentation.  The ramp settings were 20 eV start to 55 eV end. 
2.2.5.4 Culture and staining of S. coelicolor 
 
GYM plates were overlaid with sterile porous cellophane (Sigma-Aldrich) and 
inoculated to form a confluent lawn with 50 μl spore suspension.  GYM was 
chosen because of its general use from being the 2nd International Streptomyces 
Project medium (Shirling & Gottlieb, 1966). 
S. coelicolor cell time dependent morphology and viability was assessed with a 
Molecular Probes L-13152 Live/Dead BacLight Bacterial Viability Kit.  At each 
sample time point cellophane was removed and a section cut out to place on a 
slide.  This was stained following the method in Manteca et al. (2005).  Briefly, 
the SYTO 9 and Propidium Iodide reagents were separately dissolved in 2.5 ml 
filter sterilised 18.2 MΩ water, then combined in a 1:1 ratio to create the dye 
master mix.   
The mix was dropped over the sample to submerge it, a sterile cover slip placed 
over it, and left in the dark to stain for 10 min. Samples were observed using a 
Leica DMRB fluorescence microscope with 540 – 650 nm and 355 – 425 nm 
excitation to 645 – 675 nm (red) and 470 nm (green) emission filters 
respectively. 
2.2.6 Evaluation of impact of culture media on S. coelicolor 
metabolism 
 
The 8 media found in Appendix table 1 were used to fill 3 24-well plates, which 
were inoculated with 20 μl S. coelicolor spores/well.  Plates were incubated at 
 66 
 
30°C for 5, 10, and 15 d with one plate removed for processing at each time 
point.   
A 1 cm diameter corer was used to remove a plug from the centre of each well, 
which was then placed into a 1.5 mm microcentrifuge tube.  The corer was 
cleaned in fresh RO water between each well.  Samples were stored at -80°C 
prior to extraction.  After defrosting, the cores were crushed with a glass rod and 
metabolites extracted by adding 1 ml 50% aqueous methanol.  The crude extract 
tubes were vortexed every 15 min for 1 h, after which a 500 μl sample from each 
tube was syringe filtered through a Millipore 0.2 μM cellulose filter (Merck, 
Southampton, UK) into a corresponding UPLC snap top vial.   
A sterile media 24-well plate was processed in the same way to analyse blank 
media, ensuring data analysis would not focus on media compounds. 
2.2.6.1 Metabolite analysis 
 
The second set of UPLC-MS conditions, Method B, was based on literature 
examples of Streptomyces natural product metabolomics using the same UPLC-
MS equipment (Rao et al., 2011; Rao et al., 2013) 
Gradient settings changed from section 2.2.5.3 to the new method are listed in 
Table 2.4.  The mobile phase solvents A and B are unchanged. Changes to mass 
spectra acquisition are shown in  
Table 2.5.  All other conditions remain the same as section 2.2.5.3.   
Table 2.4 LC settings for Method B. 
Time/min % A % B 
Initial 95 5 
0.2 95 5 
1.1 75 25 
2.25 70 30 
3 60 40 
6 5 95 
7.5 5 95 
7.75 95 5 
10 95 5 
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Table 2.5 Method A and B MS settings. 
 Method A Method B 
Sampling cone/V 25 35 
Extraction cone/V 3 4 
Source temperature/°C 80 120 
Desolvation 
temperature/°C 
350 500 
Desolvation gas flow/l/h 500 1000 
Collision energy/V 15 60 
 
2.2.6.2 Data mining with MZmine  
 
 Waters RAW data files were converted to 32-bit .mzML files using MSConvert 
(Chambers et al., 2012).  The MS Level filter ScanEvent was set at 0 – 1 to 
remove UV data.  The processed files were imported into MZmine v2.37 (Pluskal 
et al., 2010; Myers et al., 2017).  The first stage, raw data methods, is displayed 
in shown in Figure 2.4. 
2.2.6.3 Data visualisation 
 
Structures were visualised with ChemDraw Ultra 7.  Data was processed and 
graphs produced with GraphPad Prism 8.2.1. 
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Having generated a chromatogram with the ADAP builder, these are converted to 
peak lists which are aligned into a single list, for example aligning triplicates 
(Figure 2.5). 
 
 
Figure 2.4 Raw data methods used in MZmine after data import. 
Crop filter:  
Filter to only contain 
150 – 2000 m/z, 
removing some 
common solvent 
peaks 
Mass detection: 
Set centroid mass 
detection lower limit 
to 1E3 
ADAP chromatogram 
builder (Myers et al., 
2017): 
Min. group size = 3 
Intensity threshold = 1E3 
Min highest intensity: 
1E3 
m/z tolerance = 0.1 m/z 
Prevents false positive 
chromatograms. 
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Deconvolution (ADAP): 
S/N = 1E6 
Min. feature height = 1E3 
Coefficient/area threshold 
= 25 
Peak duration range = 
0.01 – 1 min 
RT wavelet range = 0.01 
– 0.4 min 
Isotopic peak grouper: 
m/z tolerance = 0.1 
RT tolerance = 0.1 min 
Maximum charge = 2 
Representative isotope = lowest 
m/z 
Monotonic shape = yes 
Alignment: 
m/z tolerance = 0.1 
RT tolerance = 0.2 min 
Weight for m/z = 75 
Weight for RT = 25 
 
 
 
Figure 2.5 Use of peak list methods to create peak lists from each file and 
align them into a master list. 
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Aligned peak lists need further quality control before being used for statistical 
analysis.  Steps are shown in Figure 2.6. After processing, peak lists can be using 
for statistical analysis (principal component analysis, scatter plots) and exported 
to other metabolomics-related tools such as GNPS or MetaboAnalyst. 
 
 
 
 
 
 
 
 
 
 
Gap filling: 
Intensity tolerance = 25% 
m/z tolerance = 0.01 m/z 
RT tolerance = 0.01 min 
Fills in any missing 
features in an aligned peak 
list using the constituent 
lists 
 
Custom database identification: 
m/z tolerance = 0.1 m/z 
RT tolerance = 0.2 min 
Allows for identification and removal 
of media blanks or other specific 
features. 
Figure 2.6 Processing of aligned peak lists. 
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2.3 Results and Discussion 
 
2.3.1 S. coelicolor ACT production and co-culture 
 
2.3.1.1 Effect of media on ACT production and differentiation 
 
Preliminary culture of S. coelicolor on different media showed the mannitol-
peptone medium M19 enabled relatively high and early production of the blue 
pigmented antibiotic ACT.  Growth of S. coelicolor on other media is shown in 
Figure 2.14. However, differentiation was also delayed, with aerial hyphae only 
appearing in the denser regions of the colony.   
Figure 2.7 emphasises the difference culture on M19 agar media makes with a 
comparison to GYM at 3 d, which is already developing mature spores and no 
ACT production, only RED. The presence of aerial hyphae on M19 culture is 
presumably a response to the lack of nutrients caused by high cell density in 
comparison to the outer less densely packed biomass.  The identity of the 
pigment was confirmed by adjusting a culture plate extract’s pH from neutral to 
alkaline and back, causing the characteristic blue to red (alkaline) then back to 
blue colour change (Coisne et al., 1999). 
 
 
.   
 
 
 
 
 
 
 
 
Figure 2.7 (a) S. coelicolor A3(2) on M19 after 10 d showing actinorhodin 
production and sparse aerial hyphae, and (b) S. coelicolor on GYM after 3 d 
with grey mature spore pigment and prodigiosin.   
(a) (b) 
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On M19 the colonies lacked aerial hyphae for up to 5 d, the only culture condition 
to not produce any (Figure 2.14), while still activating specialised metabolism 
through ACT production.  Growth on minimal media with mannitol as the carbon 
source has been reported (Rigali et al., 2006) to restore aerial hyphae to bld 
strains.  bld, or “bald”, refers to an aerial hyphae-less phenotype caused by a 
variety of mutants; in this case, the mutation is in dasR, a master regulator 
controlling differentiation and specialised metabolism.   
Rigali et al. (2006) also note that Soya Flour Mannitol medium, which is 
commonly used to induce sporulation in Streptomyces (Shepherd et al., 2010), 
led to low sporulation and overproduction of ACT in their S. coelicolor dasR 
mutant.  Strangely the opposite situation, upregulation of dasR, also produces a 
bld phenotype with high ACT levels but on multiple media.  Both these 
descriptions match growth on M19, even though the strain used here is the wild 
type.   
While there are many other genes that can affect production of aerial hyphae, 
such as bldA (Hackl & Bechthold, 2015) or prsH (Viollier et al., 2003), these have 
different negative effects on Streptomyces pigment production and so specialised 
metabolism.  Given the similar phenotypes of growth on M19 to that of dasR 
disruption on Soya Flour Mannitol medium or upregulation, it is possible that 
either of the components of M19 (mannitol and peptone) are affecting levels of 
DasR.   
ACT production is commonly used as a proxy for specialised metabolism levels in 
Streptomyces since its secreted form – the lactone derivative γ-ACT (Coisne et 
al., 1999) – can easily be visually approximated.  The intracellular red pigment 
RED has also been used as an indicator of specialised metabolism (Sevcikova & 
Kormanec, 2004), but this was not detected.  Like other metabolites, compound 
levels are affected by a mix of abiotic factors, for example salt or rare earth 
metals (Sevcikova & Kormanec, 2004; Tanaka et al., 2010), and biotic factors 
like co-culture (Onaka et al., 2011). 
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2.3.1.2 Co-culture both increases and decreases S. coelicolor ACT 
production  
 
Selected NCIMB Streptomyces (Table 2.2) were co-cultured with S. coelicolor to 
screen for upregulation of specialised metabolism as indicated by pigment levels.  
The majority of strains either had no increase in ACT or lowered it.  Figure 2.8 
shows 2 co-cultures which either had morphological or upregulatory effects on 
ACT.  Full co-culture is displayed in Appendix figure 1. 
 
 
 
 
 
 
 
 
 
The majority of strains resulted in reduced pigment production.  The extent of 
this varies, with some (S. coelicolor/S. halstedii) totally abolishing production 
and other S. coelicolor retaining pigment at the colony edge furthest from its 
competitor (S. coelicolor/S. aridus).  Only one co-culture, S. coelicolor/S. 
purpureus positively affected ACT production, with both the intracellular and 
secreted pigment levels increasing.  Presumably this is due to upregulating S. 
coelicolor ACT levels, as S. purpureus is not a known producer of any blue 
pigments.  The S. coelicolor/S. halstedii co-culture induced aerial hyphae and 
possible sporulation in S. halstedii, not otherwise seen on this medium.   
Why some strains decreased production is unknown.  ACT requires a neutral to 
alkaline pH to be secreted as γ-ACT, which Pseudomonas species can prevent 
Figure 2.8 Co-culture of (a) S. coelicolor with S. halstedii, and (b) S. 
coelicolor with S. purpureus. 
(a) 
(b) 
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through media acidification, but this does not stop intracellular pigmentation 
(Galet et al., 2014).  Traxler et al. (2013) grew S. coelicolor with multiple 
actinomycetes, leading to altered pigmentation and other metabolites, and 
determined that siderophore production was induced through iron scavenging 
competition. 
Aside from ACT upregulation, this experiment did show the advantages of a 
multi-well screen compared to standard petri dish culture: more efficient in use 
of space, chemical and biological resources, and easier comparisons for strain 
under varying conditions.  
2.3.2 Evaluation of S. coelicolor metabolites over time 
 
As the model Streptomyces, S. coelicolor has the most characterised metabolites 
of any species in the genus.  It was therefore chosen for a trial LC-MS 
metabolomics experiment to test one OSMAC parameter – sample time – along 
with the difference in metabolites extracted by 3 different high polarity solvents, 
and whether the LC-MS conditions used were suitable.   
2.3.2.1 Fluorescence microscopy of S. coelicolor growth phases 
 
Like other Streptomyces, S. coelicolor undergoes a process of differentiation over 
time which is linked to specialised metabolism.  It was therefore hypothesised 
that specific differentiation stages may be correlated with the production of 
metabolites.  Fluorescence microscopy showed clear development of individual 
spores, germination, and rapid growth of the MI hyphae in Figure 2.9.  The first 
round of programmed cell death (PCD) is possibly also observed at 12 h, with 
some segments of hyphae stained red indicating damaged or dead cells.  PCD 
fuels further growth to produce uneven concentrated islands of biomass across 
the plate (Manteca et al., 2007), which is shown in Figure 2.10, until eventually 
aerial hyphae and spores were produced by 72 h (Figure 2.11). 
The morphology during lifecycle was compared to previous fluorescence 
microscopy of S. coelicolor, S. antibioticus, and S. lividans (Manteca et al., 2005; 
Manteca et al., 2007) where spores were seen to follow the same differentiation 
pattern and partially similar approximate timings.  These timings are compared 
with S. antibioticus and S. lividans (Table 2.6), as Manteca et al., (2005) found 
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S. coelicolor and S. lividans timings to be identical. Streptomyces development is 
asynchronous so even within a strain these will vary (De Jong et al., 2009). 
Table 2.6 Fluorescent microscopy-based timings of Streptomyces growth phases 
Species Germination MI  MII Spores Source 
S. antibioticus 4 h 6 h 14 h 45 h Manteca, et 
al., (2005) 
S. lividans 4 h 6 h 17 h 50 h Manteca et 
al., (2007) 
S. coelicolor  6 - 9 h 6 - 12 h 18 h 60 h This work 
 
More sample points were used in Manteca et al., (2005; 2007) which accounts 
for the slight gap between MII and spore formation.  However, germination and 
appearance of MI did take over double the previously recorded time.  Images at 
6 h did show spores, and while there were potential stubs on some which could 
have been early germ tubes, it was not confirmed.  Therefore, germination 
occurred between 6 and 9 h.  This extends to the MI hyphae, as a germ tube can 
be considered MI hyphae so it may be most accurate to say MI appear around 9 
h, but a typical mat of hyphae was only seen from 12 h onwards.  
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(a) 6 h (b) 9 h (c) 12 h 
(d) 12 h (e) 15 h 
Figure 2.9 Live (green) dead (red) staining fluorescence microscopy of S. coelicolor.  (a) Spores at 6 h, 200 x; (b) 
Germination tubes marked at 9 h, 400 x; (c) Early MI growth, 12 h 200 x; (d) Also 12 h, less crowded segment showing 
early clusters of growth and dead segments, marked; (e) Rapid growth around core clusters at 15 h, 100 x.  
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Figure 2.10 S. coelicolor growth island at 18 h with fluorescence microscopy showing (a) live and dead cells, (b) dead 
cells, and (c) light microscopy of the same island.  All 200 x. 
(a) (b) (c) 
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Figure 2.11 Late stages of S. coelicolor lifecycle.  (a) At 36 h growth islands cover the surface with relatively empty 
channels between them, 100 x.  (b) Cover slip print and stain of aerial hyphae at 60 h, 200 x, and (c) Cover slip and 
print stain of aerial hyphae and spores, 72 h, 200 x.  Example spore chain marked with separated oval spores visible. 
(a) 36 h (b) 60 h (c) 72 h 
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2.3.2.2 Alternation of metabolite analysis parameters 
 
Unfortunately, there was no metabolomic data to correlate to the differentiation 
cycle.  Though growth, differentiation, and pigment production were seen, LC-MS 
analysis showed no metabolite differences between the time points or the agar 
blank (Figure 2.12).  The reason for the lack of detected metabolites was likely a 
combination of the inefficient extraction method and unoptimised LC-MS 
parameters.  The nutrients and temperature (GYM agar, 30°C) were standard 
Streptomyces culture parameters (Shepherd et al., 2010). 
Therefore, the hypothesis of this section – that time and solvents will affect 
available metabolites – had not been properly tested.  The experiment was 
redesigned to use the multi-well plate format of Section 2.3.1 which more 
effectively, if in a preliminary fashion, studied metabolite differences caused by 
altering the environment of S. coelicolor.  Reuse of the multi-well plate format 
also required a new extraction method. 
Three agar culture sample processing methods were compared: 1) cutting into 
pieces then leaving in solvent; 2) crushing then solvent; and 3) cutting, 
freeze/defrosting, then crushing and solvent.  Each of the three did give 
detectable metabolites with 50% aqueous methanol extraction solvent unlike the 
previous experiment, specifically the siderophores deferoxamine B and 
coelichelin (Figure 2.13).   Cutting up gave the fewest chromatogram metabolite 
peaks, so freeze/thawing then crushing was selected as the most suitable 
method for extraction.  The LC-MS parameters were then changed to more 
Streptomyces optimised settings, specifically those in Rao et al. (2013) as the 
same model of UPLC-MS qToF was used. 
Solvent selection can have a major impact on the extracted metabolites, as 
different solvent polarities will lead to a different set of metabolites being 
extracted.   As part of a diverse OSMAC project using Streptomyces spp. and 
Salinispora spp., a predominantly marine genus within Actinomycetales, 
Crüsemann et al. (2017) sequentially extracted culture samples with the 
common solvents ethyl acetate, butanol, and methanol.  After grouping the 
metabolomic features into related clusters, approximately 6000 unique clusters 
were found, with 3000 coming from ethyl acetate extracts, 1750 in butanol 
extracts, and 1250 from methanol extracts.  When comparing overall molecular 
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families rather than feature clusters, methanol extracted the largest unique 
amount at 25 of 57 total.  This translated into some known metabolites only 
being extracted by specific solvents, such as antimycin A1 by methanol, 
salinamide E by butanol, and arenimycin by ethyl acetate. 
As these are commonly used solvents, it could be hypothesised that the use of 
uncommonly used solvents would also expand the chemical space.  Barkal et al. 
(2016) extracted Aspergillus nidulans cultures with chloroform, and the high 
boiling point solvents 1-pentanol (138°C), and γ-caprolactone (219°C).  Some 
known metabolites were preferentially extracted (for example, asperfuranone by 
γ-caprolactone), but there was no examination of whether novel metabolites 
were extracted.   
Since the overall project was focused on multiple Streptomcyes, not just S. 
coelicolor, the multi-well plate screen was remade around growth conditions 
more likely to change global specialised metabolism regulation irrespective of the 
strain.  Therefore the screen was designed around different nutritional 
conditions, since different minerals, metals, carbon and nitrogen sources are well 
documented as triggering specialised metabolite diversity (Bode et al., 2002; 
Rateb et al., 2011; Traxler et al., 2013).  The other difference from the first 
attempted screen was in sample points.  Early time points are unlikely to give 
high enough levels of specialised metabolites, since early growth is more focused 
on biomass production.  Therefore, sample points were changed to 5, 10, and 15 
days to cover stationary and nutrient depletion stages. 
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Figure 2.12 Chromatograms of S. coelicolor culture on GYM plates extracted with water, 50% methanol, and 100% 
methanol after 15 d. 
d15 m1
Time
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0
100
-0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00
%
0
100
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%
0
100
JB23Nov285 1: TOF MS ES+ 
BPI
2.08e4
13.56
495.39
1.13
525.25
0.79
446.21 12.74
551.65
2.56
138.09
JB23Nov282 1: TOF MS ES+ 
BPI
2.08e4
1.11
525.25
0.79
446.21 12.79
249.13
2.57
138.09
JB23Nov278 1: TOF MS ES+ 
BPI
2.08e4
13.60
685.611.09
525.26 2.56
138.09
JB23Nov51 1: TOF MS ES+ 
BPI
2.08e4
1.11
381.17
13.67
214.97
1.31
365.19 3.37
115.08
1.97
152.09
13.08
337.11
11.70
677.55
GYM blank methanol extract 
Water extract 
50% aqueous methanol extract, 15 d 
Methanol extract, 15 d 
Max intensity 1.7E3, no identifiable compounds 
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2.3.3 OSMAC 24-well Plate Nutrition Screen 
 
2.3.3.1 Morphological development of S. coelicolor in 24-well 
plates 
 
The S. coelicolor nutritional treatment screen (Figure 2.14) contained a mix of 
rich and poor media with different carbon and nitrogen sources. At 5 d the only 
treatment with no aerial hyphae was M19.  Grey spore pigment indicates mature 
spores in S. coelicolor, indicating that the differentiation and sporulation process 
was more rapid on the oatmeal (OM) and MYM, and 2 of 3 replicas with 
international Streptomyces project 5 medium (ISP5).  The lack of consistent 
aerial hyphae in M19 continues through to 10 d, as though they were present by 
this time it was not across all replicas. Spore pigmentation differed in MYM and 
proline yeast-malt (ProYM), the latter of which still presented white aerial hyphae 
as opposed to MYM’s dark grey pigment. 
One of the minimal mannitol medium (MMM) cultures strongly expressed 
actinorhodin compared to the other two replicates, but at the expense of aerial 
hyphae in the centre of the colony. Streptomyces is known to rapidly 
mutagensise the antibiotic-BGC containing regions of its genome (Hopwood, 
2006), which may be the reason for the difference to other MMM replicas at 10 d. 
Fr2
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189.091.97
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4.13
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4.89
189.09
Figure 2.13 Comparison of 3 sample processing methods for extraction in 50% 
methanol.  Chromatograms are representative of triplicate replicas. 
Crushed 
Freeze/thaw + crush 
Cut up 
Coelichelin 
Deferoxamine B 
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By 15 d ISP5 culture showed uniform dark grey spores, but some evidence of 
blue pigment droplets seen in previous time points remained in the leftmost well.  
These droplets, or extracellular vehicles, can contain a variety of proteins and 
peptides (Schrempf et al., 2011) including antimicrobials.  Aerial hyphae in M19 
growth was much more consistent between replicas than at previous points and 
appears to be forming in-between the wrinkled colony surface peaks rather than 
uniformly across the whole colony surface.  Like 10 d, another MMM replica 
produced much more ACT than the other 2 wells with less aerial hyphae, 
mimicking M19 culture in its productivity and differentiation.  Plating out this 
colony would have been an interesting experiment to see if this was actually due 
to mutation and maintained across generations. 
After extraction, samples were processed with MZmine (Pluskal et al., 2010; 
Myers et al., 2017) to remove media, non-triplicate, and <1E3 height features. 
An extracted ion chromatogram post-MZmine processing is shown in Figure 2.15, 
and a list of all detected S. coelicolor features in Figure 2.16.  There are 
unhighlighted peaks in the chromatogram, which does not necessarily indicate an 
undiscovered metabolite from the model species, as this LC-MS method 
consistently results in a noisy chromatogram from 6 min onwards especially due 
to m/z 383 and 365, as well as peaks for removed media components. 
The MZmine final peak list contains 122 features, of which 10 have putative 
identifications.  Metabolites were identified using a custom database from global 
natural products social molecular networking (GNPS), other published data, and 
standard compound samples (Table 2.7). There were features with m/z values 
similar to previous albaflavenone UPLC-MS detection  (Čihák et al., 2017), but no 
fragment masses were provided so albaflavenone was not listed as identified.  
Comparison spectra are shown in Appendix figure 2 to Appendix figure 8. 
Metabolites or adducts below the detection limit (>3 in a row 1E3+ height ions) 
are not listed but may still be present: MYM 10 contains CDA 4a, along with its 
Na and K adducts, and CDA 3a.  Similarly, CDA is not listed as produced under 
PepS culture as it is present at <1E3 (mean 4.63E2 height). 
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(a) 
(b) 
(c) 
Figure 2.14 Culture of S. coelicolor in multiple media over (a) 5, (b) 10, and (c) 
15 d.  The plates are split into 8 media shown to the left or right of each triplicate 
set.  Appendix table 1 lists media components. MMM = minimal mannitol 
medium; SEA = soil extract agar; OM = oatmeal medium; ISP5 = international 
Streptomyces project 5; M19 = medium 19; PepS = Peptone sucrose; MYM = 
maltose yeast malt; ProYM = proline yeast malt. 
MMM SEA 
OM 
M19 
ISP5 
 
PepS 
ProYM 
MYM 
MMM 
SEA 
OM 
M19 
ISP5 
 
PepS 
ProYM 
MYM 
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OM 
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PepS 
ProYM 
MYM 
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2.3.3.2 Analysis of metabolite variety 
 
One hypothesis was that the rich media would lead to a large number of total 
features with fewer unique features as a percentage of the overall production, 
and the opposite for poor media as the starvation response or lack of carbon 
catabolite repression upregulates cryptic BGCs.  This does not seem to be 
correct: the nutritionally poorest medium, soil extract agar (SEA), had the lowest 
total and 3rd lowest number of unique features, 27.27% of its overall total 
(Figure 2.16).  However, the 2nd lowest total and lowest unique feature count (0) 
came from growth on PepS, which contains 20 g/l of starch as its carbon source, 
not a preferred carbon source for S. coelicolor.  Three relatively rich media – 
MYM, ProYM, ISP5 – were 5th, 6th, and 7th lowest respectively by percentage 
uniqueness (10.00%, 9.52%, 6.45%).   
 
 
 
Germicidin B 
Germicidin A 
RED Coelichelin 
Defer. B + E 
Figure 2.15 MZmine extracted ion chromatogram for MYM 5 d culture 
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The largest number of unique features was obtained from growth on M19.  It 
also produced the largest amount by relative peak area of germicidins A and B, 
deferoxamines E and B, RED, and 2nd largest amount of coelichelin.  The 
relatively high numbers for 6 of the 9 identified metabolites compared to other 
media does fit with the hypothesis in 2.3.1 regarding DasR levels, since this 
would lead to an increase in specialised metabolism.  Mannitol is not a preferred 
carbon source by S. coelicolor, with a doubling time of 6.1 h on mannitol media 
compared to 1.9 h with glucose (Hodgson, 1982). 
2.3.3.3 Specific metabolite concentrations through peak area 
 
ACT was visually noted as being produced in the majority of cultures.  However, 
LC-MS analysis did not show actinorhodin at the levels it was assumed to be 
being produced at.  Culture on SEA produced the most, but visually showed a far 
less intense pigment than other cultures which according to the LC-MS results 
contained no actinorhodin.  Examining the UV absorbance for a sample with 
detected ACT (SEA 10 d) shows absorbance at 522 nm, which is replicated in 
M19 at the same retention time.     
 
 
 
 
 
 
 
 
 
 
Figure 2.16 Total and Unique >1E3 intensity (height) features detected from 
OSMAC S. coelicolor culture. 
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A similar absorbance spectrum was recorded by Coisne et al. (1999) at 535 nm 
after extraction with acidic methanol.  The equivalent peak in photodiode array 
data may be a more accurate way to determine ACT levels.  Unfortunately, 
searching the sample assumed to have the most ACT – M19 culture 15 d – for 
535 nm reveals a 2 min long additional peak which is clearly not related to a 
specific compound in a 10 min gradient elution.  Two ACT m/z peaks with 
different retention times were detected in culture on SEA (4.69 min, 5.50 min).  
The earlier peak was designated as ε-ACT due to the presence of m/z 649.15 
spectra, which is 0.02 m/z off the GNPS ε-ACT example.  Examining a method in 
the literature reported to have detected ACT (Čihák et al., 2017) does show 
some similarities, as both use the same solvents with a similar gradient in 
positive ionisation mode.  The desolvation temperature was lower at 350°C, but 
even if this were the causative difference it would not explain why ACT was 
detected in some samples but not others. 
RED was also not widely detected.  The time sample points may not be suited to 
RED, as previous research found RED correlates with biomass accumulation, 
unlike a stereotypical specialised metabolite which will be found at stationary 
phase onwards (Hobbs et al., 1990).  Despite this, comparison to a 10 μg/ml 
standard showed similar peaks and spectra in the culture extracts at the two 
later sample times (M19 and MYM).   
The detection time in later samples could fit with the previously mentioned work 
on RED and programmed cell death (Tenconi et al., 2018), where RED is 
associated with the breakdown of the substrate hyphae to fuel differentiation into 
aerial hyphae.  As aerial hyphae were not seen on M19 culture10 d, if RED is 
strongly associated with aerial hyphae then it would follow that RED would not 
appear until PCD is occurring to fuel aerial hyphae. 
Each of the siderophores (coelichelin, deferoxamines B and E) were detected in 
the same culture media extract, with some difference between time points.  Both 
B and E were produced at higher concentrations in M19, followed by ProYM and 
MYM.  Relative amounts between time points were also similar across media for 
B and E, with most of the siderophores being expressed between 5 and 10 d, 
indicating a steady rate of expression.  Coelichelin time point production differed 
between culture on different media.  From S. coelicolor culture on M19, 
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approximately 12.5% is produced up to 5 d, after which a further approximately 
62.5% of the total is synthesised, then the last 25% by 15 d.  On MYM culture, 
the majority (~75%) is produced by 5 d, though the total amount by 15 d is just 
over half that of M19 culture.  A graph showing total relative peak areas for all 
metabolites across all time points is presented in Figure 2.17, and individual 
metabolite graphs in Figure 2.18.  ε-Actinorhodin is not shown in an individual 
graph as it was only detected in SEA at 15 d.  MYM at 15 d could not be 
determined in triplicate as 2 files were unusable so has no error bars. 
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Table 2.7 Features with m/z matching previously reported S. coelicolor 
metabolites based on MZmine processing.   
Potential 
Compound 
Observed m/z 
(M+H unless 
stated) 
1E3+ Height 
Culture 
Parameters 
Confirmed by 
CDA 4a 1495.60 MYM 5, 10; 
ProYM 5, 10 
GNPS spectra 
Deferoxamine B 561.38; 614.30 
[M+Fe-2H] 
M19 5 – 15; 
MYM 5, 10; 
ProYM 10, 15 
GNPS spectra 
Deferoxamine E 601.38 M19 5 – 15; 
MYM 5, 10; 
ProYM 5 - 15 
GNPS spectra 
Deferoxamine B [M-
2H+Fe] 
   
Coelichelin 566.30 M19 5 – 15; 
MYM 5, 10; 
ProYM 5 - 10 
GNPS spectra 
ε-Actinorhodin 649.14 SEA 5 – 15 GNPS spectra; 
secreted pigment 
γ-Actinorhodin 631.13 SEA 5 – 15 
ISP5 10, 15 
GNPS spectra; 
secreted pigment. 
Germicidin A 197.12 NOT (MMM 5; 
PepS 5, 10; 
SEA 5 – 15); in 
all others. 
MS1 spectral 
comparison to 
Čihák et al., 2017 
Germicidin B 183.10 NOT (MMM 5; 
PepS 5; SEA 5 
– 10); in all 
others. 
Unconfirmed, likely 
given rt and 
spectral similarity 
to germicidin A 
Undecylprodigiosin 394.22 M19 10, 15 
MYM 5 
Standard sample 
MSE spectra; GNPS 
 
 
 90 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.17 Total relative peak areas of detected metabolites from S. 
coelicolor culture over 15 d. 
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Figure 2.18 Relative peak areas of detected metabolites from OSMAC culture 
over 5, 10, and 15 d.   
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The OSMAC 24 multi-well plate screen showed clear advantages over standard 
petri dish culture and extraction.  The initial failure of the time-based screening 
did lead to the more efficient well culture method so was useful in that respect, 
and the extra efficiency in use of space, chemicals, inoculation material, 
comparison between conditions, and easy extraction made the well screen a 
superior OSMAC method compared to the first experiment.   
While it is impossible to optimise LC-MS conditions for all the metabolites in an 
untargeted metabolomics experiment, that at least 9 metabolites were detected 
from S. coelicolor across a range of retention times or polarities indicated that 
the method was applicable to other Streptomyces.  Therefore, it was selected as 
the main method for OSMAC-based metabolomics for the NCIMB Streptomyces. 
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2.4 Conclusions 
 
The aim for this chapter was to develop a metabolomic method which could 
efficiently expand the specialised metabolome of a strain, resulting in identifiable 
metabolites which could be compared across growth conditions.  Using S. 
coelicolor to test the method was a logical choice given the amount of SMet 
research into it and its products.  Production of different metabolites was clearly 
observed under different regimes, from initial visual identification of ACT in a 
range of biotic and predominantly abiotic growth treatments.  The switch from 
standard agar plates to a more efficient well-plate culture was triggered by the 
co-culture experiments, as they demonstrated the applicability of a small-scale 
system testing multiple growth treatments while using non-model Streptomyces 
strains. 
However, the LC-MS conditions used were not appropriate for each of the 
compounds as the difference in ACT levels showed when comparing visual 
intensity to its chromatogram intensity.  Not being able to fully identify every 
class of compound is an inherent risk in an untargeted metabolomics project, 
which is compensated for by the detection of multiple other S. coelicolor 
metabolites from a range of different chemical classes.  The metabolites present 
in the sample will been affected by the choice of extraction solvent, 50% 
aqueous methanol, which both targets the relatively unexplored higher polarity 
chemical space while providing more disruption to the cell for extraction than 
would be caused by pure water. 
While metabolomics is an important tool for studying microbial natural products, 
it is only one of multiple approaches to elicit production of novel metabolites.  
Genomics-based methods are widely applied, using a full genome sequence to 
predict BGCs and so alter strain prioritisation or target expression of a BGC.  
Here, the metabolomic screening can be used to identify a specific non-model 
Streptomyces strain for further examination, including full genome sequencing.  
The combination of these methods, shown in an overall suggested workflow for 
metabolite discovery in Figure 2.19, presents a powerful multi-omics method for 
expanding metabolite variety and discovery of novel bioactive metabolites. 
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methanol 
Selection of 
unexploited strains Culture in 24-well plates using 
multiple growth conditions 
UPLC/MS analysis 
of hundreds of 
samples 
1. Strain culture and data generation 
 
Hybrid sequencing for 
genome mining 
Scale-up based on 
metabolomic analysis 
Fraction bioactivity 
using high-throughput 
assays 
3. Genomics & Scale-up  
Statistical tests and data visualisation to emphasise overall metabolite 
variety and inform main strain selection  
2. Metabolomic 
analysis 
Figure 2.19 Proposed overall workflow for microbial natural products discovery. 
 95 
 
CHAPTER 3 
 
 
 
 
 
 
 
 
METABOLOMICS-BASED PROFILING 
AND SELECTION OF UNEXPLOITED 
STREPTOMYCES STRAINS 
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3 Metabolomics-based profiling and selection of 
unexploited Streptomyces strains 
 
3.1 Introduction 
 
3.1.1 Selection of unexploited Streptomyces strains 
 
The NCIMB collection contains hundreds of Streptomyces from diverse ecological 
niches.  Many of these strains have minimal genomic or specialised metabolite 
information.  Therefore, rational strain selection for metabolomic screening and 
eventual culture scale-up required a mixture of methods to justify picking a small 
number of Streptomyces out of the whole collection.  Previously used relevant 
non-genomic methods to examine Streptomyces metabolite variety include 
isolating from non-soil niches such as marine environments (Pereira et al., 
2014), the One Strain Many Compounds (OSMAC) method (Bode et al., 2002), 
and classical bioactivity screening (Fedorenko et al., 2015).  These methods are 
directly applicable to guiding strain selection.  Combining these methods for 
strain selection along with a high-throughput metabolomics screening procedure 
provides a pipeline for enhanced metabolite variety by exploiting unexamined 
strains in the NCIMB culture collection.  
3.1.2 Untargeted metabolomics analysis of unexploited strains 
 
The metabolomic profile of a strain can be an important tool in analysing the 
metabolomic output of single strain or a larger group of microbes.  Some 
applications of profiling based on Streptomyces culture are given below. 
3.1.2.1 Metabolomic profiling of symbiotic Streptomyces strains 
 
A basic two-media OSMAC strategy was used by Viegelmann et al. (2014) to 
expand the accessible metabolome of Streptomyces sp. SM8, isolated from the 
marine sponge Halicona simulans.  A combination of LC-MS and nuclear magnetic 
resonance (NMR) was used, reasoning that the two techniques are 
complimentary to one another: UPLC-MS can be much more sensitive, but the 
ionisation method may not pick up certain classes of metabolite.  In comparison, 
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NMR is less sensitive but can convey a more complete metabolome as it is not 
biased towards metabolite classes. 
After identifying antifungal compounds that were upregulated by one medium, 
Viegelmann et al. (2014) used principal component analysis (PCA) to test 
whether metabolites produced by Streptomyces sp. SM8 were also present in 
their host.  Displaying the metabolites through scatter plot analysis showed two 
mostly separate profiles, with investigated antifungals unambiguously associated 
with S. sp. SM8 (reinforced by Streptomyces sp. SM8. having the corresponding 
biosynthetic gene cluster/BGC).  There were some shared metabolites in both 
profiles.  While this could indicate that some metabolites are produced by both 
species, it is also possible that the sponge is using bioactive metabolites 
produced by the Streptomyces symbiont. 
Another sponge symbiont study examined the metabolomic profiles of 
Streptomyces and other microbes isolated from Mediterranean sponges (Cheng 
et al., 2015).  PCA of extracts was linked to anti-trypanosomal activity, with the 
assumption that bioactive outliers were more likely to produce novel metabolites.  
This led to the selection of Streptomyces sp. SBT348 for further study.  MS/MS 
analysis could not identify the responsible bioactive compounds, indicating the 
production of an undiscovered anti-trypanosomal metabolite.    
As part of a wide-ranging study on insect Streptomyces symbionts, Chevrette et 
al. (2019) studied the metabolome of a set of 120 strains including 69 insect 
symbionts.  After culture on yeast peptone mannitol agar, metabolomic profiling 
showed significant metabolite diversity which corresponded to the diverse 
ecology and phylogeny of the strains.  From the total metabolomic features 
produced, 59% were only found in a single strain.  Using PCA to identify outliers 
led to the selection of Streptomyces sp. ISID311, isolated from a species of 
fungus-growing ant within the Cyphomyrmex genus.  Examining which 
components contributed to profile separation led to the discovery of a novel 
antifungal metabolite, cyphomycin.    
3.1.2.2 Stressors and elicitors to enhance metabolite production 
 
An alternative approach to enhance discovery of novel metabolites is through the 
addition of a stressor or elicitor, producing a parameter-specific metabolomic 
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response.  This can range from broadly applicable treatments like heat shocks 
through to addition of specific compounds that trigger upregulation of a certain 
pathway (Yoon & Nodwell, 2014).   
Scandium chloride was originally used to enhance actinorhodin levels by up to 25 
times from S. coelicolor by Kawai et al. (2007), though the mechanism of action 
of scandium and other rare earth metals to stimulate specialised metabolism is 
not known (Tanaka et al., 2010).  Applying scandium to growth media of other 
Streptomyces enhanced their metabolite production: actinomycin levels 
approximately doubled in S. antibioticus, and streptomycin from S. griseus 
tripled.  Unfortunately, as with any OSMAC project, not every condition will 
stimulate specialised metabolism.  Scandium did not have the same effect on 
each strain, so any effects on S. costaricanus metabolite production cannot be 
predicted.  
Other culture parameters like pH can also affect metabolite production, whether 
positively through upregulation of novel compounds, or negatively by causing too 
much stress for a microbe.  Kontro et al. (2005) also found that optimum pH is 
heavily dependent on the growth media used for an individual species, so as with 
scandium, it may be that use of a non-minimal medium facilitates growth at pH 
10.  As an alternative to altering the initial pH, acid and alkali shock have both 
been used to stimulate specialised metabolism (Kim et al., 2007; Jiang et al., 
2018), but again this would probably use a non-minimal media starter culture.  
pH information at isolation would be useful to mimic ecological conditions but 
given environmental variability this may not reflect optimum conditions for novel 
metabolite production.  
3.1.3 Chapter aim and objectives 
 
Chapter 2 focused on the development of an untargeted metabolomics workflow 
that assessed metabolite diversity in S. coelicolor.  The aim of this chapter was 
to apply this methodology to unexploited Streptomyces strains from the NCIMB 
culture collection to identify a suitable strain for further investigation.  This was 
achieved with the following objectives: 
1) Selection of a soil-isolated Streptomyces strain using initial bioactivity 
assays against Gram-positive and Gram-negative bacteria.  
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2) Selection of 2 non-soil Streptomyces strains from distinct niches. 
3) Comparison of total metabolomic diversity from the 3 strains when 
cultured using the 24-well plate screen. 
4) Identification of the strain producing the most different metabolomic 
profile compared to the other 2 Streptomyces, selecting this strain for 
further metabolomic screening and bioactivity assays. 
5) Analysis of metabolomic data for this single strain to identify which culture 
parameters most enabled metabolite diversity. 
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3.2 Materials and Methods 
 
3.2.1 Selection of NCIMB Streptomyces strains 
 
Streptomyces strains from the NCIMB collection without any isolation information 
were excluded, along with any model or industrially common species such as 
Streptomyces rimosus (NCIMB 9980), isolated from bee intestines, as it is widely 
used to produce tetracyclines (Petkovic et al., 2006).   
Strains selected in section 2.2.2, soil strains with minimal published specialised 
metabolite information and different soil niches, were reused.  Non-soil strains 
were chosen using similar criteria, though the selection pool was much smaller 
(Figure 3.2).  The final 2 selected non-soil strains along with the previously 
selected soil strains are shown in Table 3.1.    
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Table 3.1 Soil Streptomyces strains used in antimicrobial activity assays, and 
non-soil comparison strains. 
Strain NCIMB 
Number 
Isolated from Year of 
accession 
Soil isolates    
S. coelicolor Müller 9798 - 1965 
S. halstedii 9839 “Deeper soil layers” 1966 
S. 
pseudoechinosporeus 
9918 Desert sand, 
Kazakhstan 
1966 
S. avellaneus 11000 Cave soil, Italy 1973 
S. flaviscleroticus 11008 Soil, India 1973 
S. purpureus 11313 Soil, Hawaii 1977 
S. sp 12947 Lavender field soil, 
Hungary 
1989 
S. costaricanus 13455 Soil, Costa Rica 1997 
S. rhizosphaericus 13674 Ectorhizosphere, 
Indonesia 
1997 
S. sanyensis 14820 Mangrove sediment, 
China 
2012 
S. aridus 14965 Atacama Desert, Chile 2014 
Non-soil isolates    
Streptomyces sp. 
 
14101 
 
Marine sediment, 
Mariana Trench 
2005 
Streptomyces sp. 
 
10987 
 
PVC-coated wallpaper 
 
1973 
 
 
3.2.2 Antimicrobial activity screen of Streptomyces strains 
 
The bioactivity of 12 NCIMB Streptomyces strains was measured against E. coli 
NCIMB 10236, B. subtilis NCIMB 10113, and Methicillin Resistant S. aureus 
NCIMB 50143 using an agar overlay assay.  Spore suspension (20 μl) of each 
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strain were spotted onto agar plates of Tryptone Soya Agar (TSA), Nutrient Agar 
(NUT), OM, Bennett’s Agar (BA), medium 19 (M19), medium 400 (M400), 
international streptomyces project medium 4 (ISP4), ISP5, Deutsche Sammlung 
von Mikroorganismen und Zellkulturen medium 5006 (DSMZ 5006), glucose 
yeast malt, and maltose yeast malt (GYM, MYM).  Additional media recipes are 
found in Appendix section 8.2.  Each plate was divided into quadrants to culture 
4 Streptomyces at 30°C for 7 d.  A flask of 50 ml nutrient broth was inoculated 
with a loop of each of the 3 test strains, and grown overnight at 37°C, 175 rpm.  
This preculture was added to 2 x 450 ml freshly autoclaved NUT agar once it was 
under 50°C, mixed, and poured over Streptomyces cultures to produce an 
indicator lawn.  Zone of inhibition diameters were recorded after 24 h culture at 
37°C.  Only zones greater than 1 cm were included.  
OM, M19, ISP5, GYM, and MYM ingredients are listed in Section 2.5.2.  Other 
media are shown in Appendix table 2, except NUT and TSA which used the 
premade Sigma-Aldrich TSA and NUT mixes.  All components were obtained from 
Sigma-Aldrich (Poole, UK)  
3.2.3  24-well plate culture and extraction 
 
3.2.3.1 24-well plate nutrition screen to assess metabolomic 
diversity 
 
S. costaricanus NCIMB 13455 (S. costaricanus), Streptomyces sp. NCIMB 14101 
(Streptomyces sp. MT5), and NCIMB 10987 (Streptomyces sp.) were selected 
based on initial bioactivity tests and isolate niche variety.  Strains were grown as 
in section 2.2.6 with the following modifications: 
1) Comparison plate with liquid media for each time point. 
2) Time points reduced from 5/10/15 d to 5/10 d for agar and broth. 
3) Soil extract agar, minimal mannitol medium, proline yeast malt and 
peptone sucrose media replaced with Sucrose-Meat extract (SM), 
Soybean-Glucose-Tryptone (SGT), Molasses-Meat extract (MM), and Corn 
steep liquor-Soya flour (CS) media.  All solid media contained 20 g/l agar.   
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Additional media were formed from ingredients reported to upregulate 
specialised metabolism (Junker et al., 1998; Tormo et al., 2003; Fedorenko et 
al., 2015).  Compositions are found in Appendix table 3. 
3.2.3.2 Extraction of metabolites from 24-well plate culture 
 
Broth culture metabolites were extracted by adding 1 ml 50% aqueous methanol 
to each well, gently shaking to mix then leaving to sit for 5 min.  A syringe 
pipette was then used to transfer 1 ml from each well to a respective 1.5 ml 
microcentrifuge tube.  Agar cultures were extracted as section 2.2.6 up until the 
filtering stage.  Both agar and broth extracts were then filtered by adding 500 μl 
of each to a corresponding Whatman Mini-UniPrep G2 Syringeless Filter UPLC Vial 
(GE Healthcare, Little Chalfont UK) and filtered using a Whatman 
Multicompressor.  Samples were stored at -20°C until UPLC-MS analysis. 
3.2.3.3 24-well plate culture using minimal media and elicitors 
 
For minimal media and elicitor experiments, 24-well plates were used to culture 
S. costaricanus in the conditions given in Table 3.2 in triplicate.  The minimal 
medium used is referred to as MMM and is distinct from the nutrition screen 
maltose-meat extract medium (MM).   
Table 3.2 Minimal media growth conditions for S. costaricanus 
MMM+ 
Condition Elicitor purchased from 
No elicitor (just MMM culture) - 
25 μM Scandium chloride Sigma-Aldrich 
25 mM Sodium butyrate (NaBu) Sigma-Aldrich 
10 mM N-acetyl glucosamine (GlcNAc) Sigma-Aldrich 
MMM pH 4 - 
MMM pH 10 - 
Dead A. baumannii (100 μl)* - 
A. baumannii culture supernatant (100 μl) - 
MMM culture at 42°C - 
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*Dead A. baumannii cells were prepared from A. baumannii NCTC 13301, a 
clinical β-lactam resistant strain, which was purchased from Public Health 
England and maintained on Muller-Hinton agar plates at 4°C.  
A loop of A. baumannii NCTC 13301 colony was used to incubate in a 50 ml 
overnight culture of Muller-Hinton broth.  The culture was transferred to a 50 ml 
centrifuge tube and centrifuged for 15 min, at 5000 x g.  The supernatant was 
filtered through a 0.2 μm sterile filter into sterile 1.5 ml microcentrifuge tubes 
before adding to wells.  Pellet was resuspended in 10 ml sterile 18.2 MΩ water 
and placed in a beaker of boiling water for 30 min.  Heat killed cell suspension 
was then pipetted into wells.  Each well was inoculated and extracted as the 
nutrition screen wells above. 
3.2.4 Metabolite analysis by UPLC-MS 
 
Samples were analysed using the Streptomyces specific set of parameters found 
in Section 2.2.8.  The same MZmine (Pluskal et al., 2010; Myers et al., 2017) 
settings as Section 2.2.9 were also used.  For the minimal media screen, 
samples of Muller-Hinton broth and A. baumannii supernatant were run with LC-
MS to remove media or unwanted metabolites in MZmine. 
3.2.4.1 Actinomycin quantification 
 
A 10 μg/ml actinomycin D standard was analysed by UPLC-MS.  This was used to 
quantify other actinomycins through comparisons to the extracted ion peak area 
of actinomycin D.   
3.2.5 Statistical analysis  
 
Initial PCA was achieved using the MZmine PCA setting on the processed 
combined peak list for all 3 strains, using feature Peak Area for the peak 
measurement setting.  Further statistical analysis on S. costaricanus was 
performed by exporting the MZmine peak list to MetaboAnalyst v4.0 (Chong et 
al., 2018).  Settings used were default missing value settings, features filtered 
by Interquartile Range, normalised by sum, and data transformed using glog, 
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adapting the recommended or well performing untargeted metabolomics 
processing methods found by Di Guida et al. (2016).   
3.2.6 Overview of proposed methods 
 
This chapter builds on the 24-well plate culture and extraction procedure 
developed through chapter 2, applying it to 3 non-model Streptomyces to 
catalogue their metabolite variety and use it to inform further strain and culture 
parameter selection.  The methods are summarised in Figure 3.1. 
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Figure 3.1 Summary of methods used to screen non-model Streptomyces 
strains. 
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3.3 Results and Discussion 
 
3.3.1 Selection of NCIMB Streptomyces strains 
 
3.3.1.1 Geographical variety of isolates 
 
At the time of writing there were 469 Streptomyces strains in the NCIMB 
collection.  Of these, 287 have some level of isolation information, from just 
“soil” through to a specific country, elevation, and building (NCIMB 11762, 
“Soil…from Atacama Large Millimeter Array observatory site 4000 m above sea 
level, Atacama Desert, Chile”).  A basic overview of niche type numbers is shown 
in Figure 3.2. 
 
 
 
 
 
 
 
 
 
The older strains, generally deposited towards the end of the 1960s, frequently 
lack geographical information which biased the selection towards more recent 
isolates. The majority of continents have isolates taken from them, with 
Antarctica the only one missing from the collection.  Streptomyces have been 
isolated from Antarctica, but only recently and in small numbers (Núñez-Montero 
et al., 2019).   
 
 
Total=287
Soil (258)Marine (8)
Plant (9)
Animal (6)
Miscellaneous (6)
Figure 3.2 Breakdown of NCIMB Streptomyces strains with 
niche isolation data. 
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3.3.1.2 Antibacterial activity screen of selected soil isolates 
 
A preliminary bioactivity screen was used to inform which soil Streptomyces 
would be selected for metabolomic screening.  The soil strains were assayed 
against 3 test species: Escherichia coli, Bacillus subtilis, and methicillin resistant 
Staphylococcus aureus.  Media and strains showing bioactivity against each of 
the test bacteria are shown from Figure 3.3 to Figure 3.5.  Only strains showing 
bioactivity are included in the figures. 
Bioactivity was more common against the two Gram-positive species: of the 121 
conditions (11 strains, 11 media) tested, 10 (4 species) produced activity against 
E. coli, 18 (6 strains) against B. subtilis, and 27 (7 strains) against MRSA.  Not 
all strains were active against both Gram-positive species even if growth of 1 of 
the 2 was inhibited.  As an example, S. costaricanus inhibited MRSA after growth 
on MYM and GYM but did not inhibit B. subtilis under the same culture conditions.  
This implies some level of specificity in the antibiotics secreted. 
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Figure 3.3 Strains with bioactivity against E. coli. 
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Figure 3.4 Strains with activity against B. subtilis 
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Figure 3.5 Strains with bioactivity against MRSA 
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3.3.1.3 Antibacterial metabolites produced by bioactive strains 
 
Streptomyces aridus, isolated from the ultra-arid Atacama Desert, was most 
varied on media in activity against E. coli, producing 4 zones of which 3 were 3 
cm or larger in diameter.  The largest zone was produced by S. avellaneus 
(NCIMB 11000) on Bennett’s Agar.  This strain is a known chlorotetracycline 
producer (Ward & Allenby, 2018), a broad spectrum antibiotic active against 
Gram-positives and negatives.   
S. avellaneus also produces chromomycins (Kawano et al., 1990), which are 
active against tumour cells and Gram-positives.  Gram-negative activity is not 
reported, potentially due to difficulties crossing the Gram-negative membrane 
(Kamiyama & Kaziro, 1966), so is unlikely to be the active compound against E. 
coli unless combined with an unknown emulsifier . Running the equivalent strain 
S. avellaneus NRRL B-3447 (accession ID NZ_JOFK00000000)  through 
antiSMASH v5 (Blin et al., 2019) to predict other potentially bioactive compounds 
was not useful as the shotgun genome sequence was too fragmented for robust 
predictions.  Activity from S. avellaneus was seen from growth on BA, ISP5, and 
YM.  Both BA (6 cm inhibition) and ISP5 (4.8 cm inhibition) have glycerol as a 
carbon source, potentially indicating antimicrobial upregulation with glycerol 
growth media. 
Both Gram-positive species were inhibited by a wider set of Streptomyces.  S. 
costaricanus had the largest zone of inhibition against MRSA (7.4 cm on ISP4) 
and B. subtilis (6.4 cm on TSA), the second of which is shown in Figure 3.6.  S. 
costaricanus also consistently produced a zone on 7 of 11 media, with the lowest 
potency on M400 (4.8 cm).  No other strains produced activity on as many media 
as S. costaricanus.   
At the time of the experiment, no specific antimicrobial compound information 
was known about this species past its association with “nematode-suppressive 
soil” (Esnard et al., 1995), and inhibition of the plant pathogens Rhizoctonia 
solani and Phytium aphanidermatum (Goodfellow et al., 2012).  Liu et al. (2019) 
later published on a marine strain of S. costaricanus which was found to produce 
actinomycins D, X0β, and X2 which could explain the bioactivity against other 
Gram-positive species and orange pigmentation seen in Figure 3.6. 
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Gram-negative species are more resistant to antibiotics than Gram-positives due 
to the presence of an outer membrane in Gram-negative species (Tsuchido & 
Takano, 1988).  The outer membrane is comprised of a mix of phospholipids and 
lipopolysaccharides forming the main bilayer, with proteins performing various 
functions like porins and receptors placed throughout the layer (Delcour, 2009).  
This acts as a barrier to antibiotics that are active only when intracellular.   
The outer lipopolysaccharide layer is highly impermeable to most molecules, and 
diffusion is mostly through porin channels which provide a clear resistance target 
for natural selection.  Though 11 strains and media against 1 Gram-negative and 
2 Gram-positive species is not a large enough sample to properly represent of 
intrinsic resistance, the fewer positive results against E. coli fits the expected 
trend.  Other potentially bioactive metabolites produced by the inhibitive species 
are listed in Table 3.3.  The DSMZ equivalent strain page for S. flaviscleroticus 
list (DSMZ, 2019) lists it as producing aburamycin and “antibiotic M5-18903”, 
but no corresponding literature could be found to confirm this.   
 
 
 
 
 
Figure 3.6 Inhibition of B. subtilis caused by S. costaricanus on TSA, showing 
orange pigmentation.  Actinomycin is a red/dark orange colour. 
S. costaricanus 
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Table 3.3 Compounds produced by inhibitive strains against Gram-negatives and 
Gram-positive bacteria. 
 
3.3.1.4 Selection of soil strain 
 
S. costaricanus did not show any activity against E. coli.  However, classical 
bioactivity-based screening is also not suitable for conveying the full range 
metabolites a species produces under even one growth condition.  One bioactive 
molecule, likely one already discovered if using standard lab growth conditions, 
can hide the presence of any other similarly bioactive compounds, especially 
those expressed at low levels.  A cryptic BGC coding for a highly bioactive 
metabolite may be expressed at a low level, rather than totally silent, requiring 
Species Metabolites inhibiting Gram-negative growth  
Streptomyces 
avellaneus 
Chlorotetracycline 
Streptomyces 
flaviscleroticus 
- 
Streptomyces 
purureus 
Chloramphenicol (Goodfellow et al., 2012) 
 
 Metabolites inhibiting Gram-positive growth  
  
Streptomyces 
avellaneus 
Chlorotetracycline, chromomycins 
Streptomyces 
costaricanus 
Actinomycins (Liu et al., 2019) 
Streptomyces 
flaviscleroticus 
Chromomycins (Prajapati et al., 2019) 
Streptomyces 
purureus 
Chloramphenicol 
Streptomyces 
rhizosphaericus 
- 
Streptomyces 
sanyensis 
Potentially staurosporine (Sancelme et al., 1994; Li et 
al., 2013) 
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scaleup and fractionation to isolate.  Therefore S. costaricanus was chosen as the 
soil Streptomyces for specialised metabolite diversity evaluation.   
S. costaricanus produced at least one bioactive antimicrobial in over half of the 
media against MRSA, and 5/11 against B. subtilis.  Given the high rates of 
bioactivity it was likely that at least some of the compounds were previously 
identified.  This also makes S. costaricanus a good choice for further analysis, 
since any identified compounds can be used to benchmark production of 
unknowns and help identify bioactive metabolites against Gram-negatives. 
3.3.1.5 Selection of non-soil strains 
 
The most geographically extreme isolate is from the Mariana Trench, 
Streptomyces sp. NCIMB 14101. Based on its totally different niche to S. 
costaricanus it was selected for 24-well plate screening.  Of the remaining non-
soil strains, though both listed as biosafety level 1, S. gedanensis and S. 
willmorei are both potential pathogens. The ATCC equivalent for S. gedanensis, 
ATCC 4880, is listed as a clinical isolate, and S. willmorei was isolated from a 
patient with streptotrichosis.  While  primary Streptomyces infections both in 
healthy and immunocompromised human hosts are rare (Kapadia et al., 2007), 
to minimise risk neither were selected for further analysis.  Of the remaining 
strains, Streptomyces sp. NCMIB 10987 had the most different isolation niche 
(growth on PVC wallpaper) so was also selected as the final strain. 
3.3.2 Metabolomic analysis of Streptomyces strains 
 
The three strains selected in 3.3.1 were each cultured using the 24-well plate 
system outlined in Chapter 2.2.6 then metabolites extracted for UPLC-MS 
analysis.  After processing with MZmine, an initial PCA plot was used to reduce 
data complexity and show which strain produced the most metabolomic variety 
both within and between strains.  Both Streptomyces sp. NCIMB 10987 and 
Streptomyces sp. NCIMB 14101 clustered close to each other, with the exception 
of Streptomyces sp. NCIMB 10987 MYM 10 d culture (Figure 3.7), and S. 
costaricanus samples mostly separate. 
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The MZmine peaklists were exported to MetaboAnalyst for more in-depth 
multivariate analysis.  After processing the peak lists to produce a more accurate 
analysis (filtering, scaling, and transformation steps listed in methods), 
MetaboAnalyst PCA (Figure 3.8) also showed a clear difference between S. 
costaricanus and the other 2 strains, though the total variation explained using 2 
principal components was under 50% (37.7 + 5.2%).   
The majority of samples for each strain were grouped within the 95% confidence 
interval circles, indicating that analysed metabolites produced by each strain 
should significantly vary.  The strain selection was therefore successful in that 
there was demonstrably significant metabolite variety between strains.  There 
was some overlap between the intervals, potentially due to shared common 
Streptomyces compounds like deferoxamines.  To reinforce the overall 
separation, and check if the shared features were significant between S. 
costaricanus and the other 2 strains, the data was re-run through a Partial Least 
Squares-Discriminant Analysis (PLS-DA).   
Figure 3.7 PCA of 3 NCIMB strains in MZmine.  The three red circles in the 
upper right corner are Streptomyces sp. NCIMB 10987 MYM 10 d triplicate 
samples. 
S. costaricanus 
MM 5 d 
S. costaricanus 
M19 10 d 
S. costaricanus 
M19 5 d 
= 10987 = 14101 = 13455 
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PLS-DA is a supervised multivariate technique, so uses class identification 
information provided by the user in its analysis.  This is in contrast to PCA which 
does not use any class information to group data.  PCA is therefore considered a 
good initial exploratory tool, while PLS-DA is more suitable for separating data 
(Worley & Powers, 2012) so can act in tandem to confirm sample and class 
separation.  Figure 3.8b shows a similar PLS-DA pattern to the PCA, in that S. 
costaricanus is separated from the other two strains except with no confidence 
interval overlap.  
As a supervised method, PLS-DA can potentially group unrelated data if classes 
are randomly assigned, producing meaningless results (Szymańska et al., 2012). 
Separation validity can be confirmed using a permutation analysis, which 
randomly assigns classes and checks separation similarity against the original 
output.  Running the permutation analysis confirmed that the PLS-DA model was 
significantly different to one with random class assignments (p < 0.001), 
validating the model.   
 
 
 
 
 
 
 
 
 
 
 
S. costaricanus appeared to have the least overlap with the other 2 strains going 
by the PCA, indicating a greater metabolomic diversity was produced by S. 
costaricanus on these media than by S. sp. 10987 or S. sp. 14101.  
(a) (b) 
Figure 3.8 (a) PCA, and (b) PLS-DA of S. costaricanus (NCIMB 13455), 
Streptomyces sp. NCIMB 10987, and Streptomyces sp. NCIMB 14101. 
= 10987 = 13455 = 14101 
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Examining the PCA loadings plot, the three most important features for 
separation had m/z of 1269.67, 1293.67, and 1271.68 with rt of 6.80, 6.12, and 
6.22 min respectively.  Spectral analysis of each of the features gave a putative 
identity of actinomycins, a family of compounds produced by non-ribosomal 
polypeptide synthetases with antibiotic and anticancer activities depending on 
the family member (Katz et al., 1956).   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The most abundant feature which also contributed most to separation – m/z 
1269.67 – could be definitively identified as actinomycin X2 [M+H]+ (shown with 
comparison to the most well studied actinomycin, actinomycin D in Figure 3.9), 
and m/z 1271.63 as actinomycin X0β [M+H]+.   
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Figure 3.9 (a) Structure of actinomycin X2.  (b) Comparison of actinomycin 
D standard to detected actinomycin X2. 
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As other unidentified features also significantly contributed to separation, it was 
therefore hypothesised that focusing on S. costaricanus would give a higher 
chance of producing and identifying varied, novel metabolites rather than the 
other 2 Streptomyces species.  As a further representation of metabolomic 
diversity, the total detected features across all 3 species were displayed using a 
heat map (Figure 3.10, names of specific media and feature m/z are not shown 
due to the large numbers of both), though it should be noted that as this shows 
features both metabolites and their MS-derived fragments are included.  The 
heat map showed S. costaricanus metabolite intensities fluctuating more 
compared to the other 2 species, while also identifying which media produced the 
most variation and overall production within a strain. Therefore, data for S. 
costaricanus was re-run to produce the heat map of 569 features shown in 
Figure 3.11. 
This heat map more clearly shows the compartmentalisation of features derived 
from S. costaricanus culture on different media.  It also allowed basic overall 
comparison of the effect of sample time.  As an example, CS agar and broth 
culture at 10 d share a run of higher intensity detected features which is not 
seen at 5 d.  These features are not common to 10 d culture with every media, 
indicating that both the correct media and later culture time are required to 
produce the corresponding metabolites.  Culture with ISP5, OM, and SGT 
produced the smallest blocks of uniquely higher detected features.  This could 
have been due to a mix of poor growth, as in the case of ISP5 broth, unsuitable 
culture time with that media, or simply a non-optimal set of nutritional 
parameters for widespread novel metabolite production.  In comparison, M19, 
MM, and MYM culture features all had larger runs of increased detection, as well 
as clear progressions from 5 d to 10 d over both agar and broth media, with M19 
showing the longest run of features. 
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Figure 3.10 Heat map of 3 Streptomyces strain metabolomic features produced 
by growth on 8 agar and 8 broth media with an MS detection limit of 1E3 signal 
intensity.  Left to right: S. sp. NCIMB 10987, S. costaricanus, S. sp. NCIMB 
14101.  Each row is a separate feature which retains its identity across the map 
for all the 3 strains.  Blue indicates relatively lower feature detection, red higher 
feature detection.  Blocks of higher intensity detection within a column does not 
indicate feature similarity, only that MZmine arranged higher detected features 
together from that sample, which are from multiple metabolites.   
S. sp. NCIMB 10987 S. costaricanus S. sp. NCIMB 14101 
Higher 
intensity 
Lower 
intensity 
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Figure 3.11 Heat map of features derived from S. costaricanus culture on agar 
and broth media.  There are 2 columns present in each colour segment, which 
represent the 2 sample time points at 5 d then 10 d.  Blue boxes indicate 
actinomycin feature containing rows, identified as the main cause of 
separation from the other 2 Streptomyces strains.  Feature intentisty is 
indicated with grey (low intentsity) to red (high intensity) cell colour.   
Putative actinomycin [M+H] rows 
 121 
 
While the overall method did appear to have given useful information for strain 
selection, there are potential considerations to widespread application. One is if 2 
of the 3 selected strains were closely related, for example two Streptomyces sp. 
strains that were actually S. coelicolor and S. lividans or even the same species.  
This would effectively skew the metabolomic results towards one strain by 
unintentionally decreasing the available comparative variety.  While it cannot be 
confirmed without species classification, this is unlikely to apply here, as the 
non-soil strains were intentionally selected from different niches with vastly 
different survival pressures.  Full genome sequences for the strains would also 
prevent this, but they were not available at the time of selection. It would also 
have enabled genome mining, giving an alternative – or complementary – strain 
selection process.  Ideally this would be included earlier in any further strain 
comparison projects, especially given the decrease in long-read sequencing 
costs.   
Secondly, as the overall aim was to create a generalised screen to expand 
specialised metabolism, the growth conditions may not be optimised for each 
individual strain. This issue is arguably shared by most OSMAC projects as 
without any prior knowledge about a strain’s niche preferences or genetic 
regulation it is impossible to directly optimise an OSMAC screen.  This can be 
partially resolved by using multiple growth conditions, but this needs to be 
weighed against the practical considerations of how much more data processing 
and analysis there will be for each strain.  Similarly, though using a strain from 
an extreme environment may be a promising new metabolite source, its extreme 
environment may lead to different metabolite activation conditions than a typical 
soil Streptomyces.  As the project was based on NCIMB Streptomyces, the 
majority of which are soil strains, this problem is another balance between a 
broad condition screen and tailoring to an individual isolate.  
3.3.2.1 Impact of media on actinomycin production 
 
As stated in section 3.3.2, the metabolites most contributing to separation in PCA 
were the actinomycins, specifically actinomycins X0β and X2.  Actinomycin X2 
differs to the most well studied family member, actinomycin D, by the addition of 
an oxygen R-group.  The other detected actinomycin, X0β, contains an OH R-
group at this location.   Actinomycin D was produced but contributed less to PCA 
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separation.  The main metabolite family data broadly agrees with a recently 
published paper on a marine strain of S. costaricanus where actinomycin D was 
found to be the main product; here on most media it was actinomycin X2 (Liu et 
al., 2019). 
General characteristics are given for the 3 detected actinomycins in Table 3.4.  
Antibacterial activity is strongest against Gram-positives as actinomycin is less 
able to penetrate the Gram-negative outer membrane to bind DNA and prevent 
transcription.  Activity is still seen against some Gram-negatives for different 
family members, but the literature is not consistent about activity levels.  Wang 
et al. (2017) detected the same actinomycins from a marine isolate of S. 
heliomycini, tested against E. coli and found it to be ineffective, whereas Zhang 
et al. (2016) report an MIC of 0.12 μM for actinomcyins D and X2. 
Production of actinomycins by S. costarcianus grown on different media was 
compared as they were the most important PCA separation feature.  Actinomycin 
X2, the predominant actinomycin, was produced by S. costaricanus at a 
maximum concentration of 15.14 μg/ml from M19 broth cultures after 10 d.  The 
combined concentrations for all actinomycins over both broth and agar culture 
are shown in Figure 3.12, which displays significant variation in X2 production 
across S. costaricanus culture.  Trends for actinomycin levels also varied from 5 
to 10 d, with the majority of media leading to increasing production levels over 
time.  Culture on other media like M19 or CS broth did not produce a significant 
increase over 5 d to 10 d. 
 
Table 3.4 Detected actinomycins and their characteristics 
 
Actinomycin 
member 
m/z of 
[M+H]+ 
Formula of 
[M+H]+ 
Bioactivity 
against 
Source 
D 1255.64 C62H86N12O16+ Tumours 
Gram-positives 
Gram-negatives 
(weaker, less 
applicable) 
Xiong et al. 
(2012); Liu et al. 
(2016); Zhang 
et al. (2016); 
Wang et al. 
(2017)  
X2 1269.63 C62H84N12O17+ 
X0β 1271.63 C62H86N12O17+ 
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ISP5 agar culture gave significantly less compound at 5 compared to 10 d (3.71 
μg/ml up to 13.12 μg/ml respectively), with an approximately 4-fold difference.  
Similarly, MYM broth culture produced 2.11 and 8.98 μg/ml over the time points.  
In comparison, CS broth culture did not significantly change.  The medium 
leading to the most consistent production of actinomycin was M19 agar, which 
gave a slight decrease from 11.09 down to 10.08 μg/ml over the sample points.  
The M19 broth equivalent does not follow the same pattern, showing a 3-fold 
increase from 5.46 up to 15.14 μg/ml. 
The greatest difference was seen between ISP5 agar and broth media, which 
gave one of the largest yields from agar but none from broth.  This comparison is 
not wholly useful since growth was severely restricted, potentially absent, in 
ISP5 broth.  Why S. costaricanus did not grow is unknown since ISP5 does not 
contain any abnormal components which would prevent growth without agar.  
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Figure 3.12 (a) Concentrations of 3 detected actinomycins derived from S. 
costaricanus agar culture, and (b) actinomycins derived from S. costaricanus broth 
culture.  Key for actinomycin types and culture times: 
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3.3.3 Impact of minimal media culture supplemented with 
elicitors on metabolite production 
 
The 8 media used in the nutrition screen contained a diverse range of carbon and 
nitrogen sources, and minerals.  While growth on complex media can lead to a 
different metabolome in each condition, it also made it more difficult to link 
specific media components to specialised metabolites. Therefore, to further 
explore the metabolite diversity of S. costaricanus, it was grown in minimal 
mannitol media (MMM) with a single parameter altered over 9 other wells: 25 μM 
scandium chloride, 25 mM sodium butyrate (NaBu), 10 mM N-Acetyl 
Glucosamine (GlcNAc), pH 4, pH 10, Acinetobacter baumannii cells, A. baumannii 
supernatant, constant 42°C, and 42°C heat shock for 1 h after 5 d culture. 
Actinomycins were not detected above the 1E3 MS1 cutoff from minimal media 
culture.  Analysis of MS/MS files of 24-well plate minimal media culture 
processed with MZmine with lower signal intensity inclusion (1E1) did detect 
actinomycins D and X2, along with deferoxamine B complexes [M+Al-2H; M+Fe-
2H]. 
3.3.3.1 Elicitors upregulate production of S. costaricanus 
metabolites in minimal media culture 
 
Comparing the other culture conditions to standard minimal media growth and 
removing those with no new metabolites eliminated scandium chloride and 42°C 
heat shock.  This left 5 conditions, shown in Figure 3.13, producing 20 features 
not seen from minimal media culture.  Features were predominantly specific to 
their elicitors, with only 1 being shared over multiple elicitors: m/z 625.19 rt 
1.45 min, shared between pH 4 and 100 μl A. baumannii culture supernatant.  
Though elicited by culture supernatant this feature was not produced in response 
to heat-killed A. baumanii cells.   
One feature was upregulated after addition of dead A. baumannii (m/z 648.31 rt 
1.71) to minimal media.  A feature with the same m/z and rt is present in the 
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original minimal media culture, but at an intensity approximately two orders of 
magnitude less than with A. baumannii added (2 – 3E1 against 2 – 4 E3).   
 
 
 
 
 
 
 
 
 
 
 
Co-culture mediated induction of specialised metabolism can occur through a 
variety of methods, including secreted metabolites (D Wang et al., 2013) or cell-
cell contact (Onaka et al., 2011).  This study showed living cells along with 
physical contact were necessary for SMet upregulation; another study on S. 
coelicolor A3(2) used dead Bacillus subtilis and Staphylococcus aureus cells to 
increase production of undecylprodigiosin (Luti & Mavituna, 2011).  Murphy et al. 
(2007) increased production of bacitracin A from B. lichenformis by adding 
oligosaccharides to the growth medium, indicating that the biochemical itself was 
sufficient for upregulation.  S. costaricanus could be similarly reacting to A. 
baumannii thermostable cell wall components. 
Figure 3.13 Heat map of features found in MMM+elicitor S. costaricanus 
cultures but not in MMM-only culture.  Dark blue through to white then dark 
red indicates relatively lower to higher LC-MS feature intensity as a proxy for 
metabolite production.  Deferoxamine B, upregulated by culture at pH 4, was 
detected from rich media culture but not from minimal media. 
Deferoxamine 
B 
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Similarly, higher temperature treatment elicited metabolites (m/z 316.33 rt 
5.85; m/z 281.06 rt 7.29) that were produced under minimal media culture of S. 
costaricanus but below detection levels: m/z 316.33 goes from a mean intensity 
by height of 7.3E1 to 3.1E3, and m/z 281 1.4E2 to 3.3E3. Of the 2 pH4-specific 
metabolites, 1 (m/z 561.39, deferoxamine B) was already seen in the nutrition 
screen. 
3.3.3.2 Putative metabolite family upregulated by addition of 
GlcNAc 
 
GlcNAc has been shown to pleiotropically activate specialised metabolism in a 
range of Streptomyces, though unsurprisingly given the variety of the genus and 
complexity of genetic regulation, can also repress or have no effect on SMet 
(Rigali et al., 2008). Of the 6 potentially novel metabolites produced by S. 
costaricanus under this condition, three (m/z 341.26, 355.27, 369.30, or 0, +14, 
+28) elute close together over 3.6 to 4.7 min.  A similar fragmentation pattern is 
shown maintaining the 0/14/28 m/z difference, potentially indicating a molecular 
family separated by CH2 and C2H4 fragments (Figure 3.14).  Manually searching 
the GNPS database for these masses did not find any matches. 
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3.3.4 Selection of media for scale-up culture 
 
Originally selection of the target strain for further investigation was based on 
PCA to show overall diversity in the S. costaricanus metabolome.  However, 
while the PCA did separate the sample replicas into groups (Appendix figure 10), 
the variance explained by PC1+PC2+PC3 was not high (21.5%+9.1%+8.0%) 
and there was significant overlap between conditions.  This made PCA unsuitable 
for deciding which condition should be used.  Instead, total and unique feature 
numbers were used to show the most productive conditions.  The overall effect of 
varying culture conditions on S. costaricanus is displayed in Figure 3.15, and was 
used along with carbon source repression likelihood and growth levels to make 
the scale-up selection. 
Although MM culture gave the highest number of total detected features (202), 
there were a relatively low number of unique features (60), meaning those which 
were not detected from culture in any other growth media.  As MM contains 3 
potential carbon sources, 20 g/l molasses, 5 g/l glucose, 1 g/l yeast extract, the 
total number likely reflects high growth with no nutritional stress for S. 
costaricanus. A full comparison of features total and unique features for media is 
shown in Figure 3.15.  This figure also shows the number of features found as a 
result of broth or agar culture from a specific medium, as well as any features 
shared between the two.  For most conditions, broth led a greater number of 
features with the only exception being ISP5, in which S. costaricanus was not 
seen to grow. 
 
 
 
 
 
 
 
 130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The media leading to the highest number of unique features relative to its overall 
production was ISP5 (81.0%), followed by culture on SGT (73.7%), OM (61.6%), 
MYM (57.7%), SM (55.9%), M19 (48.6%), MM (29.7%), and CS (29.3%).  This 
should not be taken as rankings of the “best” media for unique metabolite 
production by S. costaricanus – ISP5, though it is at the top of the list, gave no 
Figure 3.15 (a) Total and unique features detected from S. costaricanus 
OSMAC culture, and (b) Features from broth and agar culture, or shared 
between them 
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growth in ISP5 broth and fewer unique features than all but CS and OM.  CS and 
SGT included 1 g/l of glucose in case the potential main carbon source (Corn 
Steep Liquor and Soybean Oil respectively) could not be effectively utilised by S. 
costaricanus.  Culture of S. costaricanus on both CS and SGT conditions gave 
good confluent growth, but SGT clearly outperforms CS with 133 to 92 total 
features and 71 to 27 unique features.   
S. costaricanus produced consistently good growth on media without glucose 
(OM, M19, ISP5, MYM, M19, and MYM) with relatively high total/unique feature 
numbers.  The least globally repressive carbon source used in the screen is 
potentially mannitol (Romero-Rodríguez et al., 2016), which is the sole source of 
M19.  Culture on M19 also gave the 2nd most overall (181) and 3rd most unique 
(88) features, and interestingly matched the bald phenotype shown by S. 
coelicolor on M19 in Chapter 2.  Given its good growth and high-ranking feature 
production, M19 was selected as the scale-up medium.  M19 broth gave more 
detectable features than Agar (148 against 70) so was selected for scale-up 
culture.  Both MM and MYM were good candidates for scale-up, but the MM 
extracts contained fewer unique features than M19; MYM extracts had a similar 
number of unique features, but fewer overall.  Maltose can also be a restrictive 
carbon source, especially as a glucose disaccharide (Sánchez et al., 2010).  Both 
of these points reinforce M19 as a suitable medium for further studies. 
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3.4 Conclusions 
 
The NCIMB Streptomyces collection was surveyed for unexploited strains diverse 
range of isolation niches, using zone of inhibition-based bioactivity assays to 
select from the soil strains and niche variety for 2 other non-soil strains.  This led 
to the selection of the strains NCIMB 13455 (Streptomyces costaricanus, Costa 
Rican soil), NCIMB 14101 (Streptomyces sp., Atacama Trench sediment), and 
NCIMB 10987 (Streptomyces sp., growth on PVC wallpaper).  The 3 strains were 
screened using the 24-well plate culture screen developed in Chapter 2, leading 
to the identification of S. costaricanus as the most distinct from the other 2 
strains.   
The nutrition screen data for S. costaricanus showed the main produced 
metabolite family to be the actinomycins, followed by deferoxamines.  Production 
levels of both of these families varied across media type and sample time, with 
M19 and ISP5 culture producing the most actinomycin on agar media, and M19 
and MM culture producing the most in broth.  Comparing the total features 
produced across all of the media showed M19, MYM, and MM culture gave the 
most features.  Of those, M19 was selected for further culture scale-up as it 
enabled production of a relatively large number of unique features and contained 
a less repressive carbon source than other media. 
In addition to rich media culture, S. costaricanus was also cultured in minimal 
media with multiple additives or stresses that could potentially have upregulated 
specialised metabolite production.  While some of the produced metabolites were 
shared with the rich media screen, like deferoxamine B, addition of GlcNAc and 
heat-killed A. baumannii cells both elicited production of potentially novel 
metabolites.  Unfortunately, production levels were too low to reasonably scale 
up and investigate the novel features.  It was therefore decided that focusing on 
M19 culture would be more productive and so was chosen as the main culture 
scale-up parameter. 
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4 Characterisation of the S. costaricanus genome and 
its biosynthetic gene clusters 
 
4.1 Introduction 
 
4.1.1 Genomic variation of specialised metabolism in 
Streptomyces 
 
The linear genomes of Streptomyces contains a core region of approximately 
2000 genes over 5 to 7.5 Mbp (Kim et al., 2015; Wang et al., 2015), most of 
which are essential for cell survival.  Gene functions include vital processes like 
DNA replication, cell division, translation, and primary metabolism (Hopwood, 
2006).  This region displays considerable synteny not just in the genus but 
across the phylum, with analogues in both S. coelicolor and M. tuberculosis 
(Choulet et al., 2006).  The shared core region varies depending on which 
species are examined and how strict the criteria are for the core region: S. 
coelicolor and S. avermitilis are given as sharing around 4000 genes, gaining and 
losing them at approximately 10 genes every 1 million years since their last 
common ancestor (Chater & Chandra, 2006).  In comparison, the flanking 
segments – or “arms” – are skewed towards genes which allow adaptation and 
survival in a changing environment, such as chitinases, other enzymes and 
biosynthetic gene clusters (BGCs) responsible for specialised metabolism.   
The arms are also more genetically varied and malleable between strains, with a 
high rate of horizontal gene transfer aided by transposons, conjugative plasmid-
associated genes, and a high rate of insertions and deletions (Hopwood, 2006; 
Choulet et al., 2006).    Localising this variation to the arms avoids damaging the 
essential core region, thereby increasing the potential of natural selection to act 
on specialised metabolism and other genes related to environmental adaption.  
Rearrangement on the arms can be rapid: Zhang et al. (2019) re-streaked 15 
random S. coelicolor colonies, and found morphology varied from the original 
colonies, which increased again after a 2nd round of re-streaking.  Sequencing 8 
random colonies showed significant chromosome terminus rearrangement, with 
insertion sequences producing multi-300 kb amplifications mixed with deletions 
up to 878 kb long.  Mutant variety correlated with altered specialised metabolite 
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profiles as well as increased inhibition of B. subtilis; colonies were essentially 
found to be split into mutants overproducing antibiotics, and non-producers 
dedicated to growth and expansion. 
Exact examples of a specific gene, or BGC, as adaptions to a specific condition 
are rare due to the difficulty of determining previous gene acquisition events and 
if they correlate with a proposed environmental selective pressure.  Larger scale 
genomic analysis can potentially be more informative.  Tian et al. (2016) 
investigated 9 marine Streptomyces from across the South China Sea and 
compared them to publicly available sequences.  Despite being from a broad 
range of locations across the sea, the marine strains shared increased levels of 
K+ transporters, suggested to help with osmolarity regulation, as well as 
increased numbers of the transporter NhaA which exports Na+. 
A secreted metabolite which aids survival and so replication can be compared to 
an evolutionary biology concept usually associated with animal evolution, the 
“extended phenotype” (EP; Dawkins, 1982; Hunter, 2018), where a gene’s 
impact on the animal and its corresponding evolutionary fitness is expressed 
separately from the animal.  A beaver’s dam or termite’s nest are simple 
examples of the EP; the behaviour of a parasite-infected animal is a more 
complicated example of the parasite’s EP.   
Similarly, a secreted bioactive metabolite, whether a messenger molecule to its 
own strain or an antimicrobial weapon, or the breakdown of Streptomyces 
hyphae induced by programmed cell death to fuel its neighbour’s differentiation 
can be viewed as benefiting the microbial host’s own EP.  Since the specialised 
metabolite regions of Streptomyces genomes change so frequently, this 
corresponds to accelerated selection of the microbe’s genomic content and how 
the EP aids reproduction.  Kamoun, (2007) uses EP in a similar sense to describe 
effector proteins secreted by microbes inside plants, as although they are 
produced by the microbe the protein itself functions on or inside a plant cell, 
thereby modifying the environment of the producing species. 
The high genomic variation means that even closely related strains can differ in 
their specialised metabolome.  Strain-level recombination has been found to 
exceed species-level recombination rates in the S. flavogriseus clade by over two 
orders of magnitude (Doroghazi & Buckley, 2010); this partially explains the 
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phenotypic and chemotypic diversity seen from a single species. Seipke (2015) 
compared the BGCs of S. albus strains, which contain between 25 and 30 
clusters, and found a core set of 18 BGCs.  Aside from those 18, each strain had 
at least 1 of 17 unique BGCs, with a range of 1 to 6 unique BGCs per genome.  
Of those 17, 3 had a precise predicted product: paulomycin, NRPS-
oligosaccharide; kendomycin, type I-III PKS; fredericamycin, type II PKS.  The 
remainder were a mix of NRPS, PKS, butyrolactone, bacteriocin, and lantipeptide 
BGCs. 
This does not mean that specialised metabolism is completely variable across the 
genus: Kim et al. (2015) located 27 such genes conserved across 17 
Streptomyces, including well known Streptomcyes metabolites geosmin, 
deferoxamine, and hopene.  However, these genes are clearly in the minority 
compared to the overall fluidity of specialised metabolism.  The falling price of 
Whole Genome Sequencing (WGS; Didelot et al., 2012) has made routine 
genotyping more accessible, leading to a rapid increase in the amount of useful 
genomic data. 
4.1.2 Sequencing Streptomyces genomes 
 
As a complex multicellular genus, Streptomyces, especially non-model strains, 
can be challenging to work with.  This is carried over to their genome, which has 
presented multiple challenges for bioinformaticians attempting to produce a 
robust complete genome.  Two characteristics are particularly problematic: high 
GC content (Gomez-Escribano et al., 2016), and similar repetitive sequences in 
BGCs (Xu & Wright, 2019).   
High GC content is a key trait of Streptomyces and other actinomycetes with a 
typical minimum of 70% (Liu et al., 2013).  GC rich regions have a higher 
melting point than an evenly split sequence, and may form single-strand hairpin 
loops after the initial melting step which are not further amplified in PCR (Frey et 
al., 2008).  As a result, GC rich sequences can be under-amplified and so 
produce uneven to no sequencing coverage; as some assembly programmes 
treat uneven coverage as an error, this can lead to genuine sequences being 
ignored (Chen et al., 2013).   
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Even if the uneven coverage regions are not ignored, other problems can arise in 
assembling repetitive regions as found by Scott & Ely (2015).  These problems 
predominantly extend across short read sequencing technologies as the longer 
read methods do produce better coverage (Quail et al., 2012).  Both non-
ribosomal peptide synthases (NRPS) and polyketide synthases (PKS) contain 
highly repetitive sequences which cannot be easily distinguished from each other 
(Gomez-Escribano et al., 2016), especially if the assembly errors occur.   This 
will lead to either fragmented BGCs spread across the genome, or two separate 
sequences being incorrectly assembled together.  
However, as with GC richness, the longer read technologies are more suited to 
BGC sequencing as the longer read window prevents assembly errors over 
repetitive and GC rich sequences.  This was reported by Goldstein et al. (2019), 
who in their comparison of MiSeq and MinION sequencing, found their Illumina 
Pseudonocardia, a GC rich Actinomycetales genus, generated a fragmented 
sequence of thousands of contigs.  Analysing the full genome sequences in 
antiSMASH reinforced that the MiSeq sequence was biased away from GC and 
comprised fragmented BGCs.  The addition of MinION data to the MiSeq reads 
using both SPAdes and Unicycler assembly programmes resulted in fewer and 
also larger contigs, though Unicycler was the better option for hybrid assembly.   
The differences in Streptomyces genome quality between sequencers are well 
known; unfortunately, older database deposited sequences using Illumina, 454 
or other shorter read technologies are likely to have both of the above problems. 
Studholme (2016) lists multiple examples with the then 653 Streptomyces 
assemblies in Genbank.  Searching for 40 universally conserved single copy 
genes showed 239 of the 653 genomes to be missing genes, indicating their 
incompleteness.   
It is further noted that the original sequence read data may not be published, 
making it impossible to check the assembly quality. These issues make it clear 
that the correct next generation technologies should be used for Streptomyces 
WGS, ideally using long reads as the structural basis with high coverage 
additional shorter reads to improve quality by minimalising frame shift and 
random base calling errors.  Both long and short read technologies have their 
own advantages and disadvantages, so using a hybrid mixture of the 2 is a valid 
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option for a range for prokaryotic and eukaryotic species (Koren et al., 2012; 
Zimin et al., 2017; Wick et al., 2017).  In particular the longer, structurally 
correct reads which have a higher base calling error rate are complimented by 
the shorter reads, which call basses more accurately but would be difficult to 
correctly arrange without the longer read scaffolds.  
A robust genome sequence is vital for predicting the full range of BGCs.  
Screening genomes to determine a microbe’s BGC amount and so biosynthetic 
potential is a key part of genomics-based metabolite discovery.  The huge 
increase in available, hopefully high quality, data on BGCs means that 
assessment of the BGC potential of a Streptomyces is achievable early on in a 
project and can provide useful information for metabolite dereplication and BGC 
targeting.   
4.1.3 Genome mining for biosynthetic gene clusters 
 
4.1.3.1 BGC rich bacterial clades 
 
Genome mining is the process of searching a genome for a specific class of gene, 
which here are specialised metabolite BGCs.  This can then be used to guide 
strain selection or as a base for genetic manipulation to elicit production of novel 
specialised metabolites (Lautru et al., 2005; Corre & Challis, 2009).  
Streptomyces are not unique within bacteria as having high BGC numbers as 
other phyla contain high BGC clades (Baltz, 2017), some of which are briefly 
listed.   
Within Firmicutes, a selection of Paenibacillus spp. and Bacillus spp. were found 
by Baltz (2016) to contain up to 17 BGCs and produce multiple antimicrobials 
such as surfactins and bacilysin from B. subtilis (Hamdache et al., 2013).  
Burkholderia spp., a β-proteobacterium, are another source of natural products, 
with an average of 15 BGCs/species and a high of 27 in B. pseudomallei, (Liu & 
Cheng, 2014), a strain of which was exploited using a genome mining strategy 
by Biggins et al. (2011) to express a cryptic BGC.  Finally, δ-proteobacteria 
contain the order Myxococcales, or myxobacteria, most notably Sorangium 
cellulosum (32 BGCs in Sorangium cellulosum so ce56, the most of any non-
Actinomycetales member thus far) and the genus Myxococcus.  Like 
Streptomyces, these are predominantly found in the soil, have a high GC%, 
 140 
 
undergo a complex multicellular lifecycle ending in sporulation, and have a large 
genome (Garcia et al., 2009).   
While these are all valid candidates for genome mining and natural products 
research in general, Streptomyces remain the most BGC-dense genus, with a 
range of 3 – 43 BGCs and an average of 21.6 per genome from a set of 341 
strains  (Doroghazi et al., 2014).  This set did not include S. rapamycinicus NRRL 
5491, which contains at least 48 BGCs (Baranasic et al., 2013), so the actual 
average may be higher.  There are reports of Streptomyces strains with over 50 
BGCs (Jackson et al., 2018), but given their rarity are worth confirming with 
multiple sequences to avoid fragmented BGCs artificially raising the total count.  
Multiple methods and software exist to mine genomes for BGCs, some of which 
are still applicable to genomes.  One example is the detection of mbtH genes, 
which code for small proteins, typically 60 – 70 amino acids long, which act as 
chaperones for NRPS products (Baltz, 2011).  The original MbtH protein is found 
in Mycobacterium tuberculosis, where it helps solubilise the NRPS mycobactin 
(McMahon et al., 2012).  Homologues of mbtH are common across bacteria, but 
especially in Actinobacteria, for which NRPS are one of the most common BGC 
classes along with PKS and terpenes (Baltz, 2014).  Searching for MbtH 
homologues will therefore indirectly assess NRPS numbers in a genome, with less 
homologous results potentially indicating a more novel NRPS. 
The most widely used method for Streptomyces genome mining is the Antibiotics 
and Secondary Metabolite Analysis Shell, or antiSMASH (Medema et al., 2011; 
Blin et al., 2019).  antiSMASH detects a wide range of BGCs, from the common 
NRPS/PKS/terpene clusters to rarer specific types like lassopeptides, 
cyanobactins, or bottromycins.  Importantly it is also presented with an easy to 
use web interface making it accessible to anyone without needing to run the 
underlying command lines, vastly increasing adoption.  It also supports multiple 
file formats (GenBank/FASTA/EMBL), will perform basic compound structure 
prediction where possible, and provides links to the antiSMASH database.  The 
database provides a wide range of information on cluster type phylogeny, overall 
cluster type representation, and customisable cluster searches (Blin et al., 2019). 
antiSMASH detects BGCs within data by searching for core regions specific to 
cluster types then using the surrounding genomic context to build up the cluster, 
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identifying ancillary genes (transport, resistance, regulation, and others) 
potentially linked to the biosynthetic genes.  These can be used to predict further 
information about the gene or its eventual metabolite product.  This includes 
product location (intra or extracellular, based on transport genes e.g. multiple 
ABC transporters), regulatory elements like TTA codons in Streptomyces (Chater 
& Chandra, 2008) or cold/heat/other stress related sigma factors, and resistance 
genes which could identify a bioactive compound’s mechanism of action. 
Resistance-based prediction is more comprehensively examined in the Antibiotic 
Resistance Target Seeker tool (Alanjary et al., 2017). 
4.1.4 Chapter aim and objectives 
 
Integrating metabolomics and genomics data would result in a powerful tool to 
analyse metabolite production, regulation, and untapped potential of a microbe.  
The high variation of Streptomyces genomes would also make for an interesting 
comparison between the conserved likely core region genes and the more 
diverse specialised metabolite genes.  Therefore, the aim of this chapter is to 
characterise the genome of S. costaricanus and its BGCs.  This will be 
accomplished by:  
1) Obtaining a high-quality full genome sequence for S. costaricanus. 
2) Initial genome exploration and comparison to model Streptomyces  
3) Genome mining to identify BGCs. 
4) Determining if similar strains within the S. costaricanus clade share BGCs. 
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4.2 Materials and Methods  
 
4.2.1 DNA extraction and whole genome sequencing of S. 
costaricanus 
 
All DNA extraction and sequencing steps were done by the Identification 
department at NCIMB Ltd.   
4.2.1.1 DNA extraction of S. costaricanus for Illumina library 
preparation and MiSeq sequencing 
 
S. costaricanus was cultured for DNA extraction on yeast malt agar at 25°C for 7 
d after which a loop of colony was used to inoculate a 20 ml vial yeast malt 
broth.  The culture was incubated at 25°C, 150 rpm, for 5 d to generate biomass 
for DNA extraction.   
DNA was extracted for Illumina MiSeq sequencing using a DNeasy UltraClean 
Microbial Kit (QIAGEN NV, Venlo NL) following the manufacturer’s instructions.  
DNA amplification is required before the extracted DNA can be sequenced. MiSeq 
library preparation used an Illumina Nextera DNA Flex Library Prep Kit (Illumina, 
Cambridge UK).  After generation, Protocol A: Standard Normalization was used 
to denature and dilute the library, after which samples were run in the MiSeq 
using a MiSeq v3 600 cycle cartridge.  Sample documentation was created using 
Illumina Experimentation Manager. 
4.2.1.2 DNA extraction of S. costaricanus for Oxford Nanopore 
library prep and MinION sequencing 
 
The same S. costaricanus culture method was used for DNA extraction as was for 
Illumina sequencing.  DNA was extracted using a Qiagen MagAttract HMW DNA 
kit, again following the manufacturer’s instructions. 
After extraction, the 1D Genomic DNA by Ligation protocol was followed using a 
SQK-LSK109 kit to repair fragmented DNA and attach sequencing adapters to the 
DNA ends.  After repair and ligation to prepare the library, DNA was loaded into a 
FLO-MIN106 R9 flow cell and run in a MinION using MinKNOW. 
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4.2.2 Sequence assembly 
 
All assembly and quality checking steps were done by the Next Generation 
Sequencing department at NCIMB Ltd.   
WGS runs were assembled by Unicycler v0.4.7 (Wick et al., 2017), SPAdes v3.13 
(Bankevich et al., 2012), and polished using Pilon v1.22. Sequence data was 
used to generate four assemblies for comparison: MinION + paired end (PE), 
MinION + combined PE/single end (SE) with no PE read pair linking, MinION + 
PE/SE with PE read pair linking, and MinION only. Sequence analytics were 
derived from QUAST v5.0.2 (Gurevich et al., 2013) and genome completeness 
assessment by BUSCO v3.0.2 (Simão et al., 2015) or CheckM (Parks et al., 
2015).  Plasmids were searched for using the Gram Positive option of the 
PlasmidFinder tool (Carattoli et al., 2014). 
4.2.3 Streptomyces BGC Prediction with antiSMASH  
Fast-All (FASTA) files were used as the input for antiSMASH v5.  All Extra 
Features (KnownClusterBlast, ActiveSiteFinder, ClusterBlast, Cluster Pfam 
analysis, SubClusterBlast, and protein family-based gene ontology term 
annotation) were included.  After running, GenBank cluster files were 
downloaded to create a DNAPlotter gene map in Artemis v17 (Carver et al., 
2012). 
4.2.4 autoMLST cladistics 
S. costaricanus and Streptomyces sp. endophyte N2 FASTA files were submitted 
to autoMLST in denovo mode with the default settings to produce a concatenated 
alignment.  For the remainder of this chapter, “Streptomyces sp. endophyte N2” 
will be referred to as “Streptomyces sp. N2”. 
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4.3 Results and Discussion 
 
4.3.1 Whole genome assembly of S. costaricanus 
 
All genome sequencing and assembly in this section was done by the Next 
Generation Sequencing department of NCIMB Ltd. 
4.3.1.1 Initial single technology sequencing 
 
Initial sequencing of S. costaricanus with an Illumina MiSeq produced 2 
assemblies, both of which led to BGCs under 1 kb long when analysed 
antiSMASH v4 (Blin et al., 2017) indicating a fragmented misaligned genome.  
Therefore, to compliment the short MiSeq reads, prevent misalignment, and 
bridge gaps in the short reads, a longer read Oxford Nanopore MinION sequence 
was generated.  Characteristics for these sequences are listed in Table 4.1. 
Table 4.1 Statistics for 3 initial full genome sequences 
Sequencer Coverage Sequencing 
type 
Contigs Size/Mbp 
Illumina MiSeq 20x 250 bp PE 1210 7.94 
Illumina MiSeq 65x 300 bp SE 87 8.31 
Nanopore MinION 140x 1 strand (1D) 1 8.25 
 
4.3.1.2 Hybrid genome assembly 
 
The 3 assemblies were processed into 4 combinations:  
Assembly 1) Nanopore plus 250 PE. 
Assembly 2) Nanopore plus a combined 300 SE and 250 PE library, but only 
using SE data from both. 
Assembly 3) Nanopore plus 300 SE and 250 PE, using SE and PE data. 
Assembly 4) Nanopore only. 
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Statistics for each hybrid assembly are shown in Table 4.2.  This includes the 
N50, which refers to the length of the contig required to reach ≥50% of genome 
size when the contigs are ordered longest to shortest, and the L50, which is the 
number of contigs used to reach N50.  A more complete sequence is likely to 
have a high N50 and low L50, but this on its own is not enough to confirm 
genomic quality.  Assembly 4 is made of just 1 contig so has a low L50 and high 
N50 but is smaller than the other assemblies, indicating that there may be some 
missing data.  
Assembly 1 is the largest sequence, but a large number of contigs – 19 out of 23 
– under 5k bp, which indicates that the MinION data could not fully align all of 
the shorter read contigs produced from the MiSeq runs.  Aligning assembly 1 to 
what should be the most structurally correct assembly (assembly 4, as it is 1 
contig) using progressive MAUVE (Darling et al., 2010) shows inconsistent 
genome mapping between the two assemblies; in comparison, aligning 
assemblies 2 and 4 shows very high synteny (Figure 4.1).  Therefore, assembly 1 
was not used for any further analysis as the comparisons of assemblies 1 and 4 
versus 2 and 4 shows assembly 1 to be structurally incorrect.  Furthermore, the 
low PE coverage will have led to incorrect base calling and likely amplified any 
low GC read bias.  If this data were used to enhance the MinION sequence, the 
low short read quality would likely be insufficient to produce any improvement. 
Assembly 4 has the lowest Benchmarking Universal Single-Copy Orthologs, given 
in in Table 4.3 (BUSCO; Simão et al., 2015) score, despite its use as the 
structural reference.  This indicates relative genomic incompleteness, and as the 
assembly also lacks any improvement from the MiSeq data assembly 4 will also 
not be used further.  Although the long read length is advantageous for overall 
genomic structure and repetitive sequences, Nanopore – and other long read 
technologies, like Pacific Biosciences – assemblies can have a higher error rate 
per base than Illumina, at 5 to 15 against <1% (Wick et al., 2017).   
Nanopore technology operates through measurement of electric potential as a 
single strand of DNA passes through a nanopore, with each base giving a distinct 
alteration in potential and so allowing inference of the sequence (Rang et al., 
2018).  This is also the first potential source of error, which can be induced 
through the DNA passing through at varying speeds, pushing multiple bases 
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through at once, especially if the bases have additional chemical modifications, 
or with a low signal to noise ratio.  This can easily lead to fragmentation as 
errors build up over the sequence, resulting in a low BUSCO score.  
Of the two most remaining assemblies – 2 and 3 – assembly 2 produced better 
BUSCO results with only 2 contigs.  Assembly 2 was therefore chosen for further 
analysis as the best assembly and was re-processed to remove sequencing 
adapters and other contaminants followed by final polishing of the assembly 
using both sets of MiSeq data. This gave the final assembly sequence, for which 
statistics are shown in Table 4.4. Further genome quality checking with CheckM 
(Parks et al., 2015), which like BUSCO uses a set of reference genes and their 
position within a genome to determine assembly quality, gave a completeness 
score of 99.89%, outperforming assembly 3.
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Table 4.2 Statistics for the 4 hybrid assemblies.   
 
 
 
 
 
Assembly Statistic Assembly 1  Assembly 2  Assembly 3  Assembly 4  
Genome size (bp) 8588679 8350565 8568038 8246559 
N50 (bp) 7318482 5487367 3578644 8246559 
L50  1 1 2 1 
GC % 71.73 71.79 71.71 71.76 
Total contigs 23 2 13 1 
Contigs larger than 1 kb 23 2 13 1 
Contigs larger than 5 kb 4 2 6 1 
Contigs larger than 10 
kb 
4 2 5 1 
Contigs larger than 50 
kb 
3 2 5 1 
Largest Contig (bp) 7318482 5487367 3842139 8246559 
 148 
 
Table 4.3 Genome assembly completeness as determined by BUSCO.   
Assembly Complete 
Genes 
Complete Single 
Copy Genes 
Duplicate 
Genes 
Fragmented 
Genes 
Missing 
Genes 
Completeness 
% 
1 143 141 2 0 5 96.7 
2  143 141 2 0 5 96.7 
3  143 139 4 0 5 96.6 
4  69 69 0 42 37 46.6 
 
Table 4.4 Final assembly statistics. 
 
 
 
 
Assembly Statistic Value 
Length (bp) 8349884 
Contigs 1 
GC % 71.79 
Complete BUSCOs 143 
Duplicated/Fragmented BUSCOs 0 
Missing BUSCOs 5 
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Assembly 4 
(MinION) 
Assembly 1 
(+PE) 
Assembly 4 
(MinION) 
Assembly 2 
(MinION) 
(a) 
 
(b) 
Figure 4.1 Progressive MAUVE sequence alignment of Assemblies 1 vs 4, and 
2 vs 4 to determine structural correctness.  
 150 
 
4.3.2 Genomic exploration of S. costaricanus with RAST  
 
The S. costaricanus genome FASTA file was run through the Rapid Annotation 
using Subsystem Technology-SEED (RAST; Aziz et al., 2008) server. RAST 
detected 87 RNAs and 7,449 coding sequences (CDS) across 341 subsystems; a 
subsystem is defined by Overbeek et al. (2005) as a set of functional roles which 
implement a biological process or structural complex.  As an example, the 
process of glycolysis is comprised of enzymes carrying out different functional 
roles, and the ribosome complex is made of proteins performing functional roles.   
Of the 7,449 CDS, 21% were located to a subsystem and 79% unallocated 
(Figure 4.2).  This corresponds to 1546 proteins (1481 non-hypothetical, 65 
hypothetical) and 5903 proteins (3172 non-hypothetical, 2731 hypothetical).  
The largest subsystem is “Amino Acid and Derivates” subsystem with 507 genes, 
followed by Carbohydrates at 396. Headings are not necessarily immediately 
reflective of gene function: the “Virulence, Disease and Defence” category 
contains Mycobacterium virulence operons, but these are given protein synthesis 
and DNA transcription functions.  Subsystems may not include relevant genes 
which are known to be in the organism because there is no appropriate sub-
category.  For example, desferrioxamine E genes are detected, but another 
siderophore’s genes are not as desferrioxamine E is the only microbial 
siderophore category. 
Included in this category is the “Resistance to Antibiotics and Toxic Compounds” 
subsection.  As a prolific bioactive specialised metabolite producer, Streptomyces 
species must be able to resist the toxic effects of their own antibiotics, e.g. with 
efflux pumps (Hopwood, 2007), so resistance genes should be expected even 
more than for a standard soil-inhabiting microbe.  Resistance genes for 
streptothricin (an acetyltransferase), fluoroquinolones (2 topoisomerases and 2 
DNA gyrases), and beta-lactams (class A beta-lactamase, metal-dependent 
hydrolase beta-lactamse) were detected.  As stated in section 1.2.1, 
Streptomyces and other antimicrobial producers need resistance genes to avoid 
self-destruction and may be the source of some of these in the wider microbial 
population, so the presence of resistance genes is expected. 
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Specific resistance genes may also imply production of the associated antibiotic 
(Alanjary et al., 2017).  Efflux pumps may be more linked to self-resistance 
compared to destructive enzymatic methods since a pump will not destroy the 
metabolite, which would invalidate the energy cost used to make it.  There are 
specific tools dedicated to detecting potential resistance genes associated with 
biosynthetic machinery (Alanjary et al., 2017), but no immediately significant 
results were produced for S. costaricanus.
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Figure 4.2 RAST Subsystem distribution for S. costaricanus.  
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Multiple subsystems relate to characteristic Streptomyces processes like 
specialised metabolism and sporulation, though the Secondary Metabolism 
subsystem itself contains categories more tailored towards plant metabolites and 
is not designed specifically for bacterial specialised metabolite detection.  The 
“Iron Acquisition and Metabolism” subsystem contains genes for desferrioxamine 
E biosynthesis (desA – E) and secretion.  Siderophores are widespread 
metabolites with a vital role in iron uptake, making them one of the few 
metabolites with known ecological functions (Wibberg et al., 2018).  
S. costaricanus was then compared to the model species S. coelicolor to assess 
homology between the two species.  An overall protein sequence homology 
comparison between the two species is shown in Figure 4.3, along with any non-
matching regions (white space in the circle), and a protein BLAST dot plot, which 
displays conservation and sequence order within the genome.  Comparing the 
two species gives 24 proteins which retain 99%+ similarity most of which code 
for important ribosomal subunits transcriptional regulators or sporulation-
associated proteins, the last of which are especially relevant for Streptomyces. 
The dot plot shows some significant sequence inversions compared to S. 
coelicolor.  As stated above, one Streptomyces characteristic is the variability of 
its genome to enhance BGC evolution, and as such inversions are seen when 
comparing between different species.  As examples, S. ambofaciens is closely 
related to S. coelicolor but its genome contains 2 inversions around its origin of 
replication (Choulet et al., 2006), S. albulus ZPM showed inversions to 11 other 
strains (Wang et al., 2015), as did S. albus J1074 against S. coelicolor and S. 
bingchenggensis BCW 1 (Zaburannyi et al., 2014). 
Any of the 99%+ protein functions listed as hypothetical in both S. coelicolor and 
S. costaricanus were analysed with BLASTP to search for any further information.  
One protein remained hypothetical and could only be identified as a multispecies 
actinobacterial AURKAIP1/COX24 domain-containing protein; the DNA sequence 
s conserved in Streptomyces as shown by a BLASTN search, with 100% query 
cover in Streptomyces sp. N2 and S. collinus Tu 365 having the joint highest 
scores.  AURKAIP1/COX24 has been identified as part of the S22 subunit in the 
Mycobacterium smegmatis ribosome (Hentschel et al., 2017), which would 
 154 
 
explain the level of conservation. The full list of ≥99% proteins is shown in Table 
4.5, mostly comprising ribosomal subunits and transcription factors.  
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Figure 4.3 (a) Comparison of protein identity homologies in S. coelicolor to S. costaricanus.  (b) Blast dot plot comparison 
of S. coelicolor to S. costaricanus.  Diagonal lines show conserved regions between the two species.  Perpendicular sections 
indicate inverted sequences that are otherwise conserved.   
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Table 4.5 List of sequences with >99% homology between S. coelicolor and S. 
costaricanus.  
S. costaricanus 
Function 
Homology % to 
S. coelicolor 
S. costaricanus 
Function 
Homology % to 
S. coelicolor 
RbpA, RNAP-
binding 
100 Ribosomal 
Subunit L30p 
100 
Sporulation cell 
SsgB, sporulation 
and cell division 
100 RNA Polymerase 
Alpha Subunit 
100 
WhiB, Sporulation 
regulator 
100 LuxR family 
transcriptional 
regulator 
100 
Hypothetical 100 Peptidase/RNAse 
associated 
protein 
100 
Ribosomal Subunit 
L34p 
100 LuxR family 
transcriptional 
regulator 
99.54 
Ribosomal Subunit 
S18p 
100 Ribosomal 
Subunit S7p 
99.36 
BldC, DNA binding 100 GTP-ase 
activator 
99.29 
CarD-like regulator 100 Ribosomal 
Subunit S11p 
99.25 
Ribosomal Subunit 
L33p 
100 Ribosomal 
Subunit L14p 
99.18 
Ribosomal Subunit 
S12p 
100 Anti-sigma 
factor BldG 
99.12 
Ribosomal Subunit 
S10p 
100 Putative electron 
transport protein 
99.1 
Ribosomal Subunit 
S14p 
100 Putative integral 
membrane 
protein 
99.09 
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4.3.3 Biosynthetic Gene Cluster Prediction with antiSMASH 
 
The full genome sequence was comprised of 2 contigs.  Prior to running in 
antiSMASH these were concatenated into a single contiguous sequence 
orientated to start at dnaA.  BGCs in S. costaricanus were detected by running 
the single contig FASTA file through antiSMASH v5 (Blin et al., 2019).   
antiSMASH results includes searches to known clusters based on the Minimum 
Information about a Biosynthetic Gene Cluster database (Medema et al., 2015; 
Blin et al., 2019), providing a homology score for any matching clusters.  This 
score does not necessarily reflect product identity, whether of the metabolite 
synthase or metabolite itself, as genes for transport, tailoring, resistance and 
other non-core functions are included in the score. 
In total 33 BGCs were detected (Table 4.6), approximately 50% above the genus 
average of ~22 (21.6) reported by (Doroghazi et al., 2014).  Just under half (16) 
of these were designated as “Hybrids”.  This does not indicate a chemical hybrid 
product, or a true hybrid BGC like a PKS-NRPS.  antiSMASH v5 first detects 
protoclusters using conserved core BGC sequence.  After this, it assigns them to 
1 of 4 types of candidate BGC based on the vicinity of the core region to the next 
nearest BGC: chemical hybrids, interleaved, neighbouring, and single.  Cluster 
types, breakdown of all clusters into their constituent single protoclusters are 
shown in Figure 4.4, and their locations in Figure 4.5. 
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Figure 4.4 antiSMASH v detected BGCs. (a) Initial antiSMASH designations of the 33 clusters. (b) Breakdown of clusters into 
their protoclusters.  Streptomyces typically contain mostly NRPS and PKS modules, so this distribution is expected.  Clusters 
can contain multiple instances of a single class. LAP = linear azoline containing peptide 
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Table 4.6 Full list of all the BGCs detected by antiSMASH.  Of the 33 clusters, 10 
show 75%+ homology to known clusters, with all but one other under 30%.  No 
homology at all is detected for 4 clusters. 
BGC Genomic 
location/bp 
BGC Type 
 
Homology % 
to known 
BGCs 
Most similar 
known product 
1 509431-570824 NRPS 8 
PM100117 / 
PM100118 
2 
1227505-
1247571 
Terpene 100 Albaflavenone 
3 
1569701-
1589303 
Terpene 0 - 
4 
1878472-
1956681 
NRPS-
Siderophore-
T1PKS 
22 Kinamycin 
5 
2090546-
2148149 
Other-T1PKS-
PKSlike 
6 Meilingmycin 
6 
2219984-
2230770 
Bacteriocin 0 - 
7 
2241446-
2262833 
Terpene 100 Geosmin 
8 
2390342-
2440380 
NRPS-T1PKS 2 Meilingmycin 
9 
2446874-
2516868 
NRPS-
Siderophore 
18 Friulimicin 
10 
2741819-
2835191 
NRPS-
Betalactone 
16 Kirromycin 
11 
2931217-
2983913 
Terpene-
Thiopeptide-
LAP 
92 Hopene 
12 
3140929-
3187387 
NRPS-T1PKS 19 
Salinosporamide 
A 
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13 
3353513-
3421730 
NRPS-
Lanthipeptide 
12 Bleomycin 
14 
3436936-
3497258 
NRPS 78 Mirubactin 
15 
3525529-
3566670 
T1PKS 3 Tetronasin 
16 
3631967-
3642182 
Bacteriocin 28 Informatipeptin 
17 
3726161-
3772157 
NRPS-
Betalactone 
6 
Formicamycins 
A-M 
18 
3827264-
3959841 
NRPS-T1PKS-
Terpene 
21 Conglobatin 
19 
3985861-
4023927 
Other 7 A-503083 
20 
4135970-
4293147 
T1PKS-NRPS 100 Pentamycin 
21 
4316655-
4362268 
NRPS 66 SF2768 
22 
4368966-
4415961 
NRPSlike-
T1PKS 
11 Borrelidin 
23 
4577293-
4598966 
Terpene 0 - 
24 
4994760-
5063175 
Other-NRPS 89 Actinomycin 
25 
5399527-
5518637 
NRPS-Ectoine 27 Stenothricin 
26 
5522190-
5563254 
T3PKS 7 Herboxidiene 
27 
5617099-
5668844 
T1PKS-hglEKS 19 Cinnamycin 
28 
6273774-
6284184 
Ectoine 100 Ectoine 
29 
6979189-
7001879 
Lanthipeptide 0 - 
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30 
7207958-
7218563 
Melanin 100 Melanin 
31 
7292799-
7304568 
Siderophore 83 Deferoxamine B 
32 
7460750-
7483303 
Lassopeptide 12 Ikarugamycin 
33 
7945683-
8018288 
T2PKS-T1PKS 83 Spore pigment 
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BGC BGC Type Homology % Product  
2 Terpene 100 Albaflavenone 
7 Terpene 100 Geosmin 
11 Terpene-
Thiopeptide-
LAP 
92 Hopene 
14 NRPS 78 Mirubactin 
20 T1PKS-
NRPS 
100 Filipin 
24 Other-NRPS 89 Actinomycin 
28 Ectoine 100 Ectoine 
30 Melanin 100 Melanin 
31 Siderophore 83 Desferrioxamine 
B 
33 T2PKS-
T1PKS 
83 Spore pigment 
Table 4.7 75%+ homology clusters and their potential products.  
Of these, Actinomycin and Desferrioxamine are the only ones 
identified in LC/MS spectra, though some (Geosmin) are too 
volatile for LC/MS. 
 
Figure 4.5 Broken circle genome map of S. costaricanus with 
BGCs. Rings from outer to inner: Forward and Reverse coding 
sequences; BGC locations with 75%+ homology clusters 
numbered; GC% plot; G vs C skew with above the line skewed 
towards G. 
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4.3.4 Targeted cluster and product analysis 
 
A minority (10/33) of clusters had 75%+ homology to known BGCs with 
designated products (Table 4.7).  Of the remaining 23, 4 had 0% (BGCs 3, 6, 23, 
and 29), 7 under 10%, a further 7 under 20%, 4 under 30%, and 1 at 66%.  
Without genetic manipulation to induce production of each of the unknown 
clusters, which would likely be a difficult and time-consuming task in a non-
model Streptomyces for a single BGC alone, further analysis will be limited to 
selected high (75%+) and low (0%) homology clusters, and where possible their 
diversity within the wider antiSMASH database.  The selected BGCs coded for 
albaflavenone, actinomycin, and an unidentified terpene.   These were chosen to 
include an identified BGC that was not detected from S. costaricanus culture, one 
that was both identified and detected in culture, and a totally unknown BGC as a 
core Streptomyces metabolite, known metabolite, and an unidentified product.  
4.3.4.1 BGC 2: albaflavenone 
 
The sequence and gene classification for BGC 2 is shown Figure 4.6, and is 100% 
predicted to code for an albaflavenone terpene synthase.  “other genes” indicates 
genes that are not strictly relevant, such as transposases, some primary 
metabolism genes, and hypothetical or totally known genes. 
Albaflavenone is a sesquiterpene antibiotic active against B. subtilis (Gürtler et 
al., 1994) and is well known as a Streptomyces metabolite due to its presence in 
the S. coelicolor genome (Čihák et al., 2017).  Despite being a widespread BGC, 
it is not always expressed under standard culture conditions.  Takamatsu et al. 
(2011) investigated a cryptic cluster in S. avermitillis, which is the industrial 
producer of the antihelminith avermectin.  The cluster consists of two genes, 
sav3031 and sav3032, with sav3031 located downstream of sav3032.  These 
genes are homologous to those for albaflavenone production in S. coelicolor, 
sco5222 and sco5223.   
Sav3031 codes for a cytochrome P450, which is maintained in S. costaricanus 
according to the predicted function of the equivalent gene.  Sav3032 has high 
homology to an S. coelicolor gene coding for an epi-isozizaene synthase, which 
catalyses conversion of epi-isozizaene to albaflavenone.  The predicted S. 
costaricanus product is a “Terpene synthase/cyclase metal-binding domain” 
 164 
 
product, which matches Takamatsu et al. (2011) who found that activity was 
dependent on Mg2+.  The metal ion binds to Sav3032 at Asp101 into a metal 
binding domain with the motif DDRHD, found in the translated amino acid 
sequence from S. costaricanus. 
Searching the antiSMASH database for the corresponding MIBiG cluster gives 
248 strains: 244 Streptomyces, Actinospica acidiphila – another actinomycete – 
and 3 unknowns.  All of the results show 100% similarity, indicating a widely 
conserved cluster.  Widespread conservation over Streptomyces and other 
genera could indicate an important ecological function for albaflavenone, but like 
the characteristic Streptomyces terpene geosmin, its function is unknown 
(Seipke, 2015).  
4.3.4.2 BGC 24: actinomycin 
 
The sequence and gene classification for BGC 24 is shown in Figure 4.7, and is 
89% predicted to code for an actinomycin “NRPS-Other”.   
The cluster designated as a core biosynthetic “other” gene codes for LmbU, 
which regulates expression of the antibiotic lincomycin (Imai et al., 2015).  
Therefore, the gene is likely better classified as a regulatory element, leaving the 
BGC as an NRPS.  Other elements in the BGC include a cassette of 3 transport-
related genes, which are predicted to code for 2 adenosine triphosphate-binding 
cassette (ABC) transporters, and 1 ABC-2 type transporter but running a BLASTP 
search further identifies it as a major facilitator superfamily (MFS) transporter.  
While this family does include many transporters, an MFS in multidrug resistant 
Candida spp. is able to use actinomycin as a substrate and transport it outside 
the cell (Redhu et al., 2016), much as S. costaricanus will have to do to avoid 
self-toxicity.   
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Figure 4.7 BGC 24 (actinomycin) gene classifications 
Figure 4.6 BGC 2 (Albaflavenone) gene classifications   
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Figure 4.8.  BGC 3 gene classifications. 
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The cluster contains 3 TTA (Leucine) codons, which are rarely seen in 
Streptomyces due to the GC richness: in S. coelicolor, there are only 147 
instances of it, and they are associated with global scale regulation of antibiotic 
production and differentiation (Chater & Chandra, 2008; Liu et al., 2013).  This is 
due to their rarity as a codon, meaning that it can be used to designate genes 
which will only be properly transcribed and translated under TTA specific 
conditions.   
This impacts on antibiotic production, sporulation  and MI/MII differentiation, 
though Streptomyces can survive in axenic culture if its ability to use TTA codons 
is knocked out (Hackl & Bechthold, 2015).  One of the codons appears within a 
putative transposase, identified via BLASTP ISL3 family transposase.  A 
transposase-associated regulatory element would be a risky regulation method, 
so this is more likely to be by chance than selected regulatory function.  
However, the terminal ends of Streptomyces genomes are known for frequent 
transposon and plasmid mediated rearrangement, so this is standard 
Streptomyces genomic organisation. 
4.3.4.3 BGC 3: unknown terpene 
 
The sequence and gene classification for BGC 3 is shown in Figure 4.8, and is 
predicted to code for a terpene with 0% additional identification.  There are 
multiple BGCs in S. costaricanus, and any non-model Streptomyces, with low 
levels of homology.  Cluster 3 was selected for 2 reasons. Firstly, compared to 
many of the unknown “Hybrid” BGCs, it is a relatively simple 1-BGC type gene so 
is more likely to be reflective of its final product and would potentially make any 
later confirmatory genetic manipulation easier.  Secondly, it displays very limited 
homology to strains outside of Streptomyces.  Running a BLASTP search gives 2 
Streptomyces with acceptable coverage and match levels, followed by Frankia 
sapropphytica – another Actinomycetales species – but low match % (Table 4.8). 
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Table 4.8 Highest BLASTP results for cluster 3 core synthase. 
 
 
 
 
Searching the BGC as a whole in MiBIG also produces limited results, with only 
two results: 28% identification to a pentalenene synthase in the pristinol cluster 
of S. pristinaespiralis, and the same ID to PntA in the pentalenolactone cluster of 
S. arenae.  
This implies that BGC 3 is very tightly conserved to a few species, or 
alternatively that other strains holding the BGC simply haven’t been uploaded to 
the database yet.  Assuming that the first choice is correct, one reason for the 
limited spread could be a very specific ecological niche requirement.  If all 3 of 
the Streptomyces, as they had the most similar homology, are from niches with 
similar requirements then there would be pressure to maintain the terpene.  The 
issue then is why it has not spread to other Streptomyces, given the tendency of 
specialised metabolite genes to recombine and spread throughout the genus.  
Knowing the ecological isolation information for S. costaricanus and the other 
strains would help identify any niche-specific pressures, but unfortunately there 
is no specific information past nematode suppressive Costa Rican soil.  
4.3.5 Comparison to other members of the S. costaricanus clade 
 
4.3.5.1 Difficulties with Streptomyces classification 
 
Streptomyces species are notoriously difficult to classify.  Classical phenotype-
based cladistics is unreliable given a strain’s phenotypic variation even within a 
single colony; the commonly used 16S approach will show high similarity 
between species without reflecting the extreme levels of recombination in the 
genomic arm regions (Guo et al., 2008).  Unsurprisingly, this leads to species 
with identical 16S regions but different specialised metabolomes (Antony-Babu et 
Strain Coverage % Match % 
Streptomyces sp. N2 100 99 
Streptomyces murinus 98 98 
Frankia saprophytica 90 38 
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al., 2017), which is an issue if using phylogeny to determine which isolate should 
be screened for natural product production.  
As noted in Section 4.3.4, BGC component BLAST searches produce the same set 
of strains at high (97%+) homologies.  Streptomyces sp. N2 is the most 
frequent, followed by S. sp. LamerLS-31b, S. sp. DconLS, and various S. 
griseofuscus strains.  Given the above difficulties with Streptomyces cladistics, it 
was decided to compare Streptomyces sp. N2’s antiSMASH and classification 
outputs to S. costaricanus for any similarities. 
Figure 4.9 shows antiSMASH outputs for the two strains.  The BLAST results had 
already identified significant similarity between BGC identity between the two, 
but not their locations within the genome.  Orientating both genomes to DnaA 
shows a near total identity in both BGC composition and also localisation.  BGC 1 
position differs by under 1 kb, with similar differences for all other clusters, with 
the exception of a Streptomyces sp. N2 specific furan BGC.
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Figure 4.9 Comparison of the order of (a) S. costaricanus BGCs to (b) Streptomyces sp. N2 BGCs.  Colours indicate 
antiSMASH BGC type: 
(a) 
(b) 
1 BGC difference between strains 
= Hybrid = Terpene, and additional furans in (b) = PKS = Bacteriocin 
= Siderophore = Ectoine = Lanthipeptide = Melanin = Lassopeptide 
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Labeda et al. (2012) group S. costaricanus into a clade with S. graminearus, S. 
griseofuscus, S. murinus, and S. phaeogriseichromatogenes based on their 16S 
sequences.  A separate previous study (Kurosawa et al., 2006) forms a similar 
clade linking S. murinus to S. padanus and S. misionensis, which were not 
included in Labeda et al. (2012).  While 16S has been the standard tool for 
microbial classification, it can be an unreliable guide if used in isolation (Alanjary 
et al., 2019).  A more comprehensive approach is to use multi locus sequence 
analysis, which spans a range of marker genes to form a Multi Locus Sequence 
Tree (MLST).  One recent tool, autoMLST (Alanjary et al., 2019), queries the full 
genome input against reference genomes plus BGC predictions to give a mix of 
classification and secondary metabolite information.  autoMLST uses the average 
nucleotide identity (ANI) of two strains to determine if they are the same 
species, with 95%+ being sufficient. 
4.3.5.2 autoMLST and BGC-based cladistics 
 
S. costaricanus was run through autoMLST along with Streptomyces sp. N2 to 
determine their taxonomic relatedness and compare it to the noted BGC 
similarity.  The full tree is shown in Figure 4.10.  Streptomyces sp. N2 has been 
putatively identified by the depositors as S. padanus based on its secondary 
metabolite profile (Worsley & Hutchings, personal communication) so unless the 
inferred 16S matches between Labeda et al. (2012) and Kurosawa et al. (2016) 
are not correct the two strains should be in the same clade. 
S. costaricanus and Streptomyces sp. N2 were mapped to the same clade and 
given an estimated ANI of 97.6% and 97.5% respectively to S. griseofuscus, P 
value <0.05.  This indicates that both species are potentially strains of S. 
griseofuscus, which would take precedence over the type strain of S. 
costaricanus as S. griseofuscus is the older type strain (Nagaoka et al., 1986).  
S. costaricanus was re-run through RAST to compare protein homology against 
Streptomyces sp. N2, S. griseofuscus, and S. coelicolor as a relative outgroup.  
The results (Figure 4.11) followed autoMLST cladistics: Streptomyces sp. N2 was 
the most similar with 2798 100% homologous proteins, and 2680 more at 
99%+.   
Given the high ANI between the two strains, and the exceptionally close 
antiSMASH results, it is suggested that microbial drug discovery projects use a 
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mixture of antiSMASH and autoMLST results to ensure a diverse set of 
Streptomyces.   
The suggested overall workflow does include antiSMASH as a predictor of 
specialised metabolite potential but following metabolomic screening.  As 
genome sequencing becomes more affordable and efficient, moving genomics to 
the front of a project with multiple candidate microbes is arguably more useful 
especially when combined with autoMLST and other tools.  Using the BGC 
similarity alongside cladistics would ensure a wide taxonomic range, increasing 
the chances of novel BGC expression and discovery.   
Using the autoMLST-selected strains to search for patterns in the spread of 
actinomycin production did not show a similar clade-limited pattern as with the 
terpene cluster 3, possibly indicating that more common BGCs are not useful for 
ensuring diversity.  A literature search found actinomycin to be produced by 6 
other Streptomyces species in the autoMLST list, outside of S. costaricanus and 
S. sp. N2: S. avermitilis (Chen et al., 2012), S. antibioticus (Katz et al., 1956), 
S. griseofuscus (Kurosawa et al., 2006), S. griseoruber (Praveen & Tripathi, 
2009), S. iakyrus (Bitzer et al., 2006), and S. luteus (Zeng et al., 2019). 
The 3 antiSMASH-designated core regions of the actinomycin BGCs in both S. 
costaricanus and S. sp. N2 were compared using BLASTP.  The combined genes 
had an equal number of bases with an overall identity of 98.61% similarity after 
conversion to amino acids, corresponding to 7235 of 7337 matching residues.  
The 102 differences were not significantly located in any region of the sequences.  
The most common changes both involved alanine, with 15/102 differences from 
alanine to threonine (or vice versa) substitutions, and 10/102 from alanine to 
valine.  Neither of these valine nor threonine share the exact same properties as 
alanine, though valine like alanine is aliphatic (Ud-Din et al., 2020) possibly 
limiting any beneficial or harmful impacts on actinomycin synthesis.  Comparing 
the sequence differences and synthesis efficiencies across the BGC-containing 
strains would be an interesting project, possibly using purified enzymes in a cell 
free system (Li et al., 2018) to limit the effect of other components.  
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Figure 4.10 autoMLST of S. costaricanus and Streptomyces sp. N2.  Colours 
represent ANI groups of 95%+.  Arrow shows the location of S. costaricanus 
and S. sp. N2.  Red stars mark production of actinomycins by either the given 
strain or its species   
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S. coelicolor 
S. griseofuscus 
Streptomyces sp. N2 
Figure 4.11.  RAST protein homology comparison of S. griseofuscus, 
Streptomyces sp. N2, and S. coelicolor to S. costaricanus  
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4.4 Conclusions 
 
The objectives for this chapter were to obtain a high-quality genome sequence of 
S. costaricanus and use this to explore BGCs along with general genome 
characteristics compared to other well-studied Streptomyces.  Using standard 
genomic completeness and quality tools the sequence was found to be of good 
quality, which enabled further exploration.  
Some results like the presence of the deferor4xamine BGC were expected, given 
its presence in the core Streptomyces genome region, and others – actinomycins 
– confirmed metabolomic results from previous chapters.  The large number of 
unknown BGCs highlighted the novelty of the genome, as well as the deficiencies 
in linking available clusters and known metabolites. This emphasised that the 
metabolomic screening strategy developed over Chapters 2 and 3 correctly 
selected a strain with high novel BGC potential. 
The final use of the sequence was to analyse S. costaricanus cladistics.  That 
Streptomyces sp. N2 closely grouped to S. costaricanus was expected, given its 
BGC similarity and genomic orientation.  Further species reassignment of S. 
costaricanus is outside the sc ope of this thesis, but MLST and BGC similarity 
does suggest a close familial link between S. costaricanus and Streptomyces sp. 
N2 if not also with S. griseofuscus.  
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5  Scale-up culture of S. costaricanus for extraction and 
isolation of bioactive metabolites 
 
5.1 Introduction 
 
5.1.1 Effect of culture scale-up on metabolite production 
 
The previous chapters examined the impact of nutrition, stresses, elicitors, and 
solid versus liquid medium on metabolite production in S. coelicolor A3(2) and S. 
costaricanus.  These studies were all performed on a relatively miniaturised scale 
to enable more efficient comparison of metabolomic and phenotypic data 
compared to standard flask and plate culture.  While this did lead to generation 
of a wide range of metabolomic and genomic data, culture scale-up is essential 
for isolation and extraction of metabolites for use in bioactivity assays, chemical 
dereplication and characterisation.  This adds potentially multiple variables to the 
project, as how scale-up proceeds can affect metabolite production.  This could 
be impacted by, for example, the vessel shape, oxygenation levels, inoculum 
differences, messenger molecules, or pH change.  Some examples are discussed 
below. 
5.1.1.1 Vessel Depth and Diameter 
 
Barkal et al. (2016) used their own miniaturised system to study specialised 
metabolism in Aspergillus nidulans, altering both physical and chemical 
parameters to study the resulting chemotypes.  The physical parameters 
included both diameter and depth of the culture vessel, though only well 
diameter was found to influence metabolism.  Using principal component analysis 
to visualise the separation, there was a significant difference between 
metabolites produced by A. nidulans grown in 2, 3.5, 5.5, and 10 mm diameter 
agar-containing wells, with no separation found from well depth.   
The example is not perfect in that well depth will be less relevant using agar 
since it is a solid medium and so will restrict movement especially in a 
filamentous microbe, though this will depend on the organism growth speed and 
culture duration.  As growth through the medium to unused nutrients still 
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happens, nutrient starvation in the smaller volumes is not the primary factor for 
the variation.  The principal component analysis levels of variation explained 
were not particularly high (29% PC1, 18% PC2) limiting its predictive power and 
potentially giving a false impression of the diversity of metabolism.   
Separation was still significant especially when comparing between the smallest 
and largest wells, then to the standard agar plate extract control, so the overall 
example is still valid.  It is unknown if there is a linear relationship between 
specific metabolites produced and the physical characteristics of the culture 
vessel or if after a certain diameter there are no additional metabolite changes.  
The wells of the 24-well plate are 15.6 mm wide, larger than that reported by 
Barkal et al. (2016), so assuming the same regulation applies to S. costaricanus 
as A. nidulans, some of the differential impact of scale-up should be relatively 
low. 
5.1.1.2 Oxygenation and Growth Rate  
 
Physical characteristics can also affect oxygenation levels.  Growth in baffled or 
spring-coiled flasks is common in culture of Streptomyces (Kieser et al., 2000) 
since it increases oxygen availability and prevents some of the clumping 
exhibited in liquid media, leading to higher and more dispersed growth. As with 
nutrition levels, this does not mean that more oxygenation necessarily leads to 
improved metabolite production, since specialised metabolism is regulated by 
multiple factors.   
This was demonstrated by growth of S. lividans in baffled and spring-coiled flasks 
where production of undecylprodigiosin (RED) was consistently lower than in 
standard shake flasks, in some cases 385 times less efficient (Gamboa-
Suasnavart et al., 2018).  The lower oxygenation from the standard shake flasks 
was reflected in an anaerobic level respiratory quotient and slower growth rate.  
It was therefore proposed that a low oxygen transfer rate can trigger the onset 
of specialised metabolism and reducing primary metabolite production, lowering 
the growth rate but increasing specialised metabolite production.  In contrast, 
expression of the antifungal metabolite pimaricin from S. natalensis is 
upregulated via quorum sensing, so will be positively affected by higher 
oxygenation and growth rate (Recio et al., 2004) 
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The literature is not entirely in agreement over the positive impact of low oxygen 
transfer to specialised metabolism, especially given the complex regulation of the 
expression of different metabolites.  Streptomyces species are obligate aerobes 
and are unable to grow under anaerobic conditions.  S. coelicolor can survive 
anaerobic conditions for 24 d then immediately resume growth once oxygen is 
added, as do the majority of strains tested to date, although spores of S. 
avermitilis decline to 20% viability by 10 d and reach 0% by the end of the time 
course (van Keulen et al., 2007).  S. coelicolor can express a set of respiratory 
nitrate reductases normally found in facultative and obligate anaerobes.  These 
may help anaerobiosis through reducing nitrate to maintain the proton motive 
force (Falke et al., 2016).    
Sohoni et al. (2012) used 24-square deep well plates to make their own 
miniaturised cultivation system for S. coelicolor, adding glass beads of various 
sizes to the wells to study the effect on chemotype and phenotype.  Oxygen 
transfer was increased by 3 mm beads, as was production of the characteristic 
pigment actinorhodin by approximately 25 times.  The two studies cannot be 
directly compared since they study different metabolites in different vessel types 
with different organisms, but it is a useful reminder of the potential variety in 
regulation between strains and culture types.  Since this study has so far not 
investigated glass beads and used standard wells, scaling up to standard shake 
flasks without beads or baffles will ideally give a similar metabolite profile.  
5.1.1.3 Inoculum Type 
 
A standardised inoculum is a vital part of maintaining consistency across 
cultures.  There are two common master stock storage methods: freezing 
mycelia (Charusanti et al., 2012) and spore suspensions (Shepherd et al., 2010), 
each of which has advantages in certain situations.  When maintaining a large 
Streptomyces or other mycelial microbe library, frozen mycelia arranged on a 
plate are a simple way to quickly replicate stocks using a multi-pin replicator.  
For specialised metabolite experiments which rely on transitions between growth 
phases (Wentzel et al., 2012), cell density and messenger molecules (Polkade et 
al., 2016), a spore suspension is a more precise way of measuring out the same 
concentration of inoculum each time.  All other factors remaining equal, this 
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guarantees identical growth rates for each experiment and so reliable metabolite 
production.   
Using a pin replicator for the 24-well plate would have technically saved 
inoculation time, but the time saving is easily outweighed by the differences in 
inoculum densities.  A spore suspension is not ideal for inoculating a larger 
culture volume.  Even if it would standardise the inoculum between scale-up and 
the 24-well plate screen, the 1 ml spore suspension obtained per plate is 
inadequate to seed multiple larger culture volumes.  Starter cultures are a 
frequent way to maintain inoculum equality between scale-up vessels (Rateb et 
al., 2011; Thaker et al., 2013; Xie et al., 2014) while limiting master stock 
usage. 
While a complete link cannot be maintained between the 24-well plate screen 
and scale-up culture, a logical choice of vessel type and culture techniques 
ensure that the difference between the small and large cultures can be 
minimised.  This will in turn keep variation between scale-up replicas minimal, 
giving reliable metabolite production in each flask. 
5.1.1.4 Scale-up of S. costaricanus 
 
At the start of the project there were no reports of scale-up, or any recent 
experiments, using S. costaricanus.  Since then, 1 study has appeared on the 
actinomycin D biosynthetic gene cluster in a marine strain of S. costaricanus (Liu 
et al., 2019).  The volumes of media used in the study are also smaller than the 
planned scale-up (50 ml, 250 ml flasks) and is focused on smaller scale 
extraction of actinomycin D to explore the effects of different mutants on 
biosynthesis. 
Both agar and broth media were used for scale-up, but this is not a direct 
comparison since extracting from the agar and biomass will include both 
intracellular and secreted metabolites.  While some Streptomyces metabolites 
are intracellular, such as RED, most antimicrobials are thought to be secreted 
into the environment (Senges et al., 2018).  This will be affected by the 
differences of agar versus submerged growth but explains why metabolomics 
experiments frequently use only the supernatant instead of the pellet. 
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5.1.2 Chapter Aim and Objectives 
 
Chapters 2 and 3 developed an untargeted metabolomics workflow based on 
metabolite extraction from 24-well plates.  The media volumes used in the plates 
are not sufficient for metabolite isolation from S. costaricanus, so scale-up was 
required.  The growth condition selected was M19 media after 5 d growth, since 
these parameters produced relatively high numbers of both total features and 
those specific to culture in M19, and principal component analysis (Section 3.2.3) 
showed 5 d as significantly different from most other conditions.  Therefore, 
scale-up using M19 broth would enable the final part of the early stage 
metabolite discovery workflow: metabolite purification through fractionation, 
bioactivity, and novelty assessments.  The objectives for this chapter were 
therefore to: 
1) Scale-up S. costaricanus using M19 agar and broth culture. 
2) Extraction of agar culture metabolites and analysis with UPLC-MS. 
3) UPLC-MS analysis of broth culture supernatant. 
4) Flash fractionation of both supernatant and agar extract to purify 
metabolites. 
5) Bioactivity guided investigation and further purification of metabolites in 
relevant fractions. 
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5.2 Materials and Methods 
 
5.2.1 Scale-up of S. costaricanus culture, metabolite extraction, 
and fractionation 
 
5.2.1.1 S. costaricanus broth culture and extract collection 
 
S. costaricanus inoculum was prepared as in Chapter 3, Section 3.3.6.  Inoculum 
(2 ml/flask) was used to inoculate 15 x 500 ml baffled shake flasks containing 
200 ml M19 broth for a total of 3 L.  Flasks were shaken at 200 rpm, 30°C, for 5 
d.  The supernatant was separated from biomass by centrifuging at 4,122 x g 
and for immediate fractionation to prevent enzymatic degradation. 
Biomass for pellet metabolite extraction trials was extracted by suspending the 
pellet in 5 times its volume of 50% aqueous methanol and shaking at 200 rpm 
overnight, room temperature. 
5.2.1.2 S. costaricanus agar culture and crude extract preparation 
 
Inoculum was prepared as in Chapter 3, Section 3.3.6.  Inoculum (250 μl/plate) 
was added to 117 plates with approximately 25 ml M19 agar in each, for an 
approximate total of 3 L agar across the plates.  Plates were allowed to dry in a 
laminar flow hood then left to incubate at 30°C for 5 d.   
After incubation, metabolites were extracted by removing the agar and biomass 
from the petri dish and submerged in 3 L of 50% aqueous methanol. The mixture 
was left at room temperature for 24 h, then the solvent drained and centrifuged 
at 4,122 x g for 10 min to obtain the crude extract.   
5.2.1.3 Flash chromatography of broth and agar extracts 
 
The agar crude extract was diluted down to 10% methanol using 18.2 MΩ water, 
after which both the supernatant and agar extract were processed with the same 
method. 
An Isolera One Flash Purification System (Cardiff, UK) was used to precondition a 
Biotage 120 g C18 resin cartridge using 250 ml of methanol followed by 250 ml 
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18.2 MΩ water, both at a flow rate of 50 ml/min.  The extract was then loaded 
onto the cartridge at a flow rate of 50 ml/min.  A gradient using 10% increments 
of methanol (2 x column volume or 250 ml/step) was used to elute compounds 
from the C18 cartridge in 120 ml maximum fractions, monitoring the eluate at 
240 nm. 
Compounds unretained by the C18 resin were loading onto an ENV+ (Biotage) 
resin cartridge to capture more polar chemicals that would otherwise have been 
discarded. The ENV+ cartridge was preconditioned, loaded and culture fractions 
eluted in the same way as the C18 cartridge.  Both sets of fractions were stored 
at -4°C for later UPLC-MS analysis.  Dry weights were calculated by aliquoting 3 
ml of each fraction in a pre-weighed vial, then evaporated to dryness in a 
Genevac EZ2 centrifugal evaporator (Genevac, Ipswich UK) and subtracting the 
dry vial weight from the vial plus fraction weight.   
5.2.1.4 Polarity-based fraction pooling and purification 
 
Fractions were pooled into 3 groups by their most dominant metabolite family 
(Actinomycins, Deferoxamines, or Other), diluted with 18.2 MΩ water to 10% 
methanol concentration, loaded onto respective 120 g C18 cartridges, and eluted 
over pool polarity specific gradients: actinomycins from 40 to 100% methanol, 
deferoxamines 25 to 75% methanol, and the remaining fractions 0 to 60% 
methanol.  The maximum fraction volume was also set to 60 ml to further 
concentrate metabolites, and elution flow rate at 30 ml/min.  Cartridges 2 and 3 
were also flushed with 100% methanol following the gradient to elute any 
remaining metabolites. 
Deferoxamines were quantified using a semi-purified deferoxamine fraction (80% 
by mass), comparing its peak areas to dry weight and applying that to other 
fractions. 
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5.2.2 Growth and inhibition of A. baumannii 
 
5.2.2.1 Growth curve of A. baumannii 
 
A colony of Acinetobacter baumannii NCTC 13301 growing on Muller-Hinton agar 
was used to inoculate a 50 ml Muller-Hinton broth (MHB) overnight culture 
(37°C, 175 rpm).  After overnight culture 1 ml was taken to inoculate 100 ml 
fresh MHB, which was used to determine lag, log, and stationary phase at OD600 
every 30 min in triplicate.  Measurements were taken using a Spectronic Helios 
Epsilon spectrophotometer (Thermo Fisher Scientific, Loughborough, UK). 
5.2.2.2 Assessing inhibition of A. baumannii growth  
 
Bioactivity was tested by adapting the XTT procedure used by Pettit et al. 
(2005).  The overnight culture and inoculation of 100 ml MHB was repeated.  
After 4 h (mid-log phase) a culture aliquot was adjusted to an OD600 of 0.05.  
This was transferred to a 96-well plate (100 μl/well) with an equal amount of 
stock fraction, except in the control wells (media only, A. baumannii culture only, 
A. baumannii and 1 μg/ml colistin).  Plates were wrapped in foil and left to 
incubate for 20 h at 37°C.  The sodium salt of XTT (Sigma-Aldrich, Poole UK) was 
dissolved to 1 mg/ml in PBS and combined in a 12.5:1 ratio with 1 mM 
Menadione (Sigma-Aldrich) dissolved in acetone.  The mixture was added to 
wells (25 μl/well), shaken gently, and incubated for a further 1 h.  The plate was 
then read at 490 nm, and inhibition calculated by the formula:  
100 ∗ (1 − (
𝑀𝑒𝑎𝑛 𝑤𝑒𝑙𝑙 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 − 𝑚𝑒𝑎𝑛 𝑀𝐻𝐵 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
𝑀𝑒𝑎𝑛 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 − 𝑚𝑒𝑎𝑛 𝑀𝐻𝐵 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
)) 
Colistin MIC was determined by a separate XTT assay using serial dilutions of 
0.125 μg/ml up to 32 μg/ml.  The negative control was untreated cells in MHB. 
5.2.3 UPLC-MS/MS analysis and metabolite identification  
 
5.2.3.1 UPLC-MS/MS conditions 
 
UPLC-MS conditions were as Chapter 2, section 2.2.6.  MS/MS used the Data 
Directed Acquisition setting in Masslynx V4.1, with the following MS/MS specific 
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changes compared to previous chapter conditions: m/z range was 150 – 2000, 
MS/MS collision energy ramped from 20 – 40 V, and scan duration and interscan 
delay was 1 s and 0.025 s respectively.  
5.2.3.2 GNPS dereplication 
 
Files were converted to .mzML using MSConvert (Chambers et al., 2012).  The 
Subset filter was selected from the filter menu, and the scanEvent subfilter 
selected with parameters 1 – 2 to select UPLC-MS and UPLC-MS/MS functions 
from MS/MS RAW files.  The converted files were uploaded to GNPS for 
dereplication and molecular networking.  GNPS parameters for the 
METABOLOMICS-SNETS-V2 pipeline are shown in Table 5.1. 
Table 5.1 GNPS settings used to search M19 culture fractions. 
Parameter Setting 
Precursor Ion Mass Tolerance 0.2 Da 
Fragment Ion Mass Tolerance 0.2 Da 
Minimum Library Peak Match 6 
Score Threshold 0.7 
 
GNPS results were refined using MolNetEnhancer v1.2.5 (Ernst et al., 2019) , 
and the graphml output used to create a molecular network in Cytoscape v3.1.7.  
The network was filtered to exclude blank compounds, and networks which were 
comprised of only one node. 
5.2.4 Overview of proposed methods 
 
The methods used in this chapter are designed to exploit an area of the S. 
costaricanus chemical space that is less likely to have previously been examined.  
The methods are summarised in Figure 5.1. 
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Figure 5.1 Summary of methods for culture scale-up, fraction bioactivity, 
and metabolite dereplication. 
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5.3 Results and Discussion 
 
5.3.1 Metabolites produced by S. costaricanus in broth culture 
 
5.3.1.1 Comparison of 24-well plate samples and scale-up culture 
supernatant 
 
The supernatant was analysed by UPLC-MS to give an initial overview of the 
main metabolites produced by S. costaricanus under standard shake flask 
culture.  As in the 24-well plate screen, the main components were 
deferoxamines and actinomycins, but unlike the 24-well plate screen, the 
predominant actinomycin was actinomycin D not X2.  This more closely matches 
the actinomycin production profile found by Liu et al. (2019), reflecting a 
difference between the well plates and large shake flask production.  A 
comparison between the two UPLC-MS profiles is shown in Figure 5.2, both of 
which are representative of triplicate cultures.  Only one metabolite is identifiable 
in the 24-well plate supernatant, actinomycin X2.  The scale-up culture 
supernatant includes other actinomycins D, X0β, and one putative actinomycin 
with similar spectra but with an m/z difference of -28 to actinomycin D.  
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One potential reason for the difference between the two profiles is oxygenation.   
Although the 2 ml cultures were rotated at the same rpm as the flasks, the 
vessel shapes and media to total volume ratios will affect growth rates and so 
metabolite production.  This is supported by the lower overall intensity in wells 
versus plate growth at 8.32 E4 against 1.58 E5.  Furthermore, the main feature 
in the wells is m/z 205.07, a media blank compound, so the true well maximum 
intensity is closer to 3.5 E4.  However, the 24-well plate screen was designed to 
show differences between culture conditions, which it did effectively, while still 
mostly representing larger scale metabolite production.  Miniaturised deep well 
plates do exist which are able to mimic oxygenation levels in shake flasks (Kosa, 
Zimmermann, et al., 2018; Kosa, Vuoristo, et al., 2018), so a potential future 
experiment using this plate type would help identify if oxygenation was one of 
the reasons for enhanced metabolite production. 
MetaboAnalyst 4.0 (Chong et al., 2018) was used to calculate which metabolites 
changed production by more than 5-fold between the two broth culture vessels.  
Flask culture resulted in 42 features, and 39 from well culture.  The full volcano 
plot of changes is shown in Figure 5.3.  Of the two predominant metabolite 
Deferoxamine B (b) 
Figure 5.2 Comparison of UPLC-MS chromatograms from  (a) 24-well plate and 
(b) shake flask culture of S. costaricanus.   
(a) 
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families, deferoxamines shows a higher fold change: 54 times higher in the flask 
than well culture for deferoxamine B.  This may be due to the effect of the 
increased flask culture biomass increasing nutrient depletion faster than the less 
productive well culture, more rapidly upregulating scavenging molecules like 
deferoxamine B. 
 
 
 
 
 
 
 
 
 
 
5.3.1.2 Comparison of unknown actinomycin to actinomycin D  
 
An unknown compound with m/z 614.34 [M+2H]+ and m/z 1227.68  [M+H]+ was 
putatively identified as an actinomycin (Figure 5.4).  No previously identified 
exact spectral match for this compound could be found in GNPS or streptomeDB.  
Its rt – 4.7 min – is earlier than actinomycin D, which elutes at 5.9 – 6 min, 
indicating elution in a more polar segment of the gradient.   
 
 
Higher in 
Flasks 
Higher in 
Wells 
Figure 5.3 Volcano plot of features that differ by over 5-fold between well and 
flask culture (x axis, pink dots) and were statistically significant (y axis). 
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Comparing the higher energy spectra of actinomycin D to the unknown 
actinomycin shows it contains many of the characteristic actinomycin fragments 
m/z minus 28 daltons (Figure 5.5).  This could be due to the loss of C2H4, which 
would increase the overall polarity.  Alternative losses could be -CO or an N, but 
these would not account for the difference in polarity.  The higher energy spectra 
in Figure 5.5 did not produce the double charged ion. 
Figure 5.4 Spectra indicating a double charged ion of the putative actinomycin.  
m/z 614.34 has an isotope pattern of +0.5, which along with m/z 1227.67, 
indicates a double and single charged ion respectively.  Therefore, these are 
ions from the same metabolite.     PH Supernatant 1
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The main actinomycin D mass fragments have previously been mapped out by  
Wills & O’Connor (2014).  The authors analysed collision activated dissociation 
and electron induced dissociation-produced spectra for actinomycin D which were 
used to link mass fragments to structural fragments.  This is useful for 
determining which section of a similar metabolite a structural difference occurs 
in, as identical sections of metabolite will fragment to identical m/z, and non-
identical should maintain the m/z difference.  This was applied to the unknown 
actinomycin.  Actinomycin D consists of a chromophore linker with two identical 
rings joined to it (Figure 5.6), so any differences between variants may be in one 
ring or both, which should be observed in the spectra.  This figure also shows 
fragmentation points, based on Wills & O’Connor (2014), for the major fragments 
956.5 m/z (red arrow; C48H62N9O12+) and 857.4 m/z (black arrow; C48H53N8O11+), 
both to 1 decimal place to account for approximately 0.2 m/z difference between 
source article and obtained spectra here. 
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Figure 5.5 High energy spectra of (a) actinomycin D, and (b) putative 
actinomycin.  Example -28 m/z differences from (a) to (b) outlined. 
(b) 
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The minus 28 difference is maintained through most of the major fragments 
down to m/z 300, the mass of the linker chromophore, which indicates that any 
difference is due to the ring amino acids.  Thomas et al. (1995) suggest that 1 of 
3 amino acids substitutions is responsible for a similar m/z difference, such as 
Nme-Gly to Gly, but without purified metabolite there is no evidence to predict 
which one. 
Another putative actinomycin was detected with an m/z of 1257.64 which could 
not be linked to any known spectra, though it presented the standard spectral 
fragment m/z at both lower and higher fragmentation energies.  However, there 
are many actinomycin variants that have been isolated but do not have spectral 
information so the novelty of these potential actinomycins is unknown. 
5.3.1.3 Composition of supernatant fractions 
 
Separation of the supernatant through the C18 resin produced 24 fractions with 
a peak UV absorption intensity of approximately 1200 milli-absorbance units 
(mAU), shown in Figure 5.7, and fraction weights in Figure 5.8. 
O
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Figure 5.6 Actinomycin D structure with amino acid building blocks.  The rings 
are identical.  The arrows refer to the major fragments 956.5 m/z (red arrow; 
C48H62N9O12+) and 857.4 m/z (black arrow; C48H53N8O11+) 
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5.3.1.4 Purification of deferoxamines 
 
Measuring the fraction weights gave a maximum of 3.53 mg/ml for fraction 10, 
or approximately 423.6 mg for the full 120 ml fraction. The UPLC-MS 
chromatogram shows that this is predominantly deferoxamine B, indicating a 
high level of purity as a result of flash chromatography purification.  The peak 
Gradient steps 
UV absorption 
Figure 5.7 Flash chromatogram of supernatant fractionation using C18 resin. 
Figure 5.8 C18-derived fractions from S. costaricanus broth culture 
supernatant 
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area of deferoxamine B in this fraction was approximately 48,000 intensity units 
of 60,000 total.  This equates to around 2.89 mg/ml deferoxamine B in the 
fraction or 345.94 mg in the full 120 ml.  It is also useful for quantifying levels of 
deferoxamines in other fractions, as if 48,000 units equals 2.89 mg/ml, this can 
be used to work out amounts in other fractions.  A similar calculation was made 
for MZmine to facilitate faster calculations: corresponding peak area 2920175 = 
2.9 mg/ml; deferoxamine peak area/2.9E6 x 2.9 x fraction vol (120) = mg in 
fraction.  
The peak next to deferoxamine B has similar spectra to another siderophore, 
deferoxamine D1 (m/z 603.37 [M+H]).  This was logical as they are members of 
the same metabolite family with similar structures, though D1 does have a 
slightly longer carbon chain backbone than B making it less polar hence the 
slightly later rt.  Fraction 10 and compound peak areas, spectra and structures of 
deferoxamine B and D with mass fragmentation points for deferoxamine B 
(Senges et al., 2018) are displayed in Figure 5.9.  There were no deferoxamines 
detected above 1E3 intensity for ENV+ fractions, giving a total of 1431 mg per 3 
L culture or 477 mg per L. 
The majority of deferoxamine elutes across 7 fractions, 9 – 16, with relatively 
small concentrations of deferoxamine D1 (9.48 μg/ml) appearing only in fraction 
10.  A further minor peak was seen in fraction 10 matching the [M+H] of 
deferoxamine G1 at m/z 619.36, but the spectra was too unclear to confirm a 
match.  
The fraction with the lowest total yield (0.3 mg/ml, fraction 24) has a larger 
variety of metabolites, with potentially a small family of metabolites under m/z 
459.38 as the dominant one in this fraction. Across all C18-derived fractions 
there was a total of 3135 mg material, or approximately 1 L worth of culture to 
produce 1 g, not accounting for media compound.  The ENV+ cartridge produced 
23 fractions with a peak of approximately 420 mAU.  The lesser mAU of the 
ENV+ resin-derived fractions was reflected in the fraction weights (Appendix 
figure 11), with C18 at a total of 26.13 μg/ml and ENV+ at 11.03 μg/ml.  S. 
parvulus has been used in the production of deferoxamine E, a similar metabolite 
to deferoxamine B, producing up to 2 g/l of the compound (Gáll et al., 2016).  
Optimisation of deferoxamine B is less common in the literature, but has reached 
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as high as 5 g/l from S. pilosus (Chiani et al., 2010).  Actinomycin purification is 
examined in the next section, and amounts of deferoxamines and actinomycins 
for both C18 and ENV+ are shown in Figure 5.10. 
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Figure 5.9 (a) C18-derived Fraction 10 peak areas, (b) deferoxamine B spectra 
and structure with fragmentation points, (c) deferoxamine D1 spectra and 
structure. 
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5.3.1.5 Purification of actinomycins 
 
The other previously detected metabolite family, actinomycins, appeared from 
fraction 12 (C18-derived) onwards, first actinomycin X0β then the other 2 
members, actinomycin D and X2, in fraction 17.  This correlated to their positions 
in the supernatant chromatogram, where X0β would elute before D or X2.  D and 
X2 were also present in the ENV+ fractions from 15 onwards though X0β was 
not, despite the resin’s focus on retaining more polar compounds.  This was 
presumably due to the small amount of X0β being captured by C18 even if it 
would also have been retained by ENV+. The highest concentration of 
actinomycin D was in C18-derived fraction 21, at 16.07 μg/ml, translating to 
Figure 5.10 Supernatant actinomycin and deferoxamine weights in (a) C18-
derived fractions, and (b) ENV+-derived fractions. 
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1.93 mg for the whole fraction, or 8% of the 24 mg total from the full 120 ml.  
Across all the supernatant C18-derived fractions there was a total of 4.45 mg 
actinomycin D, 2.28 mg actinomycin X2, and 1.50 mg actinomycin X0β. 
Unlike in the C18-derived fractions, X2 is the dominant family member in ENV+ 
fractions though the overall amount of product is less.  Actinomycin X0β was 
barely detected in the ENV+ fractions at a high of 2.4 μg/ml for a total of 8.4 μg.  
Actinomycin X2 and D were each found at a total of 1.64 mg and 988.80 μg 
respectively. 
The produced yield is well below historical production of actinomycin D from 
Streptomyces, as 600 μg/ml were achieved from S. parvulus by Williams & Katz 
(1977).  This species is preferred as it does not produce analogues in relatively 
large amounts, as S. costaricanus does; however, other researchers later 
working with supposedly the same strain of S. parvulus only managed to elicit a 
maximum of 80 μg/ml (Dalili & Chau, 1988).  More recent efforts have used a 
mix of other species, such as S. triostinicus, with algorithmically aided medium 
optimisation to produce up to 452 μg/ml actinomycin D (Singh et al., 2009) from 
broth culture.   
Actinomycin is a relatively easy metabolite to collect since it is secreted into the 
media with little left in the pellet, which is discarded after centrifuging.  
Unfortunately, after centrifuging Singh et al. (2009) do not give clear instructions 
on any purification or crude extraction of actinomycin.  In comparison Praveen & 
Tripathi (2009) describe their purification of actinomycin using 1 L of S. 
griseoruber broth culture.  After centrifuging, the supernatant was passed 
through a silica gel column and eluted with ethyl acetate.  The eluate was 
vacuum-concentrated to give 240 mg crude extract, which was then fractionated 
using LH-20 resin for a final amount of 210 mg actinomycin D per litre of culture. 
As mentioned in section Scale-up of S. costaricanus 5.1.1.4, actinomycin 
production from a separate strain of S. costaricanus has recently been examined.  
Liu et al. (2019) used a different extraction method to the ones already 
described, adding each of their 50 ml cultures to 100 ml butanone and mixing for 
30 min.  The butanone phase was evaporated to dryness and the residue 
analysed by HPLC and UPLC-MS, but no further preparative chemistry was done.   
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One main difference between the methods used above and in this work is the use 
of solvents prior to fractionation, essentially adding a liquid-liquid extraction step 
prior to solid phase extraction.  If a metabolite has already been identified for 
collection, and is effectively partitioned by a solvent, then liquid-liquid extraction 
is a sensible step to optimise yield and negate compound loss caused by 
successive processing steps.  However, for an untargeted project, adding a 
liquid-liquid or resin prior to fractionation will reduce the accessible chemical 
space.    
5.3.1.6 Commercial value of identified metabolites 
 
Both actinomycin D and X2 are commercially available, though D far more 
frequently than X2 likely due to its usage as an antitumour drug.  At current 
prices, the components of M19 broth cost £126.00 (Fisher, Peptone) and £34.10 
(Sigma, Mannitol) for 500 g.  At 20 g/l each, the 3 L of M19 used cost £15.12 + 
£4.09, £19.21, to produce 5.40 mg actinomycin D.  Sigma sells 5 mg 98% purity 
actinomycin D for £121 (product ID A1410), so at this rough estimate it would 
technically be profitable to make actinomycin D with unoptimised medium, not 
accounting for labour, equipment, or other costs.  Actinomycin X2 is less widely 
available, potentially due to it not being medically used.  It is sold by AdipoGen 
(product ID BVT-0089-M005) at £40 for 5 mg, far less cost effective than 
actinomycin D.  Deferoxamine B would also not be very profitable, if at all after 
additional costs: Sigma sells 1 g for £79.20, and 1.4 g is produced from 3 L.  As 
with the actinomycins this is unoptimised culture.   
5.3.1.7 Compounds unretained by C18 captured by ENV+  
 
Initially, ENV+ was included to capture highly polar compounds which were not 
retained on C18 and so would normally be lost to waste.   Unfortunately, the 
majority of the higher weight ENV+ fractions were comprised of media 
components, which are always evident at the start of the chromatogram.  This 
higher polarity would fit with C18 not retaining them and their presence in ENV+ 
eluent.  This also made detecting novel metabolites more difficult, since any 
features found in ENV+ fractions may be media components and their 
derivatives. 
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Figure 5.11 shows a comparison of the supernatant to ENV+ load, both of which 
are representative of triplicate UPLC-MS runs.  There were 2 identified 
metabolites in the ENV+ load, deferoxamine B and actinomycin X2.  No 
deferoxamines were found in the ENV+ fractions despite being loaded on, 
indicating it did not adsorb to the resin. 
 
 
 
 
 
 
 
 
 
 
Using MZmine to compare the total features found in both C18 and ENV+ 
fractions found 34 features unique to ENV, 210 features unique to C18, and 23 
shared features.  ENV fraction 1 contained multiple unique features in clearly 
defined peaks: of the 12 total features in fraction 1, 9 were included in the 
unique list (Figure 5.12).  That Fraction 1 was mostly potentially unique polar 
compounds was logical, since Fraction 1 was eluted with the highest percentage 
of the more polar solvent.  Manually searching the GNPS database for these 
masses did not find any similar spectral patterns.   
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Figure 5.11 UPLC-MS spectra comparison of (a) S. costaricanus broth culture 
supernatant, and (b) Compounds unretained by C18 used as ENV+ load  
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However, given the low fraction weights (0.93 μg/ml for ENV+ fraction 1) any 
further characterisation would require substantial optimisation and extra scale-up 
assuming that they are novel metabolites.   
5.3.1.8 Flash chromatography of biomass crude extract 
 
Metabolites were extracted from S. costaricanus biomass to determine if any 
could be detected that were not found in the supernatant.  The flash 
chromatography mAU was low at a maximum of 240 with little absorbance 
across the chromatogram (Figure 5.13).  There were no unique features seen in 
the UPLC-MS spectra, so focus remained on the supernatant and agar extracts. 
 
 
 
 
 
Figure 5.12 MZmine UPLC-MS chromatogram of ENV+-derived fraction 1 features 
not found in C18-derived fractions. 
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5.3.2 Metabolites produced by S. costaricanus on agar culture 
 
5.3.2.1 Agar culture extract UPLC-MS profile 
 
UPLC-MS analysis of the crude extract (Figure 5.14) showed an overall lower 
intensity with fewer obvious metabolites than the supernatant.  While this was 
not surprising, given the differences in nutrient availability and mixing between 
solid media and broth in a shake flask, this was reflected in only 1 identifiable 
metabolite being immediately visible (actinomycin D).  Magnifying the 
chromatogram to exclude the major media peak and actinomycin enhanced the 
minor peaks, but none of them were identifiable metabolites. 
The major feature (m/z 205.07, rt 1.00) matched the media blank, indicating 
that nutrients were still available, which would be expected after only 5 d culture 
in rich media. 
 
 
 
 
Figure 5.13 Flash chromatogram of pellet extract from C18-derived fractions. 
  
 
  
205 
 
 
 
 
 
 
 
 
 
 
 
5.3.2.2 Metabolite analysis of fractions from agar culture 
 
Eluting the C18 and ENV+ loaded cartridges produced 22 fractions from each 
cartridge; the flash chromatogram is shown in Figure 5.15, with a mAU of 
approximately 800.  Similar to the crude extract profile, the fraction weights for 
agar culture were lower than the broth culture supernatant.  Also like the 
supernatant, the C18-derived fractions overall contained more weight than the 
ENV+ fractions: 14.97 mg for C18 versus 13.73 mg for ENV+.  Examining the 
chromatograms for the ENV+ higher weight fractions, the dominant peaks 
appear to be media components, with relatively small amounts of actinomycins.  
ENV+ fraction weights are shown in Appendix figure 12 . 
 
 
 
 
 
 
Figure 5.14 UPLC-MS chromatogram crude extract from S. costaricanus 
growth on M19 agar. 
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Figure 5.15 Flash chromatogram of agar culture extract fractionated using C18 
resin. 
Figure 5.16 Agar culture crude extract C18-derived fraction weights. 
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The identified actinomycins – D, X2 and X0β – were mostly divided between 
fractions 20 and 21. C18-derived fraction 21 contained the highest 
concentrations of actinomycin D from agar culture, but also had a low weight at 
0.2 mg/ml (Figure 5.16).  Quantification of actinomycin D through comparison to 
a 10 µg/ml actinomycin D standard came to 15.39 μg/ml, or slightly less than 
the 16 μg/ml supernatant fraction 21 equivalent.  Actinomycin produced by S. 
costaricanus grown on agar reached 9.06 μg/ml for X2, and X0β 9.01 μg/ml or 
108.68 and 108.16 μg respectively.  
Deferoxamine production was reduced when grown on agar, to the point where 
very little – if any – could be observed above the limit of detection in UPLC-MS 
chromatograms.  Processing the data with MZmine showed a feature with a 
similar, but not exact, mass and rt: m/z 561.74, with a maximum height of 2E3 
in ENV+ fraction 5.  Taking the actinomycin and deferoxamine results together in 
comparison to broth culture, M19 agar is not an effective culture condition for 
these 2 specialised metabolites. 
 
5.3.3 Metabolite purification through polarity-based fraction 
combination  
 
5.3.3.1 Fraction combination 
 
Multiple rounds of fractionation can be used in natural products analysis, often 
following identification of a bioactive fraction.  In another metabolomics approach 
to drug discovery, Kellogg et al. (2016) sub-fractionated a bioactive Alternaria 
sp. culture fraction and used the sub-fraction data to identify the bioactive 
component contributing to partial least squares separation, though this resulted 
in the identification of an already known metabolite.  A separate method focusing 
on MS/MS spectral networks to predict bioactivity identified one fraction from 
extracts of the tree Euphorbia dendroides, which was further fractionated to give 
4 new compounds (Nothias et al., 2018).  Fractions can also be combined 
together to increase concentrations of a desired metabolite in the resulting sub-
fractions.  This was shown in Erenler et al. (2017), who divided 400 Origanum 
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rotundifolium derived fractions into groups with similar polarities to isolate 
specific metabolites from each group.  
Combining fractions has the added advantage of allowing a fraction that was 
otherwise too low in compound weight to be useful, especially as material is lost 
at each processing stage.  Fraction weights varied, with multiple sequentially 
eluted fractions under 0.5 mg/ml.  This could have potentially split a bioactive 
metabolite into several fractions.  Unidentified features were also shared across 
agar and broth culture over both C18 and ENV+ derived fractions.  Therefore, as 
no target bioactive metabolite had been identified at this stage, to increase the 
concentration of identical or same family metabolites within a fraction, it was 
decided that the fractions should be combined and re-fractionated.  This was 
done by separating the fractions into 1 of 3 groups, based on the most dominant 
metabolite family in each fraction, acting as a proxy for overall fraction polarity.  
The families were actinomycins, deferoxamines, or the remaining unknown most 
polar fractions.  Specific fractions that make up each pool are shown in Table 
5.2, using high polarity pool (HP) for the remainder fractions, medium polarity 
pool (MP) for deferoxamine fractions, and low polarity pool (LP) for actinomycin 
fractions. 
Table 5.2 Groupings for fraction combination and re-fractionating. 
 
 
 
 
 
 
After pooling and purifying, the LP separation resulted in 24 fractions, MP 28, 
and the HP 24, of which the HP was the heaviest.  Fraction weights are listed in 
Appendix table 4. 
The fractions with the highest weights for each pool were expected to contain the 
majority of the pool-deciding metabolite for actinomycins and deferoxamines, so 
Fraction type Metabolite pool 
LP MP HP 
Supernatant C18 18 - 24 9 – 17 1 – 8 
Supernatant ENV+ 15 – 22 9 – 14 1 – 8 
Agar C18 17 – 22 12 – 16 1 – 11 
Agar ENV+ 16 - 22 9 – 15 1 – 8 
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20 – 22 for LP and 12 – 18 for MP.  In addition to deferoxamines B and D1, 
deferoxamine A1 and Bisucaberin-01 – previously reported by Wibberg et al. 
(2018) – were also identified in the HP (fractions 13 – 14; deferoxamine A1 m/z 
547.34 [M+H]; Bisucaberin-01 m/z 443.25 [M+H], Figure 5.17).  While an 
already known metabolite, A1 has an identical elution time to deferoxamine B at 
1.9 min.  The 100% methanol eluted fractions had low intensities and potentially 
weights (signal intensity <5E3) with no additional novel compound so were set 
aside to only be used in metabolite dereplication. 
 
 
 
 
 
 
 
 
 
Therefore, though by no means as efficient as MS/MS based strategies, the 2nd 
round of fractionation did contribute to metabolite analysis and dereplication.  
The other fractions in this range were overwhelmingly deferoxamine B (peak 
area approximately 13000 of 14000), which at 93% is an efficient level of 
purification given the untargeted nature of the purification.  As no further 
metabolites could be manually identified the actinomycin purification levels in the 
LP were investigated. 
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Figure 5.17 Manual identification of bisucaberin-01 after purification. 
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5.3.3.2 Purification of actinomycins across LP fractions 
 
Actinomycins were spread across fractions 17 – 24 corresponding to their 
originally seen rt: the first eluted metabolite was the putative double charged 
actinomycin (m/z 614.34 [M+2H]2+) in fraction 17, followed by the other less 
polar metabolites with actinomycins X2 and D least polar.  Figure 5.18 shows the 
amount of the detected actinomycins over relevant pool fractions. 
 
 
 
 
 
 
 
 
 
 
5.3.3.3 Purification enhanced discovery of an actinomycin 
analogue 
 
These fractions contained 6 actinomycins which were quantified (3 known – D, 
X2, X0β – and 3 unidentified).  Partially purifying the actinomycins allowed more 
robust spectral identification, since co-eluting members of the same family will 
share many mass fragments and so confuse characterisation.  Chromatograms 
and mass spectra for each of the actinomycins plus actinomycin D are shown 
from Appendix figure 20 to Appendix figure 25, with diode array absorption 
showing similar absorption wavelengths. 
Figure 5.18 Amount of 3 identified actinomycins, and the next 3 most 
concentrated putative actinomycins. 
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Actinomycins are a large family of metabolites with many structurally similar 
members.  This makes mass spectral differentiation of known and unknown 
actinomycins members challenging as there will be many shared fragments 
between them, so without a fully purified sample precise spectral differences 
may be unclear.  Of the 6 actinomycins here, 1 minor metabolite (the analogue 
m/z 1241.61) was found following the semi-purification step, as it was otherwise 
hidden by the more concentrated actinomycin D due to the similar retention 
time. 
This metabolite shares many, if not all, of the actinomycin D fragments identified 
by Wills & O’Connor (2014).  However, many of these also have a fragment at 
m/z minus 14.  The presence of the “reference” fragment and a separate -14 
indicated that the difference from actinomycin D is on one ring rather than both.  
The chemical difference could be a -CH2 loss, which could explain the slightly 
earlier, more polar rt compared to actinomycin D.   
This difference was maintained for all major fragments down to m/z 300, which 
according to Wills & O’Connor (2014) cleaves the chromophore-containing 
central linker plus Thr and Val (plus an H2O; C14H26N3O4+) from the remainder of 
the molecule.  Therefore, the difference is in the remaining ring amino acids: Me-
Gly, Pro, and NMe-Val.  Thomas et al. (1995) found a similar situation when 
dealing with impurities of actinomycin D.  The authors suggest a range of 
potential amino acid substitutions, with either NMe-Val, NMe-Gly, or Val being 
substituted.  Of those, only NMe-Gly matches the remaining amino acids given 
above.  Therefore, the difference is a substitution in NMe-Gly, potentially to Gly.  
This would account for the mass difference.  Thomas et al. also note that another 
actinomycin family member, actinomycin D0, varies from D exactly by a NMe-Gly 
to Gly change.  This gives a potential identification for 1 of the 3 unknown 
actinomycins. 
5.3.4 A. baumannii growth and inhibition 
 
The supernatant and agar crude extract fractions were assayed against 
Acinetobacter baumannii, a Gram-negative nosocomial pathogen listed as one of 
the multi-drug resistant microbes most needing new antibiotics for treatment by 
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the World Health Organisation (Tacconelli et al., 2018).  The strain used was a β-
lactam/carbapenem resistant hospital isolate (NCTC 13301), matching the World 
Health Organisation list.  
5.3.4.1 XTT Assay Optimisation 
 
The bioactivity test selected was a colourmetric assay using the tetrazolium salt 
2,3-bis {2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-
hydroxide}, commonly known as the XTT assay (Pettit et al., 2005).  The XTT 
assay is a cell viability assay which indirectly measures respiration through the 
properties of tetrazolium salt reduction.  Upon reduction with an electron donor – 
in this case NADPH – a water soluble formazan pink/red dye is formed, distinct 
from the clear-coloured XTT (Berridge et al., 2005).  The amount of reduction, 
and indirectly respiration, is indicated by the colour intensity: a darker colour 
implies more respiration, and vice versa.  The assay can therefore be used to 
measure the effect of fractions or metabolites on cell viability.   
Measuring the growth of A. baumannii in shake flask culture showed mid-log 
phase to occur at approximately 4 h.  Mid-log culture was used to optimise the 
dose of the positive control, colistin, to determine the minimum inhibitory 
concentration (MIC).  Growth was inhibited above 1 μg/ml (Figure 5.19), which 
had an OD490 of approximately 0.17 against 0.2 for an MHB blank and did not 
decrease at higher colistin concentrations. The Clinical Laboratory Standards 
Institute recommends a dose of ≤2 μg/ml for susceptible A. baumannii , and ≥ 4 
μg/ml for resistant strains (CLSI, 2018).  This mirrors Papp-Wallace et al. (2018) 
who also found an MIC of 1 μg/ml for colistin against the same strain of A. 
baumannii.  Therefore, 1 μg/ml colistin was chosen as the positive control.  
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5.3.4.2 Fraction Bioactivity 
 
Fractions eluted from the C18 and ENV+ resins were tested against A. baumannii 
at 50 μg/ml through the XTT assay to determine if any of the fractions led to a 
negative change in cell viability and so inhibition of growth (Figure 5.20 for 
supernatant fractions, Figure 5.21 for agar extract fractions).  The majority of 
supernatant fractions provoked an increase in viability, potentially due to unused 
M19 nutrients.  The largest increase in viability was found in supernatant C18-
derived fractions 10 and 11 at 45% and 49%% respectively.  Both of these 
fractions are almost entirely siderophores – either deferoxamine B or D1 – so no 
inhibition was expected and would explain the increase in viability.  
Only 1 of the supernatant C18-derived fractions produced >10% inhibition: 
fraction 2 at 22%.  Fraction 1 increased viability by 9%, with a statistically 
significant difference between the fraction 1 and fraction 2 inhibition levels.  
Therefore, any differences between the fractions visible in their UPLC-MS 
chromatograms could have been responsible for bioactivity.  Unfortunately, no 
significant differences could be seen between the 2 fractions.   
 
 
 
 
 
  0.125    32 
Figure 5.19 XTT assay plate with 2-fold dilutions of colistin, starting at 
0.125 μg/ml on the left and ending at 32 μg/ml on the right. 
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The supernatant ENV+ fractions were more inhibitory.  Fraction 6 resulted in 
22.58% inhibition, but again there was no obvious difference between UPLC-MS 
chromatograms of fraction 6 and the growth-promoting fraction 7, indicating that 
not all compounds within these fractions are ionising.  After 6, there was a run of 
>20% inhibitory fractions from 16 – 22, peaking at fraction 20 (52%).  The 
major peak in fraction 20 is m/z 1269.66, corresponding to actinomycin X2. 
Actinomycin D is not active against A. baumannii and other Gram-negatives at 
this concentration (Luna et al., 2017), and was not seen to be in the assay at 
this concentration of 10 μg/ml.  There is limited information on the Gram-
negative antimicrobial activity of actinomycin X2.  It was found to be active 
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Figure 5.20 Inhibition of A. baumannii by metabolites in culture supernatant 
fractions at 50 µg/ml, split into (a) C18-derived, and (b) ENV+-derived.  
Negative inhibition indicates growth greater than the negative control. 
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against E. coli at 0.73 μg/ml (Xiong et al., 2012), but no specific E. coli strain 
information was given by the authors so E. coli used may not have been multi-
drug resistant.  Xiong et al. (2012) also did not test against A. baumannii. 
Whether actinomycin X2 is active against resistant Gram-negatives or not, it may 
not be the bioactive component in ENV+ fraction 20.  The most inhibitory fraction 
from agar culture was the ENV+ separation from 21, which produced 66% 
inhibition (Figure 5.21).  This fraction contained an actinomycin X2 peak, but at 
approximately half the peak area: 2297.66 (supernatant) against 1377.29 
(agar), or approximately 2 against 1 μg/ml.  With less peak area but higher 
bioactivity, actinomycin X2 is unlikely to be the major bioactive component.  
The largest feature in the agar ENV+ fraction 20 is m/z 245.16, which is a match 
for an isoleucine/leucine dimer, but otherwise could not be identified.  As with 
the other bioactive fractions, an unambiguous bioactive metabolite candidate 
could not be identified.  This could have been due to the effect of a minor 
inhibitory bioactive metabolite competing against growth-promoting compounds, 
as the fractions are a complex mix of different compounds.  Therefore, groups of 
fractions were pooled for further purification. 
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(a) 
(b) 
Figure 5.21 Inhibition of A. baumannii by S. costaricanus agar culture 
metabolites, split into (a) C18-derived, and (b) ENV+-derived.  Negative 
inhibition indicates growth greater than the positive control. 
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5.3.5 Pooled Fraction Bioactivity 
 
Fraction pooling combined similar potentially bioactive metabolites by their 
polarities, with the aim of increasing their concentrations while separating non-
active or growth promoting compounds.  The LP contained the primary bioactive 
fractions, so was re-assayed against A. baumannii with the XTT assay at 50 
μg/ml.  Results for the assay are shown in Figure 5.22.  The highest inhibition 
came from fractions 22 and 20 (48% and 35% respectively) and fractions 8 to 9 
(37% and 32% respectively).  Fractions 7 and 8 were predominantly leupeptins 
(Figure 5.23).  As a protease inhibitor (Ding et al., 2002) leupeptin is unlikely to 
be the antibiotic component.   
 
 
 
 
 
 
 
 
 
 
Figure 5.22 LP fraction pool activity against A. baumannii using a concentration 
of 50 μg/ml. 
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Despite being sequentially eluted between 20 and 22, fraction 21 showed 
dissimilarly low inhibition (10 %).  Like the other similar elution fractions, 21 is 
predominantly actinomycins (D, m/z 1257.65 and 1271.69).  This showed a 
similar pattern to the original set of fractions where inhibitory actinomycin 
containing fractions were present along with non-inhibitory actinomycin 
containing fractions.  This was shown by fraction 21, which additionally contains 
actinomycin X2, but has an inhibition level of only 10%.  This suggests that the 
actinomycins were not responsible for bioactivity, especially actinomycin D as 
this is the major compound in both fractions 21 and 22 at similar levels.  To 
confirm this actinomycin D was tested using the XTT and disc diffusion assay, 
both of which showed no inhibition of A. baumannii. 
There were minor metabolite differences between fractions 21 and 22, making 
bioactivity difficult to assign to any particular compound.  Bioactivity could also 
have been due to the synergistic interactions of multiple metabolites, for 
example an emulsifier to facilitate movement of an antibiotic through the 
Figure 5.23 Pooled fractions (a) 8 and (b) 9 containing leupeptin and analogues, 
with (c) GNPS core matched set of fragments. 
(a) (c) (b) 
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bacterial membrane (Zhang et al., 2017), which could also apply to bioactivity in 
any of the other fractions. There were variations in levels of some unknown 
compounds, such as m/z 783.49 rt 5.35 (peak areas 22 versus 21: 1672.84 
versus 199.74, respectively).  For this compound to have been responsible with 
no synergy required, any other fractions containing it should have had respective 
levels of bioactivity, assuming no growth promoting compounds are present.  
Fraction 23 inhibited A. baumannii growth by 19 % and contained this compound 
with a peak area of 606, approximately 3 times that of fraction 21.  While the 
increase in inhibition from fraction 21 to 23 was not totally proportional, there 
was a relevant bioactivity increase from fraction 21 and decrease from 22 
approximately in line with the peak area levels of m/z 783.49.  Therefore, this 
may be the metabolite responsible for bioactivity, but further purification would 
be required to prove this.   
Cytoscape was used to screen for other metabolites in bioactive fractions by 
deleting all nodes that were not found in LP fraction 22. The majority of the 
remaining nodes were actinomycin-related parent ions and fragments.  Excluding 
these left only non-actinomycin fraction 22 MS/MS features, one of which was 
the previously mentioned m/z 1492.76.  Another potential bioactive feature was 
m/z 628.31, which appeared in fractions 22 and 8 (fraction 8, 37 % inhibition).  
However, the signal levels of this feature were low with peak areas of 17 and 4 
for fractions 8 and 22 respectively.  Therefore, either this feature is a highly 
bioactive metabolite or, more likely, a feature that is coincidentally shared 
between the two fractions, especially as they eluted at different ends of the 
gradient. As stated above, further purification is needed to determine the 
bioactive metabolite given the inhibition differences between actinomycin-
containing fractions. 
The chromatograms for the above discussed pool fractions (LP, fractions 8, 9, 21, 
22, 23) are shown in Appendix figure 14 to Appendix figure 18. 
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5.3.6 UPLC-MS/MS Metabolite Identification 
 
5.3.6.1 GNPS Identification 
 
Each of the fractions from the 3 pools (LP, MP, HP) was analysed using the 
Masslynx Data Directed Acquisition UPLC-MS/MS tool, which were then processed 
with MZmine and submitted to the Global Natural Products Social Molecular 
Networking (GNPS) server for metabolite identification.  In total 13 matches 
were found, which are listed in Table 5.3.  Multiple compounds may appear more 
than once due to separate library entry matches, as is the case with 
deferoxamine B. 
 
Table 5.3 GNPS-detected compounds found from the 2nd round of fractions 
 
GNPS Compound GNPS m/z  Pool Molecular 
formula 
Actinomycin D 1255.64 LP C62H86N12O16 
Actinomycin X2 1269.63 LP C62H84N12O17 
Deferoxamine B 561.36 MP C25H48N6O8 
Desf-05 575.38 MP C26H51N6O8 
Deferoxamine A1 547.35 MP C24H47N6O8 
Deferoxamine B 
[M+Al-2H] 
585.32 MP C25H46N6O8Al 
Deferoxamine B 
[M+Fe-2H] 
614.27 MP C25H46N6O8Fe 
Leupeptin analogue 
LVR 
413.29 LP C19H36N6O4 
Maltotriose 527.16 MP C18H32O16 
Methiazole 266.10 LP C12H15N3O2S 
“Unknown peptide” 1025.57 HP - 
Polysaccharide hexose 527.16 HP - 
Triphenyl phosphate 327.08 MP C18H15O4P 
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One notable compound not previously detected was methiazole (not 
methimazole, a treatment for hyperthyroid).  Methiazole is an antihelminth 
compound (Reuter et al., 2006).  Earlier papers on S. costaricanus described it 
as being isolated from “nematode-suppressive soil”, indicating some level of 
antihelminth activity (Esnard et al., 1995) but no responsible metabolite.  
Methiazole is a benzimidazole derivative (Shimomura et al., 2019), along with 
many other synthetic compounds not naturally produced by Streptomyces or 
other microbes.  The spectrum for methiazole in the GNPS library is taken from 
the National Institute of Health’s pharmacologically active small molecule library, 
which contains synthetic compounds. It is likely that methiazole was developed 
as a result of or along with other azole-drugs in the 1970s (Vicente et al., 2003); 
azoles are further listed as synthetic drugs by Vengurlekar et al. (2012). 
Therefore, it cannot be stated that methiazole is the responsible metabolite for 
the originally detected bioactivity of S. costaricanus.  However, it may be that a 
similar azole-based metabolite is produced, since non-human synthesised azole 
natural products do exist with the azole moiety itself being responsible for 
bioactivity (Jamison et al., 2019).  The antiSMASH results do contain a Linear 
azol(in)e-containing peptide BGC, though it is part of a larger terpene-
thiopeptide-azoline hybrid product with no definitive identity.   
So, while methiazole is likely not produced by S. costaricanus, a compound with 
similar MS/MS fragmentation is produced by it which closely resembles an 
azoline product.  The cluster is reproduced below in Figure 5.24, which includes a 
terpene, thiopeptide, and the LAP BGC.  The terpene, while potentially part of a 
hybrid BGC, is predicted to produce hopene, a widely occurring metabolite. It is 
also designated as “neighbouring” relative to the overlapping “chemical hybrid” 
thiopeptide and LAP BGCs, further indicating that it may be a wholly separate 
BGC.   
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Figure 5.24 AntiSMASH-derived BGC 11 of S. costaricanus comprising terpene, thiopeptide, and LAP clusters.   
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5.3.6.2 Cytoscape View of Pooled Fractions 
 
Cytoscape (Shannon et al., 2003) is a bioinformatics tool which allows for the 
analysis and comparison of large scale biological data from a variety of sources.  
The GNPS Molecular Networking workflow produces a cytoscape-compatible file 
which can be used to visualise spectral networks.  Cytoscape groups metabolites 
by MS/MS spectra similarity following the GNPS output, linking families of 
metabolites together alongside user-specified cosmetic or feature specific 
information.  This can be useful for identifying novel metabolite analogues, 
production differences between culture conditions, or to aid bioactive compound 
identification with additional in silico predictions (Nothias et al., 2018).   
As MS/MS and GNPS analysis was done post-fraction pooling, here the network 
was used to examine groupings of known compounds, if there were any unseen 
family members, and any other potential networks indicating metabolites. 
The overall network is shown in Figure 5.25.  Individual nodes are coloured by 
their polarity group: LP red, MP blue, and HP grey.  If a feature is found in 
multiple groups, the pie chart colouring will change to be proportionally coloured 
based on the number of fractions in each of those groups.  For example, if a 
feature is found in 5 LP fractions and 1 MP fraction, the pie chart will be 5:1 
red:blue.  This is less likely to happen for the major metabolites which were used 
to decide polarity groupings but could potentially be to non-archetype family 
members – so not actinomycin D or deferoxamine B – which were split during 
pooling.  The primary networks for these 2 families are shown in Figure 5.26.  
Separation is more likely to happen for unknown metabolite families which may 
be split across polarity groups, but as features are grouped by spectra, they will 
remain linked in cytoscape. 
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Figure 5.25 Cytoscape network of pooled fractions.  Red – LP, Blue – MP, Grey – HP. 
Actinomycins 
Deferoxamines Leupeptins 
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The deferoxamine node m/z 502.267 was found in HP fractions 23 – 28, but 
there is also an identical m/z found in MP fractions 13 – 16 which likely represent 
the original gradient and 100% methanol eluted fractions.  The MP spectra were 
used for analysis due to their higher intensity. 
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Figure 5.27 m/z 502.27 deferoxamine network offshoot spectra. 
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Figure 5.26 Networks for (a) actinomycins, and (b) deferoxamines. 
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The ion was not immediately visible on the chromatogram due to its proximity to 
the major deferoxamine A1 peak approximately 10 times larger (6E2 against 
6E3) but it does become the most intense ion for 6 scans.  As an offshoot of the 
main deferoxamine branch, if assigned correctly then there should be shared 
spectra between this feature and other deferoxamines.  The MS are shown in 
Figure 5.27; this was chosen over the MSe or associated MS/MS as the low signal 
intensity gives a visually noisy spectrum.  Some deferoxamine characteristic 
fragments are present, such as m/z 443.27 and 243.14.  Given its proximity to 
deferoxamine A1, the parent ion could potentially be a partially decayed remnant 
of A1 with the loss of C2H5NH2 from the end of its structure.  A similar fragment, 
m/z 502.33, is present within the A1 peak, but at a lower intensity than the later 
502.27.  The GNPS spectra for deferoxamine A1 does not show the potential 
parent ion, overall indicating it is a separate metabolite found by examining the 
molecular network.   
One potential novel metabolite unrelated to the known families is shown in 
Figure 5.28.  The suggested parent ion (m/z 1492.73) appears in LP fraction 19, 
which is dominated by actinomycins.  A double charged peak also appears at the 
same rt (m/z 746.86) with the appropriate 0.5 isotope increase, which 
presumably is the double charge ion of the parent ion.  Characterising this 
molecule would require targeted optimisation and culture scale-up to obtain 
conclusive fragmentation patterns, but some structural speculation can be made 
based on the spectra and the derived network.  While not every node in the 
network is necessarily a fragment (Bandeira et al., 2007) especially from a 
complex mixture analysed with generalised MS-MS settings, comparison with the 
original can help confirm authenticity.   
Assuming m/z 1492.72 is the parent ion, a loss of 78 is required to reach 
1414.72.  This could indicate the removal of a C6H5 + H ring (Gross, 2011), 
followed by a further CH2 to produce the node with m/z 1400.72.  Removal of an 
m/z 78 fragment from the overall structure is supported by the presence of m/z 
1403.72, which if also subtracted 78 corresponds to another network node, m/z 
1325.69.  Examining the original spectra again shows a separate ion (m/z 
1243.64) which also has a putative doubly charged form (m/z 622.31).  This 
second ion has a similar mass to actinomycins, but checking their spectra does 
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not show double charged ions so, assuming that these are fragments of m/z 
1492.72, it is unlikely to be an actinomycin analogue.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Identifying this potential metabolite not just amongst the actinomycin spectra 
but all the other data files would have been highly unlikely, again making 
spectral molecular networking a useful tool for metabolite discovery.
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5.4 Conclusions 
 
The aim for this chapter was to scale up culture of S. costaricanus in M19 to 
identify and purify bioactive metabolites from fractions.  These were targeted 
against a strain of multi-drug resistant A. baumannii, a pathogen globally 
recognised as needing novel treatments.  Scale-up in broth and agar culture was 
successful, with both media types requiring different extraction and chemical 
processing methods.  This led to an extract library primarily containing the well-
known and previously identified metabolites actinomycin D, X2, and 
deferoxamine B.  Through the dereplication process, involving both manual 
fraction inspection and automated MS/MS spectral screening, further metabolites 
belonging to both those families were found, as well as other non-deferoxamine 
siderophores (bisucaberin) and leupeptins.  This part of the aim was therefore 
fulfilled.  An explanation for the originally detected antihelminth bioactivity of S. 
costaricanus was also suggested through an unknown azoline metabolite. 
Fractions active against multi-drug resistant A. baumannii were detected, though 
most of them were predominantly actinomycin D and other family members, 
which – especially actinomycin D – are not known to be active against A. 
baumannii.  Running an XTT assay using actinomycin D against A. baumannii 
found no significant difference to the negative control, nor did an alternative disc 
diffusion assay.  Pooling the fractions further purified metabolites, though later 
MS/MS-based networking showed some metabolite overlap between pools.  The 
bioactive component could not be identified from a mostly actinomycin D-
containing fraction.  Assuming the bioactive metabolite was detected by the 
positive mode UPLC-MS method used, this implies one of the minor peaks was 
responsible for bioactivity.  As a minor peak within a 50 μg/ml fraction, the 
metabolite must be active at relatively low concentrations against a multi-drug 
resistant pathogen.   
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6 General discussion 
 
6.1 Thesis aim  
 
The central question at the start of this thesis was whether specialised 
metabolite diversity could be improved in underexploited Streptomyces strains.  
There were 4 main objectives stated as necessary to achieve this: development 
of a culture parameter-based screen that would elicit varied production of 
specialised metabolites, application of the screen to unexploited strains, genome 
sequencing of an unexploited strain, and finally culture scale-up and metabolite 
bioactivity.  This required several experimental stages starting with method 
development, strain selection, and culture parameters.  These were grouped into 
4 chapters, which are summarised in Figure 6.1.  These chapters contained a 
range of different methods used to complete the main aim but were not the only 
options available.  Section 6.2 details some of these and the potential impact 
their inclusion could have had on the project.  
6.2 Suitability of methods 
 
Key considerations were the applicability of the methods to the remainder of 
NCIMB strains to enable continued exploitation while incorporating modern 
metabolomic and genomic tools into the workflow.  As a culture parameter-based 
screen, the culture methods used are easily transferred not just to other 
Streptomyces strains, but also NCIMB Actinomycetales accessions and other 
specialised metabolite producers of interest.  The parameters may need altering 
depending on strain-specific requirements or when testing a specific variable, but 
the overall culture, extraction and analysis method is broadly applicable.  For the 
second consideration, both the primary genomic and metabolomic software used 
(antiSMASH and MZmine respectively) are continually updated and have user-
friendly interfaces, making them ideal for generalised strain exploitation 
workflows.  
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6.2.1 Impact of strain selection method 
 
While this overall method was suitable for the NCIMB Actinomycetales, there are 
multiple workflows for metabolite discovery.  The optimal route will depend on 
the type of sample, level of information, proposed targets, and analytical 
techniques used.  For example, if starting from a soil sample, both the culture-
dependent and metagenomic routes are viable, including focusing on lesser 
cultured Actinomycetales or specific BGC classes.  If more genetic information 
had been available at the start of the project, such as full 16S sequencing for all 
isolates, phylogenetics would likely have been incorporated into the workflow to 
better select the most varied strains.   
However, as was later noted in section 4.1.1, specialised metabolite diversity 
amongst a single species can be extensive.  Similarly, Purves et al. (2016) found 
that taxonomically close Bacillus lichenformis strains isolated from different 
niches produced different metabolites.  Had a genomics-based method been 
adopted at the start of the project, it would likely have produced an accurate 
16S-based phylogenetic map of NCIMB strains but not reflected natural product 
diversity. Therefore, metabolomics approaches remain the best starting point 
when starting from a wide-ranging collection with genetically even semi 
characterised strains.  As full genome sequencing becomes more routine this 
may change with direct access to BGC content, in turn enabling greater 
documentation of BGCs and their submission to public databases to link genomic 
and metabolomic data.  
A broad environmental categorisation was used for the NCIMB strains, grouping 
soil, marine, plant, and animal associated isolates.  Soil strains were focused on 
originally due to the majority of Streptomyces being isolated from the soil, with 
strains from the other categories included once the metabolomic screening 
method had been determined.  An alternative method could have been a focus 
on extreme environments, such as metal contaminated soil, high or low pH, 
arctic sediment, or the highly alkaline Atacama Desert isolates.  This would have 
enabled a more focused OSMAC screen, with isolate niche specific growth 
parameters and stresses being applied to relevant strains, such as 
supplementing media with copper for a high copper soil isolate.   
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While attempting to recreate environmental conditions in a lab is a logical way to 
trigger transcription of cryptic BGCs, many BGCs are upregulated by elicitors for 
unknown reasons (Jakeman et al., 2006) resulting in large scale arrays of 
elicitors being applied to activate a single cluster (Seyedsayamdost, 2014).  
Cryptic BGCs will likely be activated by unexpected elicitors or carbon and 
nitrogen sources, so a generalised OSMAC screen should still be a highly 
applicable part of the workflow.  Strain selection by extreme environment would 
have been a viable alternative with the key requirement that it did not narrow 
the OSMAC screen variety. 
6.2.2 Culture parameters 
 
The final set of culture parameters used a mixture of previously identified media 
and media based on recommended ingredients for Streptomyces metabolite 
production.  These were primarily complex media, some with multiple carbon and 
nitrogen sources, like MM which contained molasses and glucose.  Goodfellow & 
Fiedler (2010) recommend multiple complex media for Streptomyces SMet 
production and discovery, but this had the effect of creating a messy UPLC-MS 
chromatogram which slowed dereplication.  An alternative would have been to 
use only 2 components per media: one carbon source and one nitrogen source, 
enabling precise linking of metabolite production to specific media.  This would 
have benefitted both future linking of BGCs to metabolites and also novel 
metabolite detection.  However, if making media using new components, S. 
costaricanus could grow poorly or not at all, lowering the amount of new data. 
Using a complex medium with a small amount of sugar or nitrogen known to be 
metabolised by S. costaricanus ensured that growth would still occur, but not to 
the point where SMet was negatively impacted.   
The culture methods broadly used conventional broth and media cultivation.  
While these are the standard for the majority of experiments, there are some 
alternative substrates which can lead to the production of novel metabolites even 
if using the same media, or allow detection of multiple days of metabolite 
development from a single sample.  Timmermans et al. (2019) cultured the 
marine Gram-negative bacterium Pseudoalteromonas on cotton wool, observing 
changes in pigmentation and significant induction in production of other 
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metabolites, most notably of the antibiotic thiomarinol A.  Other unidentified 
metabolites were also induced, indicating that – as with Streptomyces – the 
physical structure of a culture can impact metabolism and likely differentiation.  
Growth conditions in the soil are highly dissimilar to a standard agar plate with 
many more pockets and variations in the surface.  While culture in a similar soil 
mimicking (or cotton) environment could potentially lead to the production of 
novel metabolites, the challenge would be increasing metabolite titres from the 
level a strain would normally produce in the soil.   
Pishchany et al. (2018) employed a transwell co-culture membrane to hold an 
agar plug partially submerged in a well plate, allowing secreted metabolites to 
diffuse into the liquid medium over time.  This method would allow continuous 
measurement of metabolite development, going far past the 2 time points used 
in the final OSMAC screen, potentially to daily samples.  It is limited to secreted 
metabolites and may give a false impression of production over time if some 
metabolites are slower to diffuse through the agar than others.  Despite this, the 
method could easily be adapted to examine how the S. costaricanus chemotype 
develops over a longer and more frequent time period than 5 and 10 d. 
6.2.3 Target selection 
 
Here, “target selection” refers to whether the specific objective is to produce 
novel metabolites and test for their bioactivity, or to find bioactive extracts and 
then identify a novel metabolite.  After OSMAC screening of S. costaricanus, M19 
was identified as the media which most enabled diverse metabolite production.  
This led to scale-up of S. costaricanus using M19 agar and broth for extract 
fractionation and bioactivity assays against multi-drug resistant Acinetobacter 
baumannii due to its status as a pathogen critically requiring novel treatments.  
While an approach based on activity against a single target does give a clear 
objective, it may have negatively impacted the novel metabolite discovery 
segment of the project. 
This was primarily shown from 2 areas of the project: the minimal media screen 
and the detection of putatively novel actinomycins.  Minimal media with GlcNAc 
culture of S. costaricanus led to the production of an unknown metabolite family, 
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which could potentially have been either scaled up, isolated, structurally 
characterised and then assayed against multiple disease targets.  Alternatively, 
the novel actinomycins were already partially structurally characterised and 
would have been logical choices for anticancer assays (Cai et al., 2016).  A basic 
disc diffusion assay against A. baumannii did not show activity when using the 
minimal media crude extracts, possibly due to low production levels from the 2 
ml of media per well.  The disadvantages of scale-up and wider activity testing 
would have primarily been extensive optimisation, extraction, and selection of a 
panel of targets to test against.   
The full workflow, starting from a group of uncharacterised strains through to 
metabolite identification, is generally applicable and was successful in initiating 
exploitation of S. costaricanus.  Although no novel metabolite could be identified, 
multiple metabolites previously unknown to be produced by S. costaricanus were 
detected, such as biscuberin 01 and leupeptin, which did aid bioactive fraction 
dereplication.  The 3 experimental chapters which studied S. costaricanus also 
raised novel research questions, whether in novel directions or continuing the 
chapter theme.  These are briefly listed in section 6.3. 
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6.3 Future work 
 
6.3.1 Untargeted metabolomics screening of S. costaricanus  
 
Two main areas of future work are suggested.  The first is expansion of the 24-
well plate screening for S. costaricanus metabolites but using different elicitors to 
affect either production of novel metabolites or structurally alter existing ones.  
As an example, restricting the screen to 1 media then switching out different 
halogens is a simple method; other factors such as long-term culture and heavy 
metals would help fully characterise not just the standard specialised 
metabolome, but also structurally distinct analogues. 
The second strand is continued investigation of minimal media culture, in 
particular of the features which were significantly upregulated after addition of 
an elicitor.  The N-acetyl glucosamine elicited peaks would be clear starting 
choices and would provide a more targeted route through scale-up and 
preparative HPLC, along with the feature detected after addition of heat-killed A. 
baumannii cells.  Using these elicitors in richer media could aid production, so 
long as the effect of the elicitor remains the same in less harsh conditions.  
6.3.2 Exploitation of the genomic potential of S. costaricanus 
 
This project has relied on altering culture parameters to elicit production of novel 
metabolites.  However, one consideration with this method is the lack of 
predictive power it has in which metabolites will be produced from an unexploited 
strain.  The full genome sequence identified one specific BGC with minimal 
homology to other strains which is apparently limited to its clade.  Therefore, 
genetic engineering to express this BGC – whether in S. costaricanus or a 
heterologous host – would be a further validation of the original metabolomic 
method of strain selection.   
This BGC is also relatively simple in that it is not particularly large – about 20 kb 
– and is a single BGC type, not a hybrid, so may be easier to express in a non-
native strain.  One potential method for engineering S. costaricanus would be 
through the CRISPR-enabled method CRISPR-BEST, which precisely edits the 
genome to change a C:G pair into an A:T pair (Tong et al., 2019).  This could be 
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used to introduce stop codons into other BGCs, simplifying detection of the 
desired BGC product.  Alternatively, methods like transformation-associated 
recombination capture a target BGC in a plasmid which can then be transferred 
through conjugation into a suitable host like S. coelicolor (Jia Jia Zhang et al., 
2019). 
6.3.3 Scale-up culture and bioactive metabolites of S. 
costaricanus 
 
The most logical step would be to increase scale-up to generate more material 
and unambiguously identify the metabolite, or potential synergistically acting 
metabolites, responsible for bioactivity against A. baumannii in the most 
bioactive fractions.  Alongside this, the putative novel actinomycins could be 
purified and structurally characterised by MS and NMR, expanding the known 
range of actinomycins that S. costaricanus is able to produce.  
6.4 Conclusions 
 
This thesis addressed the question of assessing specialised metabolite diversity 
using a library of underexploited Streptomyces, selecting one strain to help 
develop an overall framework for the further characterisation of NCIMB isolates.  
The overall metabolomic strategy was reinforced with modern genomic tools 
which helped guide not just specialised metabolite identification and BGC 
potential but also a potential phylogenetic reclassification for S. costaricanus 
based on its MLST profile. 
The majority of the S. costaricanus BGCs were unknown, and multiple potential 
avenues for further research were identified.  Within the context of with an 
overall resurgence into Streptomyces specialised metabolites, this project 
investigated an underutilised source of novel metabolites, and has demonstrated 
that it is a valuable candidate for continued research.    
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8 Appendix 
 
8.1 Appendix figures 
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Appendix figure 1 Full co-culture of S. coelicolor with NCIMB strains. 
  
 
  
271 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O
O
H
N
OH
O
NH
O
O
N
H
O
HNO
HN
O
HN
O
HN
O H
N
O
NH
O
NH
O
NH
O
H
N
O
OH
O
OH
HO
O
OH
O
H2N
OH
O
HO
HN
1460.57 (Hojati et al., 2002) 
CDA4a [M+K] 
CDA4a 
[M+Na] 
M2 a3 7:3
m/z
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
JB Mar6 55 206 (3.952) 2: TOF MS ES+ 
4.75e31495.6000
167.0766
197.1301
1477.5931
767.4899
681.2576237.1008
423.1980 566.2386
894.3118
786.3569
1296.4896945.3714
1165.4731
1460.5763
1517.5837
1518.5890
1533.5624
1534.5604
1535.5515
1536.5714
1549.5414
1658.4489
(a) (b) 1477.33 
767.42 1460.57 
Appendix figure 2 Spectral comparison for CDA 4a of (a) GNPS spectra, and (b) 
experimentally detected spectra. 
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Appendix figure 3 Spectral comparison for coelichelin of (a) GNPS spectra, and (b) 
experimentally detected spectra. 
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Appendix figure 4 Spectral comparison for deferoxamine B of (a) GNPS spectra, and 
(b) experimentally detected spectra. 
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Appendix figure 5 Spectral comparison for deferoxamine E of (a) GNPS spectra, and (b) 
experimentally detected spectra. 
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Appendix figure 6 Spectral comparison for ε-ACT of (a) GNPS spectra, and (b) 
experimentally detected spectra. 
  
 
  
276 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M3 a3 1:3
m/z
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
JB Mar6 67 282 (5.409) 2: TOF MS ES+ 
3.15e3631.1274
571.1057
543.1112
483.0985
455.0963
437.1238
335.0852
175.0524
653.1121
654.0729
1283.2498
671.1270
771.3668
675.1542 968.9026
772.3780
1281.1648
976.3622
1284.2362
1285.2317
1913.44211301.2212 1595.9552
631.11 
571.10 
543.10 
613.10 
585.11 
(a) (b) 
Appendix figure 7 Spectral comparison for γ-ACT of (a) GNPS spectra, and (b) experimentally 
detected spectra. 
  
 
  
277 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M2 a3 5:2
m/z
100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460
%
0
JB Mar6 38 333 (6.380) 2: TOF MS ES+ 
1.94e4394.3102
238.1137
211.0981
161.0848119.0772 147.0638
171.0645
239.1264
383.2183
252.1273 379.2747
253.1329
254.1347
327.1450
281.1531 308.1924
378.2606
362.2456
395.3086
396.3767
397.3960
399.8450 425.2181443.2617
379.25 
238.17 
252.08 
394.33 
(a) (b) 
Appendix figure 8 Spectral comparison for RED of (a) GNPS spectra, and (b) experimentally 
detected spectra. 
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Appendix figure 9 Minimal Media and elicitor culture of S. costaricanus. 
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Appendix figure 10 2D and 3D PCA of S. costaricanus nutrition screen. 
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Appendix figure 11 Flash chromatogram of supernatant fractions eluted from ENV+ resin. 
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Appendix figure 12 Dry weights for supernatant ENV+ fractions. 
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Appendix figure 13 Dry weights for agar culture ENV+ fractions. 
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Appendix figure 14 LP Fraction 8 
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Appendix figure 15 LP Fraction 9. 
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Appendix figure 16 LP fraction 21. 
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Appendix figure 17 LP fraction 22. 
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Appendix figure 18 LP fraction 23.  
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Appendix figure 19 (a) Diode array absorption and (b) UPLC-MS chromatogram for LP pool 20, used as spectral source for 
4 actinomycins: X2 (m/z 1269.65), X0β (m/z 1271.67), m/z 1257.66, and m/z 1241.63, marked with a *. 
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Appendix figure 20 (a) Actinomycin D and (b) X2 higher energy spectra; (c) X2 standard energy spectra. 
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Appendix figure 21 (a) Actinomycin D and (b) X0β higher energy spectra; (c) X0β standard energy spectra. 
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Appendix figure 22 (a) Actinomycin D and (b) m/z 1257.66 higher energy spectra; (c) m/z 1257.66 spectra. 
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Appendix figure 23 (a) Actinomycin D and (b) m/z 1257.66 higher energy spectra; (c) m/z 1241.64 spectra. 
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Appendix figure 24 (a) Diode array absorption and (b) UPLC-MS chromatogram for LP fraction 17, source of m/z 614.34 
spectra. 
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Appendix figure 25 (a) Actinomycin D and (b) m/z 614.54 higher energy spectra; (c) m/z 614.54 spectra 
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8.2 Appendix tables 
 
All media contained 20 g/l agar (Sigma-Aldrich, Poole UK) with the exceptions of 
OM agar, and glucose and maltose yeast malt (18 g/l), Glucose or Maltose Yeast 
Malt (18.  Components were dissolved in Reverse Osmosis (RO) water, 
autoclaved at 121°C for 15 min, and then transferred in 2 ml aliquots/well into 
sterile Nunc Δ-Surface 24-well plates (Sigma-Aldrich).  Media for metabolite 
production and culture maintenance were taken from Kieser et al., 2000,  
Goodfellow & Fiedler (2010), and Shepherd et al., (2010).  All media were 
adjusted to pH 7 ± 0.2 before autoclaving to avoid having pH as another variable 
between conditions. 
Appendix table 1 List of media, components, and suppliers. 
Media Amount (g/l) Purchased From 
S. coelicolor Lifecycle Library Trial Media 
Glucose Yeast Malt   
Glucose 4 Sigma-Aldrich  
Yeast extract 4 Sigma-Aldrich 
Malt extract 10 Sigma-Aldrich 
S. coelicolor 24-Well Plate Screen Media 
Minimal Mannitol Media   
Mannitol 10 Fisher Scientific 
(Loughborough, UK) 
Ammonium sulphate 1 Sigma-Aldrich  
diPotassium hypophosphate 0.5 Sigma-Aldrich 
Magnesium sulphate 0.2 Sigma-Aldrich 
Iron sulphate 0.01 Sigma-Aldrich 
Soil Extract Agar   
Lufa 2.2 Standardised Soil 50 Lufa-Speyer (Speyer, 
Germany) 
Oatmeal Agar   
Trace salts solution* 1 ml n/a – see below 
Oatmeal (Hamlyn’s) 20 Sainsbury’s (London, 
UK) 
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ISP5   
L-asparagine 1 Sigma-Aldrich 
Dipotassium phosphate 1 Sigma-Aldrich 
Trace salts solution* 1 ml n/a – see below 
Glycerol 10 Sigma-Aldrich 
Maltose Yeast Malt   
Maltose 4 Sigma-Aldrich 
Yeast extract 4 Sigma-Aldrich 
Malt extract 10 Sigma-Aldrich 
Proline Yeast Malt   
L-Proline 4 Sigma-Aldrich 
Yeast extract 4 Sigma-Aldrich 
Malt extract 10 Sigma-Aldrich 
M19   
Mannitol 20 Fisher Scientific 
Peptone 20 Fisher Scientific 
PepS   
Peptone 5 Fisher Scientific 
Soluble starch 20 Sigma-Aldrich 
*Trace Salts Solution   
Iron sulphate heptahydrate 1 Sigma-Aldrich 
Manganese chloride 
heptahydrate 
1 Sigma-Aldrich 
Zinc sulphate heptahydrate 1 Sigma-Aldrich 
General Streptomyces Growth and Maintenance 
Soya Flour Mannitol   
Soya Flour 20 Holland and Barrett 
(Nuneaton, UK) 
Mannitol 20 Fisher Scientific 
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Appendix table 2 Additional media used in antibacterial activity screening. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Component BA DSMZ 5006 ISP4 M400 
 g/l 
Glycerol 10    
Sucrose  3   
Soluble starch   10 20 
Glucose    10 
Dextrin  15   
Yeast extract  2  5 
Tryptone soy broth  5   
Beef extract 1    
Meat extract  1  3 
Peptone    3 
Tryptone 2    
NaCl  0.5   
ZnSO4   0.01  
MnCl2   0.01  
K2HPO4  0.5 1  
MgSO4  0.5 1  
NaCl   1  
FeSO4  0.01 0.01  
(NH4)2SO4   2  
CaCO3   2 3 
Agar 15 20 20 20 
  
 
  
298 
 
Appendix table 3 Replacement media for the 4 removed growth conditions to 
culture the three screened NCIMB Streptomyces. 
Media Ingredient g/l Purchased From 
CS   
Glucose 1 Sigma-Aldrich (Poole, UK) 
Corn Steep Liquor 20 Sigma-Aldrich 
Soya Flour 2 Holland & Barrett (Nuneaton, UK) 
Maize Flour Meal 5 Holland & Barrett 
SGT   
Glucose 1 Sigma-Aldrich 
Soybean Oil 15 Sigma-Aldrich 
Tryptone 5 Sigma-Aldrich 
Calcium carbonate 2 Sigma-Aldrich 
Beef extract 2 Sigma-Aldrich 
SM   
Sucrose 20 Sigma-Aldrich 
Meat extract 3 Sigma-Aldrich 
Phytone 3 Sigma-Aldrich 
Calcium carbonate 2 Sigma-Aldrich 
MM   
Black Treacle (molasses) 20 Sainsbury’s (London, UK) 
Glucose 1 Sigma-Aldrich 
Meat Extract 10 Sigma-Aldrich 
Yeast Extract 1 Sigma-Aldrich 
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Appendix table 4 Combined and purified fraction pool weights. 
 
Fraction LP pool mg/ml MP pool mg/ml HP pool mg/ml 
1 0 0 0 
2 0 0 0 
3 0.20 0 0 
4 0.10 1.77 0 
5 0 1.03 0.10 
6 0.13 0.53 1.13 
7 0.13 0.30 1.00 
8 0 0 1.00 
9 0 0.16 1.26 
10 0 0.13 1.63 
11 0 0 3.36 
12 0 0.23 2.03 
13 0 0.23 2.26 
14 0.13 0.40 2.26 
15 0 0.53 2.03 
16 0.10 0.46 2.20 
17 0.13 0.33 1.86 
18 0.13 0.30 1.56 
19 0.10 0 1.50 
20 0.36 0.20 1.00 
21 0.60 0.10 0.80 
22 0.33 0 0.53 
23 0.13 0.10 0.30 
24 0.16 0.11 0.20 
25 - 0.10 - 
26 - 0.13 - 
27 - 0.13 - 
28 - 0.00 - 
